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Estrogens play a critical role in the development and progression of breast cancer. The 
biological functions of estrogen are mainly mediated by estrogen receptors (ER), 
which act by regulating gene expression in breast cancer cells. Previously our 
laboratory identified liver receptor homologue-1 (LRH-1), a member of the nuclear 
receptor superfamily of transcription factors to which ER also belongs, as an 
estrogen-responsive gene. Subsequent work showed that LRH-1 is important in 
mediating the growth of breast cancer cells. Herein, I show that LRH-1 in turn 
regulates the expression of ERα, providing a positive feedback loop, which may act to 
promote stable co-expression of ERα and LRH-1 in breast cancer cells. To better 
define the mechanisms of LRH-1 action in breast cancer cells, gene expression 
microarray analysis was performed following RNA interference mediated LRH-1 
knockdown. Microarray analysis demonstrated that LRH-1 regulates the expression of 
many estrogen-responsive genes. ChIP-seq analysis, carried out to identify global 
LRH-1 binding sites, showed that LRH-1 is recruited to a substantial proportion of 
estrogen-regulated genes, frequently binding to ERα binding sites, suggesting LRH-1 
directly regulates a subset of ERα-target genes in breast cancer cells. Analysis of 
select binding sites confirmed the direct LRH-1 regulation of ERα target genes 
through LRH-1 binding to estrogen response elements (ERE), as exemplified by the 
TFF1/pS2 gene. Moreover, LRH-1 was shown to stimulate the recruitment of ERα to 
the ERE in the shared/common target genes, suggesting a co-operative function 
between LRH-1 and ERα. Collectively, these findings show that LRH-1 is a key 
mediator of the estrogen response in breast cancer cells and raises the possibility of 
targeting LRH-1 for the treatment of breast cancer. Towards this end, I also describe 
the identification of novel LRH-1 antagonists that inhibit breast cancer cell growth. 
Development of these compounds will offer investigational tools for validating the 
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Chapter 1 Introduction 
1.1 Breast cancer !
In the United Kingdom, breast cancer is the most common cancer in women and is the 
second most common cause of cancer deaths. In 2010 alone, 49,564 women were 
diagnosed with breast cancer, which accounted for 11,556 deaths in the UK (CRUK, 
2013. http://www.cancerresearchuk.org/cancer-info/cancerstats/keyfacts/breast-
cancer/). It is estimated that 1 in 8 women in the UK will develop breast cancer during 
their lifetime. The breast cancer incidence rates have been rising since 1970, due to in 
part to increased public awareness and the implementation of screening programmes. 
Despite increases in incidence, the mortality rates for breast cancer have been 
decreasing over the last twenty year. Advances in multidisciplinary approaches in 
treating breast cancer including surgery, radiation, chemotherapy and most 
importantly hormone therapy have reduced the risk of relapse and improved long-
term survival amongst breast cancer patients (Jones & Buzdar, 2004). Breast cancer 
survival rates have been improving in the UK, 8 out of 10 women with diagnosed 
with breast cancer survival the disease beyond five years, compared to 5 out of 10 in 
the 1970 (CRUK, 2013). Finally, early detection due to the implementation of 
screening programmes may also reduce mortality (Duffy et al, 2010; Marmot et al, 
2013), despite potential problems surrounding the use of approaches such as 
mammographic screening of women over the age of 50. 
 
1.2 Estrogen hormone in breast cancer !
A connection between estrogen and breast cancer has been recognised since the 19th 
century. It was demonstrated that bilateral oopherectomy (removal of ovaries) from 
premenopausal women with advanced breast cancer resulted in reduction in tumour 
size, at least in a proportion of women (for refs see (Ali & Coombes, 2002)). Estrogen 
was identified in the 1930s as the ovarian hormone that promotes mammary 
tumourigenesis in animal models. Extensive epidemiological evidence has also 
established that cumulative estrogen exposure is directly associated with risk of 
! 21!
developing breast cancer. Factors related to increase in estrogen exposure throughout 
a woman’s lifetime, such as early menarche, late menopause, and nulliparity are all 
associated with increased breast cancer risk (Clemons & Goss, 2001). In addition, 
high levels of endogenous sex hormones in the circulation, notably androgens and 
estrogens have been shown to strongly associate with breast cancer risk (Key et al, 
2002). Apart from endogenous estrogens, the use of exogenous hormones has also 
been linked with the development of breast cancer. The use of estrogen-only oral 
contraceptive pills and hormone replacement therapy that contain estrogen and 
progesterone has been associated with significantly increased risk of breast cancer 
(CGHFBC, 1997). 
 
1.3 Estrogen biosynthesis !
Estrogens are steroid hormones that have widespread biological functions. The 
primary roles of estrogens are in regulating the development and maintenance of 
female characteristics including the reproductive organs and the mammary gland 
(Gruber et al, 2002). Estrogens are also important in maintaining normal 
physiological functions in other tissues, including skeletal (bone), cardiovascular and 
central nervous system (Baker et al, 2003; McEwen & Alves, 1999; Riggs et al, 
2002). 17β-estradiol (E2) is the predominant and the most active form of estrogen. 
Other types of estrogen include estrone (E1) and estriol (E3) (Gruber et al, 2002). In 
premenopausal women, E1 and E2 are primarily secreted by the ovaries during the 
menstrual cycles. Ovarian estrogen production is tightly regulated by the 
hypothalamic-pituitary-gonadal axis. Luteinizing hormone release hormone  (LHRH) 
produced in the hypothalamus stimulates the release of luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH) in anterior pituitary glands. LH stimulates the 
production of the steroid hormones androstenedione (AD) and testosterone (T) in the 
theca cells in the ovary, whilst FSH stimulates the activity of the P450 enzyme 
aromatase in the granulosa cells, which converts AD and T into E1 and E2, 
respectively. Ovarian estrogens are released into the blood stream and circulate 
throughout the body to act on target tissues. The levels of E1 and E2 vary according 
to the menstrual cycle, with the highest concentrations detectable during the follicle 
maturation and pre-ovulation stages. Estrogen levels can be regulated by a negative 
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feedback loop, by which estrogen inhibits hypothalamic LHRH and pituitary LH 
production (Auchus & Auchus, 2012; Gruber et al, 2002). E3 is the weakest of the 
three forms of estrogen and very low concentrations are detected in the circulation 
when compared to E1 and E2. Significant levels of E3 are only detected in women 
during pregnancy, being produced in the placenta (Gruber et al, 2002). In 
postmenopausal women, the serum level of estrogen is lowered following the decline 
in ovarian function. Estrogen biosynthesis in post-menopausal women mainly 
involves aromatization of circulating adrenal androgens in extragonadal sites, such as 
adipose tissue, brain, the cardiovascular system and bone (Gruber et al, 2002). It has 
been proposed that estrogen no longer acts primarily as a circulating hormone in 
postmenopausal women, but that estrogen synthesised in peripheral tissues can 
achieve high local concentrations and acts locally in a paracrine or intracrine fashion 
(Simpson, 2003). 
 
Despite the normal and beneficial physiological actions of endogenous estrogens in 
women, abnormally high estrogen levels are associated with certain types of cancer, 
especially in the breast and endometrium. Breast cancer incidence correlates 
positively with estrogen levels in postmenopausal women. Women who have the 
highest levels of circulating estrogens have double the risk of developing breast 
cancer, compared with those who have the lowest levels (Key et al, 2002). It has been 
suggested that breast adipose tissue is a predominant site for aromatase expression 
and estrogen production in post-menopausal women and has been linked with 
development of breast cancer. It has been shown that the concentration of estradiol 
present in breast tumours of postmenopausal women is 20-fold greater than levels in 
the plasma (Pasqualini et al, 1996). Furthermore, an increase in aromatase expression 
has been described in breast tumours and surrounding adipose tissue when compared 
to normal breast tissue, and this is in accordance with elevated local estrogen 
concentration, implying that deregulation of estrogen production could contribute to 





1.4 Estrogen receptors (ER) in breast tissue  
1.4.1 ER in normal breast tissue !
The biological actions of estrogens are mediated by the estrogen receptors (ER), ERα 
and ERβ, which belong to the nuclear receptor superfamily of ligand inducible 
transcriptional factors. ERα and ERβ are encoded from different genes and exhibit 
tissue and cell-type specific expression. In the normal mammary gland, ERα 
expression is mainly detected in the ductal epithelial cells, whilst ERβ is more broadly 
expressed in the epithelial and stromal cells including fibroblasts and endothelial cells 
(Speirs et al, 2002). Although estrogens are not required for the prenatal development 
of the mammary gland, they are required to initiate further development during 
puberty. The importance of estrogen actions in mammary gland development has been 
demonstrated by ER and aromatase knockout mouse models. Aromatase or ERα 
knockout mice have impaired mammary ductal formation and lack breast tissue 
development beyond the pre-pubertal stage (Fisher et al, 1998; Korach et al, 1996). In 
the absence of ERβ, mice appear to have normal mammary structure and are capable 
of normal lactation. These findings suggest that ERα plays the major role in mediating 
estrogen functions in normal development and physiology of the mammary gland 
(Krege et al, 1998). In normal human breast tissue, ERα is present in 10-15% of 
epithelial cells and is distributed evenly throughout the luminal epithelium. 
Interestingly, these ERα-positive cells do not generally proliferate in the normal 
breast tissue. The proliferating cells are often observed in close proximity to ERα-
positive cells, which are often ERα-negative. It has been proposed that ERα-positive 
cells in the breast epithelium act as sensor cells for estrogen and release paracrine 
factors that stimulate the proliferation of adjacent cells (Clarke et al, 1997). 
 
1.4.2 ER in breast cancer !
In breast epithelium hyperplasia and breast tumours, ERα expression is elevated 
compared to normal breast tissue. Furthermore, a significant proportion of the ERα-
positive cells are found to be proliferative in breast tumours. These observations 
suggest disordered control of cell division in ERα expressing cells that are normally 
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non-proliferative, and provides an important pathogenic step in the development of 
breast cancer (Shoker et al, 1999). While ERα has been established as the key driver 
in breast cancer development and progression, several studies suggest that ERβ has a 
key role in opposing ERα action (Hartman et al, 2009). In contrast to ERα, the 
expression of ERβ in breast epithelium hyperplasia and breast tumours is significantly 
lower compared to normal breast tissue. The expression of ERβ is negatively 
correlated with proliferation marker in breast tumours, suggesting a protective effect 
of ERβ against the mitogenic action of estrogen and in tumour initiation (Roger et al, 
2001).  
 
1.5 Hormonal therapies in the treatment of breast cancer 
1.5.1 Ovarian ablation !
Ovarian ablation in inhibiting estrogen synthesis by surgical oophorectomy or ovarian 
radiation is an effective adjuvant treatment for premenopausal women with early 
breast cancer. Patients with ovarian ablation have been shown to have significantly 
improved survival compared to those who received chemotherapy alone (EBCTCG, 
1996). The major disadvantage of surgical/radiation ovarian ablation is the permanent 
loss of ovarian function and the risks associated with surgical/radiation procedures. 
Therefore, LHRH agonists have been developed and used to temporarily suppress 
ovarian estrogen production. LHRH agonists such as goserelin act by downregulating 
LHRH receptors in the pituitary and subsequently reduce the pituitary release of 
gonadotropins, thereby inhibiting estrogen synthesis in the ovaries (Brown & 
Davidson, 2006; Emens & Davidson, 2003). Goserelin is an effective and well-
tolerated alternative to chemotherapy in premenopausal women with ERα-positive 
breast cancer. Patients treated with goserelin for 2 years have equivalent survival 
benefits to the patients who received adjuvant chemotherapy (Jonat et al, 2002). 
However, the majority of breast cancer patients are postmenopausal, therefore ovarian 
ablation would not benefit these patients. Hence, key strategies are to inhibit ERα 
activation with anti-estrogens that compete with estrogen for binding to ERα, or with 
the use of aromatase inhibitors (AIs) that block estrogen biosynthesis and 
consequently prevent ERα activation (Figure 1.1 and 1.2). 
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1.5.2 Anti-estrogens !
Tamoxifen is an anti-estrogen that blocks the binding of estrogen to ERα and inhibits 
ERα activity. It has been used as the primary adjuvant endocrine agent for the past 
three decades. Large clinical trials have been shown that 5 years of adjuvant 
tamoxifen treatment for patients with ERα-positive breast cancer halved the annual 
recurrence rate and reduced the mortality rate by a third (EBCTCG, 2005). Tamoxifen 
has also been shown to be effective in premenopausal women, despite the 
considerably greater levels of circulating estrogen in premenopausal women 
(EBCTCG, 2005). In addition, studies showed that tamoxifen has beneficial effects as 
a chemopreventive agent in reducing the risk of developing ERα-positive breast 
cancer in women in high-risk groups, including those with family history of breast 
cancer (Cuzick et al, 2007; Powles et al, 2007). The occurrence of hot flushes is a 
common side effect of tamoxifen treatment, as a phenomenon of antagonising 
estrogen function in the brain (Benson, 2002). Although tamoxifen acts primarily to 
antagonise estrogen function, it has agonist properties in many other estrogen target 
tissues such as bone, cardiovascular system and the endometrium (Jordan, 2003; 
Lewis & Jordan, 2005). As a result, the use of tamoxifen has been linked with an 
increased risk of endometrial cancer, and thromboeblic events (EBCTCG, 2005). 
However, the use of tamoxifen is also linked with other beneficial effects such as a 
reduced incidence in osteoporotic fractures, lowered cholesterol level, reduced 
atherosclerosis and heart attacks (Ali et al, 2011; Cuzick et al, 2003; Fisher et al, 
2005). The term selective estrogen receptor modulator (SERM) has been applied to 
anti-estrogens such as tamoxifen that are able to agonise or antagonise estrogen 
functions in a tissue-specific manner (Jordan, 2003).  
 
Another SERM, raloxifene, has been approved by the FDA for use as an agent for 
breast cancer prevention in high-risk postmenopausal women. Like tamoxifen, 
raloxifene acts as an estrogen antagonist in breast tissue as demonstrated by inhibition 
of estrogen-induced breast cancer cell proliferation (Ali et al, 2011; Lewis & Jordan, 
2005). Large clinical trials showed that raloxifene significantly reduced the incidence 
of breast cancer, although it was not as effective as tamoxifen. Conversely, fewer side 
effects have been observed with women receiving raloxifene compared to those who 
received tamoxifen, including fewer incidences of endometrial cancer, uterine 
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hyperplasia, and thromboemblic events. These findings suggest that raloxifene might 
exert less agonistic effects on these tissues compared to tamoxifen (Vogel et al, 2010). 
There continues to be much interest in the development of novel SERMs. The ideal 
SERM would act as an antagonist in tissues in which estrogen effects are undesirable 
such as breast and endometrium, but would be estrogenic in tissues in which estrogen 
action is beneficial such as the cardiovascular system, bone and brain (Ali et al, 2011; 
Fabian & Kimler, 2005).  
 
Another class of antiestrogens is the so-called selective estrogen receptor down- 
regulators (SERD), as exemplified by ICI164, 384 or the related compound faslodex. 
Faslodex binds to ERα with high affinity and inhibits ERα activity. It promotes ERα 
nuclear export and degradation, resulting in abrogation of estrogen signalling with no 
agonist activity (Osborne et al, 2004). Clinical studies showed that faslodex has 
equivalent clinical efficacy including response rate and survival benefits compared to 
first line endocrine therapy such as tamoxifen and aromatase inhibitors (AIs) 
(Valachis et al, 2010). Importantly, patients who have ERα-positive breast cancer and 
relapse on tamoxifen and AIs appear to respond to faslodex, indicating faslodex 
provides an effective second-line therapy in order to prolong the response period 
(Chia & Gradishar, 2008; Howell, 2006).  
 
1.5.3 Aromatase inhibitors !
Aromatase inhibitors (AI) can be divided into two types, steroidal and non-steroidal 
inhibitors. The steroidal inhibitors such as exemestane are analogues of 
androstenedione, which bind strongly to the aromatase enzyme in competition with 
natural substrates. Non-steroidal inhibitors such as letrozole and anastrozole inhibit 
aromatase function by binding to the cytochrome P450 site in the aromatase complex 
(Johnston & Dowsett, 2003). These AIs suppress circulating estrogen levels in 
postmenopausal women by >95% with no other clinically significant effects other 
than estrogen deprivation. The use of AIs in premenopausal women leads to 
incomplete estrogen suppression and increased gonadal stimulation. Therefore AIs are 
only used in postmenopausal breast cancer patients or premenopausal patients who 
have undergone ovarian ablation (Johnston & Dowsett, 2003). Both letrozole and 
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anastrozole have been approved as first line endocrine therapy for postmenopausal 
women with ERα-positive breast cancer. Clinical studies demonstrate that patients 
treated with letrozole or anastrozole have better response rate, disease free survival 
rates and reduced disease recurrence, compared with those treated with tamoxifen 
(Baum et al, 2003; Bonneterre et al, 2001; Mouridsen et al, 2001). Side effects of AIs 
are linked with estrogen deficiency and include an increased risk of developing 
osteoporosis, joint disorder and cognitive dysfunction. Up to 35% of women on AI 
therapy experienced joint pain and this is one of the main cause of patient non-
compliance for these agents (Howell et al, 2005; Niravath, 2013). 
 
Tamoxifen has been widely used in both early and advanced breast cancer patients 
and offers substantial benefits in women with ERα-positive breast cancer. However, 
tamoxifen resistance occurs and is the main problem that limits the efficacy of the 
treatment. Almost 50% of the patients with ERα-positive advanced disease do not 
respond to first line tamoxifen treatment (de novo resistance). Furthermore, as many 
as 40% of the patients who initially respond to tamoxifen eventually relapse and die 
from the disease within 5 years (acquired resistance) (Ring & Dowsett, 2004). Despite 
the introduction of more recent endocrine agents including faslodex and AIs, 
resistance to these endocrine therapeutic agents still remains a major problem (Ali et 
al, 2011; Ring & Dowsett, 2004). Therefore, extensive studies have been carried out 
to investigate the molecular mechanisms of estrogen signalling to better understand 
the causes of endocrine resistance. These studies also aim to allow the development of 







Figure 1.1 Estrogen biosynthesis in peripheral tissues and the molecular targets 
of endocrine agents in breast cancer cells 
A) In peripheral tissues, the aromatase enzyme catalyses estrogen biosynthesis by 
converting circulating adrenal androgens, andostenedione (AD) and testosterone (T) 
to 17β-estradiol (E2) and estrone (E1), respectively. E1 can be further converted to E2 
by the enzyme 17β-hydroxysteroid dehydrogenases (17β-HSD). Peripheral synthesis 
of E2 can act locally in an intracrine and paracrine manner. B) Aromatase inhibitors 
inhibit the production of estrogens from their androgen precursors. C) Anti-estrogens 












































Figure 1.2 Chemical structures of pharmaceutically important antiestrogens and 
aromatase inhibitors 
Shown are chemical structures of the selective estrogen receptor modulators 
(SERMs), 4-hydrotamoxifen and raloxifene (A), the selective estrogen receptor down-
regulator (SERD) faslodex (B) and the aromatase inhibitors (AI) exemestane, 










1.6 Estrogen receptor structure !
ERα and ERβ are members of the nuclear receptor superfamily of ligand inducible 
transcription factors and share a common structure that is composed of six regions of 
differing amino acids sequence homology, designated A–F (Pearce & Jordan, 2004). 
The N-terminal or A/B domain contains transcription activation function 1 (AF1), a 
region subject to regulation by phosphorylation. This region is the least well-
conserved between ERα and ERβ, sharing 30% amino acid sequence identity (Pearce 
& Jordan, 2004). The C region, encoding the DNA-binding domain (DBD), is highly 
conserved between ERα and ERβ, with 96% amino acid sequence identity. The DBD 
is composed of a two zinc-finger motifs that play an important role in receptor 
dimerization, as well as DNA binding. ERα and ERβ can form homodimers or can act 
as ERα/ERβ heterodimers and bind as dimers to palindromic DNA sequences, the so 
called estrogen-responsive elements (ERE), which conform to the consensus sequence 
5’-AGGTCANNNTGACCT-3’ (Klinge, 2001). Although ERα and ERβ have been 
shown to share the same genomic targets, it has been demonstrated that the ERβ 
homodimer and the ERα/ERβ heterodimer are less potent activators than the ERα 
homodimer of ERE-containing reporter genes (Chang et al, 2006; Charn et al, 2010; 
Grober et al, 2011; Zhao et al, 2007).  
 
The E/F region contains the ligand-binding domain (LBD), which has a wedge-shaped 
structure comprised of 12 α-helices (Brzozowski et al, 1997; Shiau et al, 1998). 
Agonist binding to the ERα LBD results in a conformational change that reveals a 
hydrophobic groove which can accommodate α-helical motifs in transcriptional co-
activators, having the consensus sequence LXXLL (where L = leucine and X = any 
amino acid). The LBD also binds anti-estrogens, with tamoxifen binding resulting in a 
conformation of helix 12 such that it takes up position in the co-activator binding 
groove, hence preventing co-activator binding (Lupien et al, 2007; Shiau et al, 1998). 
An alternative mode of anti-estrogen action is revealed by the structure of the ERβ 
LBD complexed with the pure anti-estrogen ICI182,780 (Pike et al, 2001). The side 
chain of ICI182,780 protrudes from the ligand binding pocket to lie within the co-
activator binding groove, preventing co-activator recruitment (Lupien et al, 2007). 
The LBD is also known to be important for receptor dimerization and nuclear 
localization. ERα and ERβ shared sequence identity of 53% in the LBD and bind to 
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E2 with similar affinity. However, some synthetic compounds have been identified, 
which bind selectively to ERα or ERβ (Harrington et al, 2003; Mosselman et al, 1996; 
Nilsson et al, 2011). Region D is the so-called “hinge” region and is poorly conversed 
between nuclear receptors as well as between ERα and ERβ. It serves to provide 
flexibility for receptor dimerization and DNA binding. In addition, it also contains 
nuclear localization signals (Figure 1.3) (Pearce & Jordan, 2004). 
 
1.7 Mechanisms of ERα action  !
The classical paradigm of ERα function involves the binding of ligand, receptor 
dimerization, and DNA binding at target gene promoters containing the ERE 
sequence, which then recruits transcriptional co-regulatory proteins and RNA 
polymerase II in initiating target gene transcription. Alternatively, ligand-activated 
ERα can also regulate gene expression without direct binding to DNA. This occurs 
through protein-protein interaction with other DNA-binding transcription factors 
including activator protein 1 (AP-1), specificity protein 1 (Sp1), nuclear factor-kB 
(NF-kB), and cAMP response element-binding protein (CREB), and this is called the 
non-classical genomic function of ERα (Bjornstrom & Sjoberg, 2005; Green & 
Carroll, 2007).  
 
Although the activation of ERα is presumed to require binding of ligand, several 
growth factors, including epidermal growth factor (EGF), heregulin (HRG), insulin-
like growth factor 1 (IGF-1) and transforming growth factor α (TGF-α) have been 
shown to stimulate ERα transactivation in the absence of ligand. ERα phosphorylation 
at several serine residues, in particular at serine 118 and 167 in the AF-1 domain 
contribute to ligand-independent activity of ERα. Activation of growth factor 
downstream signalling cascades, particularly the mitogen-activated protein kinase 
(MAPK) and phosphatidyl-inositol-3-kinase (PI3K) pathways lead to the 
phosphorylation of ERα at these serine residues. In addition, these growth factor 
signalling pathways can also indirectly modulate ERα activity by enhancing the 
activities of co-activators or attenuating co-repressors activities (Ali & Coombes, 












Figure 1.3 Diagrammatic representation of the functional domains in estrogen 
receptors ERα and ERβ 
Shown are the amino acid sequences of human ERα and ERβ. Comparison of the 
amino acid sequence homologies between human ERα and ERβ in identified 
functional domains is also depicted.  
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Estrogen has been shown to modulate cellular processes independent of ERα, the so-
called non-genomic mechanism, via the induction of several signalling pathways 
including MAPK, protein kinase C (PKC), Janus kinase/signal transducers and 
activators of transcription (JAK/STAT), serine/threonine-protein kinase (PAK1), 
casein kinase I-γ2 and sphingosine kinases which can be tissue and cell type specific 
(Acconcia & Kumar, 2006). Apart from the classical genomic actions that act directly 
in regulating gene transcription, ERα can also mediate part of the non-genomic effects 
of estrogens. It has been proposed that ligand-activated ERα in the cytoplasmic 
membrane fraction interacts with different growth factor signalling cascades including 
epidermal growth factor receptor 1 and 2 (EGFR/HER2) and insulin-like growth 
factor 1 receptor (IGFR) signalling, which lead to the activation of downstream kinase 
signalling cascades such as MAPK/ERK and PI3K/Akt. These findings indicate that 
ERα can cooperate with growth factor signalling and can act synergistically to 
mediate cellular responses to estrogen (Figure 1.4) (Acconcia & Kumar, 2006; Ali & 
Coombes, 2002; Bjornstrom & Sjoberg, 2005). 
 
1.8 ERα-mediated gene transcription !
In order to promote transcription initiation, ligand-activated ERα recruits diverse 
transcriptional co-regulators that have various enzymatic activities to modify 
chromatin structure and stabilise the recruitment of general transcriptional factors. As 
described above, estrogen binding to ERα triggers a conformational change in the 
LBD that creates a docking site within the AF-2 domain for co-activator interactions 
(Green & Carroll, 2007). The p160 co-activator protein family consists of three 
members, SRC1 (NCOA1), SRC2 (NCOA2, TIF2, GRIP1) and SRC3 (p/CIP, RAC3, 
AIB1, ACTR or TRAM-1), which constitute the most well characterised family of 
nuclear receptor co-activators (McKenna & O'Malley, 2002; Xu et al, 2009). The 
central region of the p160 co-activators contains three LXXLL motifs, the “NR box”, 
that are required for the interaction with the LBD in nuclear receptors. The C-
terminus of p160 family contains two transcriptional activation domains (AD1 and 
AD2), this region is important in further recruiting other co-activator proteins that 
have histone acetyltranferase (HAT) activity such as p300 and CREB-binding protein 
(CBP), as well as other proteins with histone methyltransferase (HMT) activity such 
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as co-activator-associated arginine methyltransferase 1 (CARM1) and protein arginine 
N-methyltransferase 1 (PRMT1) that are responsible for histone protein modification 
in promoting chromatin accessibility (Xu et al, 2009). The ATP-dependent chromatin 
remodeling complexes such as SWI/SNF and the DRIP/TRAP mediator complexes, 
which facilitate the recruitment of general transcription factors and RNA polymerase 
II  (RNA PolII) are also recruited to ERα-regulated gene promoters in a ligand-
dependent manner to mediate gene transcription (Jeong et al, 2009; Metivier et al, 
2006). 
 
Nuclear receptor co-repressors NCoR (NCoR1) and SMRT (NCoR2) play key roles in 
repressing ERα functions in the absence of ligand or bound by antagonists. In their C-
terminal regions NCoR and SMRT possess (I/L)XX(I/V)I motifs called the “CoRNR 
box”, which have also been shown to interact with the unliganded nuclear receptor 
LBD. The N-terminal and central domains of both NCoR and SMRT possess 
interfaces for the recruitment of additional co-repressor components such as histone 
deacetylases (HDACs) and ATP-dependent remodeling complexes that lead to the 
generation of compacted chromatin structures, thus restricting the transcriptional 
process (Hu & Lazar, 1999; Perissi et al, 2010; Varlakhanova et al, 2010). 
 
The application of chromatin immunoprecipitation (ChIP) to study protein-DNA 
interactions has provided mechanistic insights into the role of ERα in promoting the 
recruitment of transcriptional co-regulatory proteins that assist in mediating gene 
transcription (Metivier et al, 2003; Reid et al, 2003; Shang et al, 2000). These studies 
have demonstrated a cyclical pattern of ERα association and dissociation from the 
gene promoter following estrogen stimulation, accompanied by cyclical association 
and dissociation of transcriptional cofactors in a temporal manner. The associations of 
co-regulatory proteins are accompanied by dynamic changes in chromatin remodeling 
and histone modification to promote gene transcription. It has been proposed that 
these cyclic changes comprise of  “opening” and “closing” of local gene structure to 
allow tight control over target gene expression by preventing permissive and 
constitutive activation of target genes (Metivier et al, 2006) . 
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1.9 Chromatin structure in controlling transcription !
Nuclear receptors and other transcription factors recognise specific DNA sequences in 
the genome in facilitating target gene transcription. However, eukaryotic DNA is 
arranged into higher complexity structures, called chromatin. This feature enables 
packing of the genome within a small space, however it also restricts access of 
transcriptional factors and the general transcriptional machinery from the DNA 
(Kouzarides, 2007; Wiench et al, 2011). The basic organization of chromatin consists 
of nucleosomes in which 146 base pairs (bp) of DNA are wrapped around a core 
histone octamer (two each of histones H2A, H2B, H3 and H4). The nucleosome 
structure is stabilised by a strong interaction between the negatively charge DNA 
phosphate backbone and the positively charged lysine/arginine residues on the surface 
of the histones. Each nucleosome is connected by a short of linker DNA usually 10-80 
bp in length (Felsenfeld & Groudine, 2003; Kouzarides, 2007; Luger et al, 1997).  
Chromatin can be divided into two categories: an open, active, inducible form known 
as euchromatin; and a closed, inactive form called the heterochromatin (Kouzarides, 
2007). DNase1 hypersensitivity (DHS) mapping is a commonly used technique in 
measuring chromatin accessibility for transcription factor binding. The DNaseI 
enzyme is an endonuclease that cleaves DNA independently of the sequence but is 
precluded by chromatin compaction (Boyle et al, 2008). Nucleosomes found across 
the human genome exhibit varying degrees of mobility. ATP-dependent remodeling 
complexes can alter the chromatin structure by rearranging the organization of the 
nucleosomes in the chromatin fibre (Bintu et al, 2012; Narlikar et al, 2013). The 
repositioning of nucleosomes allows exposure of DNA-binding motifs in linker DNA 
and creates accessibility to DNA binding proteins such as transcription factors (Bintu 
et al, 2012; Narlikar et al, 2013). Histone proteins are subjected to post-translational 
modifications, such as acetylation, methylation, phosphorylation, ubiquitination and 
sumoylation. These epigenetic marks influence transcription factor binding and target 
gene transcription by directly modulating chromatin structure, or indirectly by altering 
the affinity of interactions with chromatin-binding proteins (Kouzarides, 2007). 
Histone acetylation and methylation are the most studied histone modification marks. 
Histone acetylation promotes euchromatin formation by removing the positive charge 
on the histones, therefore decreases its interaction with DNA (Struhl, 1998). The 
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acetylation/deacetylation and methylation of histone at specific residues are closely 
linked with transcriptional control (Kouzarides, 2007).  For example, di- or tri- 
methylation of histone 3 at lysine 4 (H3K4me2 and H3K4me3) and acetylation of 
histone 3 at lysine 9 (H3K9Ac) are active histone marks and associate with promoters 
engaged in transcription (Bernstein et al, 2012; Mikkelsen et al, 2007), whereas other 
combinations, such as di- or tri- methylation of H3K27 and monomethylation of 
H3K9 and H4K20 and H3K79 are associated with a silent heterochromatic state 










Figure 1.4 Estrogen receptor α signalling pathways 
A) Classical genomic function of ERα: Estrogen (E2) binds to ERα and triggers 
receptor activation. ERα forms homodimer and regulates gene expression through 
binding to ERα binding motifs in estrogen-regulated genes. B) Non-classical genomic 
function of ERα: Ligand-activated ERα interacts with other transcriptional factors 
such as AP-1 and Sp1 factors and regulates gene expression without directly binding 
to DNA. C) Non-genomic function of ERα: Ligand-activated membrane bound ERα 
can cooperate with the growth factor receptors such as epidermal growth factor 1 and 
2 (EGRF and HER2) and insulin-like growth factor 1 receptor (IGFR) and the 
components of mitogen-activated protein kinases (MAPK) and phosphatidylinositol-














































1.10 Mechanisms of endocrine resistance 
1.10.1 Loss of ERα expression and ERα mutations !
Anti-estrogen actions in breast cancer are primarily mediated through ERα, resulting 
in reduction in recurrence and improved survival. Many patients, however, do not 
respond to tamoxifen or relapse following an initial period of response. Loss of ERα 
has been observed in 10 to 17% of patients who initially responded and subsequently 
relapsed on tamoxifen, indicating that in these patients other signalling pathways take 
over to promote tumour growth (Ring & Dowsett, 2004). Several studies have 
suggested that DNA methylation in the ERα gene promoters can lead to silencing of 
ERα expression in breast cancer cells (Lapidus et al, 1996; Ottaviano et al, 1994; 
Yoshida et al, 2000). However, the majority of patients who relapse on tamoxifen 
retain ERα expression, and a considerable proportion of these patients respond to 
second-line hormonal treatment such as AIs and faslodex, indicating that the ERα is 
still functional and important in these patients and imply the existence of other 
resistance mechanisms (Ring & Dowsett, 2004). 
 
Mutations within the ERα gene are rare in breast cancer (<1% of all primary breast 
cancer) and many identified mutations are silent changes that do not affect the protein 
sequence (Herynk et al, 2007). A mutation, A908G, resulting in a lysine to arginine 
change at amino acid 303 (K303R) was identified in pre-malignant ductal 
hyperplasias (Fuqua et al, 2000) and has been reported to be prevalent in invasive 
breast cancer (Herynk et al, 2007), although other studies conclude that it is rare 
(Tebbit et al, 2004; Tokunaga et al, 2004; Zhang et al, 2003). Moreover, only 4/1147 
primary tumours listed in the COSMIC database 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) have mutations in the 
ESR1 gene (and do not include the A908G mutation). Thus, ESR1 mutations appear 





1.10.2 Co-regulator proteins  !
Tamoxifen acts as an ERα antagonist in breast cancer but also function as an agonist 
in other tissue such as uterus and bone. Differential expression patterns of ERα co-
regulatory proteins have been shown to contribute to the tissue specific actions of 
tamoxifen and other SERMs (Jordan & O'Malley, 2007). Altered balance between the 
levels of co-activators and co-repressors appears to contribute to the mechanisms of 
resistance. Overexpressing co-activator or silencing of co-repressor proteins has been 
shown to enhance the agonist activity of tamoxifen and to promote breast cancer cells 
growth by inducing estrogen-regulated genes expression (Shang & Brown, 2002). In 
clinical studies, elevated expression of co-activator proteins such as SRC1 and AIB1, 
and low expression of the co-repressor NCoR have been associated with breast cancer 
relapse and poor response rates to tamoxifen (Anzick et al, 1997; Girault et al, 2003; 
Lydon & O'Malley, 2011; Redmond et al, 2009). 
 
1.10.3 Growth factor signalling in endocrine resistance !
There is mounting evidence supporting a role for altered growth factor receptor 
pathways and their signalling cascades in stimulation of breast cancer cell 
proliferation and survival and resistance to anti-estrogen and AI treatments (Osborne 
& Schiff, 2011). Increased expression of EGFR and HER2 thereby activating 
downstream signalling pathways including, MAPK/ERK and PI3K/AKT kinases, has 
been reported in cell line models of endocrine resistance and has been shown to 
correlate with poor response to endocrine agents and shorter duration in breast cancer 
relapse in clinical studies (Nicholson et al, 2007; Osborne & Schiff, 2011). Elevated 
activity of growth factor signalling may provide pathways independent of ERα in 
promoting proliferation and survival of breast cancer cells, therefore bypassing the 
requirement of estrogen for growth. The crosstalk between ERα and growth factor 
signal transduction pathways has also been implicated in the mechanism of endocrine 
resistance. For example, it has been shown that activation of the HER2/MAPK 
pathway induces ERα activity through the phosphorylation of ERα and AIB-1 co-
activator protein, resulting in loss of tamoxifen antagonist activity and the acquisition 
of tamoxifen stimulated growth (Shou et al, 2004). Inhibition of growth factor 
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pathways has been raised as a key strategy in combating endocrine resistance in breast 
cancer. Gefitinib (a selective EGRF inhibitor) and trastuzumab (a monoclonal 
antibody that blocks HER2) have been shown to restore estrogen sensitivity and the 
antagonistic effects of tamoxifen in HER2 over-expressing tamoxifen-resistance cell 
line models (Shou et al, 2004; Witters et al, 2002). Currently, trastuzumab is approved 
for use as a single agent or in combination with chemotherapy in HER2 
overexpressing breast cancer and has been shown to prolong patient survival 
(Nishimura et al, 2008). Many clinical trials have begun to test the efficacy in 
combining growth factor receptor inhibitors and endocrine agents in combating 
treatment resistance. Early clinical trials suggested that the combination of 
trastuzumab or lampatinib (an EGFR and HER2 inhibitor) with an AI is superior to AI 
alone in patients with ERα and HER2 overexpressing breast cancer (Kaufman et al, 
2009; Riemsma et al, 2012).  
 
1.11 Identification of ERα target genes in breast cancer cells 
 
Early molecular studies using cloning methods in breast cancer cells led to the 
identification of a number of ERα target genes including the trefoil factor 1 
(TFF1/pS2), and cathepsin D (CTSD) genes, which were subsequently shown to 
contain ERE sequences in the proximal gene promoter (Elangovan & Moulton, 1980; 
Foekens et al, 1990; Jakowlew et al, 1984). c-myc and cyclin D1 (CCND1) have also 
been identified as estrogen-regulated genes (Altucci et al, 1996; Dubik et al, 1987; 
Prall et al, 1998), however no canonical EREs are presence in the promoter proximal 
region of these genes. Subsequent mutations of various DNA binding elements within 
the gene promoter region led to the discovery of a non-classical mechanism of ERα 
action at the promoters of these genes (Dubik & Shiu, 1988; Sabbah et al, 1999). 
More recent studies ChIP-chip (ChIP coupled with genomic microarrays) and ChIP-
seq (ChIP coupled with massively parallel sequencing) studies, however, have 
identified ERα binding regions at distal enhancer binding sites, required for estrogen 
regulation of c-myc and CCND1 gene expression (Carroll et al, 2006). The 
identification of c-myc and CCND1 as direct ERα target genes also provides a 
mechanistic insight into estrogen-ERα mediated promotion of breast cancer cell 
proliferation (Foster et al, 2001). Gene expression microarray studies to identify 
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estrogen-regulated genes in breast cancer cells have led to the discovery of several 
hundred estrogen-regulated genes. Interestingly in these arrays many genes appear to 
be upregulated and downregulated in response to estrogen. Upregulated genes include 
those involved in proliferation and anti-apoptosis, while downregulated genes include 
those that are anti-proliferative and proapoptotic (Frasor et al, 2003). 
 
Current genome-wide approaches for identifying ERα binding sites to define direct 
gene targets using ChIP-chip or ChIP-Seq, have revealed that only 5-7% of ERα 
binding events map to the proximal gene promoter regions. The majority are located 
greater than 5kb away (often >50kb) from the transcriptional start site (TSS) of target 
genes, underlying the significance of distal transcription regulatory mechanism by 
ERα (Carroll et al, 2005; Carroll et al, 2006; Lin et al, 2007; Welboren et al, 2009).  A 
recent study using chromatin interaction analysis followed by paired-end tag 
sequencing (ChIA-PET) for detection of global chromatin interactions has revealed 
that most distal ERα binding sites are anchored to gene promoters through long-range 
chromatin interactions, suggesting that ERα functions by the formation of extensive 
chromatin looping in coordinating gene transcription (Fullwood et al, 2009). The 
majority of the ERα binding events contain consensus palindromic ERE motifs or 
half-ERE sites (70% and 25% respectively), indicating that ERα predominantly 
utilises the ERE sequence as a recognition sequence for DNA binding(Lin et al, 2007; 
Welboren et al, 2009). These studies also identified ERE motifs in genes with no 
previously recognised mechanism of estrogen regulation including the progesterone 
receptor (PR), nuclear receptor-interacting protein 1 (NRIP1), GREB1, GATA3 and 
Bcl-2. As mentioned above, these also uncovered putative ERE motifs in CCND1, c-
myc and IGF-1 gene that were previously believed to be regulated solely through 
indirect recruitment of ERα by interaction with other transcription factors such as AP-
1 and Sp1 (Carroll et al, 2005; Carroll et al, 2006). Interestingly, analyses of ERα 
binding region in searching for other cis-elements have identified significant 
enrichment in a number of transcription factor binding motifs, in particular with 
forkhead and GATA binding motifs, suggesting that ERα may cooperate with other 
transcription factors on the DNA in mediating gene transcription (Carroll et al, 2005; 
Carroll et al, 2006; Lin et al, 2007). 
! 42!
1.12 Pioneer factors that aid recruitment of ERα to the DNA 
 
The majority of transcription factors require euchromatin structure to facilitate their 
interaction with DNA. However, some transcription factors have the capacity to 
associate with condensed chromatin independent of other factors and are able to 
directly modulate chromatin accessibility. The binding of these factors allows 
permissive binding of other transcription factors, and these factors have therefore 
been termed “pioneer factor” (Jozwik & Carroll, 2012; Magnani & Lupien, 2013; 
Zaret & Carroll, 2011).  
 
The forkhead transcription factor FOXA1 was the first identified and has been the 
most studied pioneer factor for ERα signalling (Carroll et al, 2005; Eeckhoute et al, 
2006). FOXA1 has a winged helix that shows structural similarity to histone H1, 
which allows its interaction with histones H3 and H4. This unique structure permits 
FOXA1 to interact with compacted chromatin and to displace linker histone, which 
leads to de-compaction of chromatin and facilitates binding of other transcriptional 
factors (Cirillo et al, 1998). Bioinformatic analysis of sequences around ERα binding 
regions following ChIP-chip for chromosomes 20 and 21 highlighted enrichment of 
FOXA1 binding sites at ERα (Carroll et al, 2005; Laganiere et al, 2005b) a finding 
later confirmed by genome wide ChIP-chip and ChIP-seq studies (Hurtado et al, 
2011; Lupien et al, 2008). Depletion of FOXA1 by RNA interference resulted in a 
significant decrease in almost all ERα binding event in breast cancer cells (Hurtado et 
al, 2011; Lupien et al, 2008). However, FOXA1-chromatin interactions were not 
influenced by estrogen treatment, suggesting that FOXA1 contributes to chromatin 
opening prior to the recruitment of ERα (Hurtado et al, 2011; Lupien et al, 2008). 
Moreover, ectopic expression of FOXA1 with ERα in U2OS cells reprogrammed 
ERα-regulated genes (Hurtado et al, 2011). GATA transcription factors such as 
GATA2 and GATA4 have also been shown to function as pioneer factors in 
promoting transcription factor recruitment in tissue such as bone, liver and prostate 
(Jozwik & Carroll, 2012). A recent study discovered that GATA3 mediates ERα 
recruitment to the chromatin in breast cancer cells (Theodorou et al, 2013). It has been 
demonstrated that GATA3 is important in mediating p300 co-activator binding and 
histone modification throughout the genome prior to estrogen stimulation. GATA3 
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silencing resulted in a global redistribution of p300 and FOXA1 binding, which 
affected the ERα binding pattern that subsequently occurred following estrogen 
addition. GATA3 silencing led to loss of ERα recruitment at a fraction of GATA3 
bound sites and gain in ERα binding in concert with novel FOXA1 bound regions 
(Theodorou et al, 2013). Furthermore, around 30% of all ERα binding event are sites 
of FOXA1 and GATA3 binding and ectopic expression of all three factors in ERα-
negative breast cancer cells can restore estrogen-responsiveness (Kong et al, 2011).  
 
1.13 Pioneer factors in endocrine resistance !
Microarray expression analyses of human breast tumours clearly reveal distinctive 
gene expression patterns, with the most common type being the luminal group of 
tumours that express ERα. The ERα-positive tumours can be sub-divided into luminal 
A and luminal B types, with the latter group having a relatively poor prognosis (Perou 
et al, 2000; Sorlie et al, 2003). ERα-regulated gene expression profiles can be used to 
predict survival in ERα breast cancer patients (Oh et al, 2006), suggesting that 
dysregulation of ERα transcriptional programmes are intimately related to the 
progression of breast cancer. FOXA1 and GATA3 expression correlates with luminal 
A breast cancer and better prognosis (Asselin-Labat et al, 2007; Badve et al, 2007; Oh 
et al, 2006). FOXA1 was shown as a key determinant of ERα function in mediating 
the inhibitory actions of tamoxifen in breast cancer cells (Hurtado et al, 2011). 
Genome-wide mapping of ERα genomic targets showed an almost identical ERα 
binding profile for estrogen and tamoxifen, indicating that FOXA1 is also required in 
directing the tamoxifen-ERα complex to genomic targets (Hurtado et al, 2011). 
However, FOXA1 has also been implicated in the context of tamoxifen resistance. 
Firstly, it has been demonstrated that differential FOXA1 binding patterns in different 
cell types dictates ERα occupancy, supporting its contribution in the tissue/cell 
specific function of estrogen/ERα function (Hurtado et al, 2011; Krum et al, 2008). 
FOXA1 binding patterns in a tamoxifen-resistance (Tam-R) breast cancer cell line 
model were found to significantly differ from its parental cell line, suggesting that 
dysregulation of FOXA1 could contribute to ERα transcriptional reprogramming in 
tamoxifen resistant cells (Hurtado et al, 2011). Silencing of FOXA1 resulted in 
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decreased ERα binding and inhibited the tamoxifen-induced growth in the Tam-R 
model, confirming that the altered ERα binding and the growth of the Tam-R cells 
was still dependent on the presence of FOXA1 (Hurtado et al, 2011). Consistent with 
these findings, a recent study demonstrated that mitogenic EGF stimulus could re-
program FOXA1 binding patterns in breast cancer cells and that this resulted in an 
alteration in ERα binding patterns, in accordance with the new FOXA1 binding sites 
(Ross-Innes et al, 2012). Furthermore, a differential ERα binding pattern in primary 
breast cancer samples was observed between patients who have poor clinical outcome 
compared to those who have good clinical outcome. Novel ERα-binding events found 
in breast cancers that are more likely to relapse were consistently enriched for the 
FOXA1 motif (Ross-Innes et al, 2012). As mentioned above, GATA3 has also been 
shown to mediate ERα recruitment to the genome, and GATA3 depletion resulted in 
redistribution of ERα binding (Theodorou et al, 2013).  Since GATA3 is one the most 
frequently mutated genes in breast cancers (>10%) (Cancer-Genome-Atlas-Network, 
2012), it has been hypothesised that breast cancers with GATA3 mutations may have 
an altered ERα transcriptional programme that may be associated with differences in 
patient prognosis (Theodorou et al, 2013). Collectively, these finding suggested 
FOXA1 and GATA3 play important roles in regulating ERα function and may also 
associate with breast cancer progression.  
 
1.14 The nuclear receptor superfamily 
 
In human, the nuclear receptor (NR) superfamily consists of 48 members. Based on 
their cognate ligands and DNA binding properties, they can be subdivided into three 
classes; 1) the endocrine steroid hormone receptor family, 2) the adopted orphan 
receptor family and 3) the orphan receptor family (Figure 1.5) (Chawla et al, 2001; 
Evans, 1988; Mangelsdorf et al, 1995). 
 
The endocrine steroid hormone NR family members are the first and best 
characterized class of NR; members in this group include estrogen (ER), progesterone 
(PR), androgen (AR), glucocorticoid (GR), and mineralocorticoid (MR) receptors. 
The ligands for these receptors are steroid hormones that bind to the receptor with a 
high affinity (Mangelsdorf et al, 1995). Additional members of the steroid hormone 
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receptor subfamily are retinoic acid receptors (RAR), thyroid hormone receptor (TR) 
and the vitamin D3 receptor (VDR). The ligands for these receptors are also 
synthesised endogenously, retinoic acids, thyroid hormone and vitamin D3 
respectively. However, the physiological concentration of these ligands can be greatly 
affected by dietary intake and exogenous elements, for example retinoic acids are 
derived from the dietary vitamin A, iodine is necessary for production of thyroid 
hormones and vitamin D3 is only synthesized in the skin from cholesterol when 
exposed to the sunlight or is obtained through dietary sources. RAR, TR and VDR 
form heterodimers with the retinoid X receptor (RXR) to regulate gene transcription, 
which is unlike other steroid NR members which form homodimers (Chawla et al, 
2001).  
 
The second class of the NR superfamily is the adopted orphan NR. In contrast to 
endocrine steroid hormone receptors, adopted orphan NRs have a large ligand-binding 
pocket and respond to a wide range of dietary lipid molecules and xenobiotics that 
bind to the receptor with low affinity. All members in this class function as 
heterodimers with RXR and include peroxisome proliferator-activated receptors 
(PPARs), liver X receptor (LXR) and farnesoid X receptor (FXR). These NRs play 
key roles in the regulation of lipid metabolism by controlling the expression of 
metabolic genes in response to fatty acid, cholesterol and bile acid levels. Pregnane X 
receptor (PXR) and constitutive androstane receptor (CAR) act as xenobiotic sensors 
to respond to foreign chemicals and the build up of toxic lipid/bile acids metabolite 
species in the liver and the digestive tract (Chawla et al, 2001; Handschin & Meyer, 
2005). 
 
The third class of NRs include orphan NRs that have structurally conserved features 
as other NRs, but for which no endogenous ligands have been definitively identified. 
Out of 48 members within nuclear receptor superfamily, 25 of them are considered to 
be orphan NRs (Riggins et al, 2010). Some of these NRs are constitutively active. 
However, the existence of ligands for orphan NRs has been controversial. For 
example, hepatocyte nuclear factor 4 (HNF4-α and HNF4-γ) and NR5A subfamily 
(LRH-1 and SF-1) bind fatty acids and phospholipids respectively (Krylova et al, 
2005; Wisely et al, 2002). However, due to the uncertainty around the physiological 
and functional relevance of these ligand/receptor interactions not as yet being well 
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defined, NR5A and HNF4 are still considered to be orphan NRs (Benoit et al, 2006; 
Riggins et al, 2010). 
1.15 Nuclear receptor DNA binding properties  !
AR, PR, GR, and MR form homodimers and bind to inverted repeats of hexameric 
DNA sequences conforming to the consensus 5’-AGAACA-3’, whilst ER (ERα and 
ERβ) form homodimers or heterodimers and bind to symmetric repeats of 5’-
AGGTCA-3’, called the ERE half-site (see section 1.6). Other steroid NRs and 
adopted orphan NRs form heterodimers with RXR and bind to direct repeats of ERE 
half-sites with different spacing ranging from 1-5 nucleotides between the half sites 
(Khorasanizadeh & Rastinejad, 2001; Rastinejad et al, 1995). 
 
Orphan NRs illustrated various modes of DNA binding. Although most of them 
appear to bind to DNA as homodimers on direct repeats of ERE, such as HNF4 and 
testicular receptors 2 and 4 (TR2/TR4), some interact with RXR, for example nerve 
growth factor 1-B (NGF1-B) and nuclear receptor related 1 protein (NURR1) (Benoit 
et al, 2006). Several orphan NRs possess class specific C-terminal extension (CTE) to 
the core DBD that allow binding to extended ERE half-sites. Most of these NRs bind 
to DNA as monomer and include RAR-related orphan receptors (RORs), estrogen-
related receptors (ERRs) and NR5A family members (LRH-1 and SF-1) (Figure 1.6) 









Figure 1.5 The human nuclear receptor superfamily of transcription factors 
The classification of human nuclear receptors, based on their cognate ligands, ligand 
























































Figure 1.6 Different classes of DNA response elements used by nuclear receptors 
A) GR, PR, AR and MR bind to inverted repeats of the hexameric DNA sequence 5’-
AGAACA-3, while ER binds to inverted repeats of the ERE half site 5’-AGGTCA-3’. 
B) RXR homo or heterodimers bind to direct repeats of the ERE half site with 
different nucleotide spacing. C) Monomeric orphan nuclear receptors, RORs, ERRs, 
LRH-1 and SF-1 possess class unique C-terminal extension (CTE) in the DNA 
binding domain (DBD) that allow the recognition of extended ERE half-sites 




















































1.16 Nuclear receptor as drug targets 
NRs play key aspects in development, reproduction, homeostasis and metabolism. 
Altered and abnormal NR signalling causes wide range of diseases, such as metabolic 
diseases, diabetic, infertility and cancers. NRs are favorable drug targets, as the 
structural information of the receptor and it cognate ligands are readily available in 
aiding the design of drug molecule. Development of small molecule drugs that target 
NRs has proven to be successful, and many of them have been approved for clinical 
use (Table 1.1) (Imming et al, 2006; Sladek, 2003). 
 
Table 1.1 Drugs targeting nuclear receptors that are in medical use 
  
Nuclear receptors Activity of drugs Drug example Treatment example 
MR  Agonists Aldosterone Addison’s disease, hypoadrenalism 
  Antagonists Spironolactone Nephrotic syndrome, cardiac failure, ascites, liver cirrhosis, aldosteronism. 
GR Agonists Glucocorticoids Adrenal insufficienc, suppress allergic, inflammation and autoimmune disorders 
PR Agonists Gestagens Hormone replacement therapy, infertility and menstrual disorders 
ER Agonists Oestrogens Hormone replacement therapy, Osteoporosis 
  Partial antagonists Clomifene Infertility 
  Antagonists Fulvestrant Breast cancer 
  Selective modulator Tamoxifen Breast cancer 
  Selective modulator Raloxifene Osteoporosis, breast cancer 
AR Agonists Testosterone Hormone replacement therapy 
  Antagonists Cyproterone acetate Prostate cancer 
VDR Agonists Vitamin D, Alfacalcidol Dietary supplement, Vitamin D deficiency. 
RAR  Agonists Adapalen, Isotretinoin Skin disorder 
PPAR PPAR alpha agonists Fibrate Hypercholesterolemia 
  PPAR gamma agonists Glitazone Diabetes mellitus type 2 
TR Agonists Levothyroxine Thyroid carcinoma, hypothyroidism 
      
Adapted from: Imming et al., 2006.    
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1.17 Co-operative function between ERα and other NRs in breast 
cancer !
NRs comprise one of the largest classes of transcriptional regulators. As such, the 
mechanisms of transcriptional regulation by NR have been extensively studied, in 
particular for ERα (Green & Carroll, 2007; Magnani & Lupien, 2013; Metivier et al, 
2006). Apart from pioneer factors such as FOXA1 and GATA3 that are crucial in 
mediating ERα recruitment to the genome, emerging evidence supports co-operative 
functions and cross talk between NRs. This is highlighted by a recent report showing 
that the genomic targets of RARα shared high co-occupancy with ERα in breast 
cancer cells (Hua et al, 2009; Ross-Innes et al, 2010). Moreover, RARα is known to 
be an estrogen-induced target gene in breast cancer (Laganiere et al, 2005a). RARα 
was found as an essential component of ERα transcriptional complexes in stabilising 
the recruitment of co-activator proteins such as p300 and AIB1, which aids chromatin 
remodeling and promotes the expression of estrogen-regulated genes (Ross-Innes et 
al, 2010). Despite its co-operative functions with ERα, these studies also indicate 
RARα could antagonise ERα functions. In the presence of retinoic acids, RARα 
switches back to its classical function in forming heterodimers with RXR and 
regulates the expression of retinoic acids responsive gene via binding to retinoic acids 
responsive elements (RARE), and prevented complex formation with ERα. This is in 
accordance with treatment of retinoic acids in breast cancer cells reducing the 
expression of estrogen-regulated genes and inhibiting breast cancer cell growth (Hua 
et al, 2009; Ross-Innes et al, 2010).  
AR expression is strongly associated with ERα positivity and AR inhibits expression 
of estrogen-responsive genes in ERα-positive breast cancer cells (Peters et al, 2009). 
However, a small subset of breast tumours, termed the ‘molecular apocrine’ subtype, 
which are ERα-negative but AR positive are strongly associated with the expression 
of estrogen-responsive genes that are typically expressed in ERα-positive breast 
cancer. Interestingly, androgen treatment was found to stimulate the proliferation and 
expression of estrogen-regulated genes in MDA-MB-453 breast cancer cells (a 
molecular apocrine cell lines model which is ER-negative and AR-positive), 
suggesting that AR regulates the expression of ERα targets in these cells (Doane et al, 
2006). A recent microarray and AR ChIP-seq analysis in MDA-MB-453 cells 
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demonstrated that AR regulates many typical ERα target genes, and the AR 
recruitment to the ERα target region was found to dependent on FOXA1 (Robinson et 
al, 2011). 
 
1.18 Liver receptor homologue-1 (LRH-1)  
 
 Liver receptor homologue-1 (LRH-1; NR5A2; Ftz-F1; FTF; CPF) is a member of the 
NR5A subfamily of NRs that also includes the close homologue, steroidogenic factor-
1 (SF-1; NR5A2). LRH-1 is highly expressed in tissues of endodermal origin, such as 
liver and intestine, and its expression is also found in steroidogenic tissues such as the 
adrenal cortex, gonadal tissues and adipose tissue.  In recent years, LRH-1 has been 
established as a key transcriptional regulator involved in development, metabolic 
processes and hormone synthesis (Fayard et al, 2004; Lazarus et al, 2012). 
 
1.19 LRH-1 gene structure and isoforms 
 
The LRH-1 gene is organised into eight exons, and spans more than 150 kb of 
chromosome 1q32.11. A number of alternative LRH-1 splice variants have been 
reported, including the hLRH-1 and LRH-1v2 which both lack exon 2 encoded amino 
acids of 22-67 in the A/B domain. LRH-1v2 further lacks part of exon 5, which maps 
at the border of the hinge region and the LBD, resulting an inactive form of the 
protein (Fayard et al, 2004). Our laboratory has identified two additional variants in 
breast cancer cells (LRH-1v4 and v5) that arise from alternative promoter usage. 
LRH-1v4 transcripts are initiated in intron 1, extending the previously identified exon 
2 further 5’ into intron 1 (named exon 2a). While mapping of the 5’ end of LRH-1v5 















Figure 1.7 Representation of the human liver receptor homologue-1 gene 
structure, mRNA transcripts and encoded polypeptides 
Three LRH-1 splice variants have been described previously in human, LRH-1v1, 
LRH-1 and LRH-1v2 (Fayard et al 2004). LRH-1v4 and LRH-1v5 have recently been 
recently identified by 5’RACE analysis in MCF-7 breast cancer cells. LRH-1v4 and 
LRH-1v5 transcripts utilize alternative promoters and initiate at previously described 
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1.20 LRH-1 structure 
 
LRH-1 has a similar modular structure to other NRs, including an N-terminal A/B 
domain, a DBD comprised of two zinc fingers, a hinge region and the LBD with AF-2 
function. The NR5A subfamily of NRs is differentiated from other NRs by the 
presence of a C-terminal extension (CTE) to the DBD called the “Ftz-F1 box”, named 
after the drosophila homologue Ftz-F1 that regulates expression of the fushi-tarazu 
gene. The Ftz-F1 box allows NR5A receptors to interact with DNA as monomers and 
bind to DNA response elements having the consensus sequence 5’-YCAAGGYCR-3’ 
(Y=C or T, R=A or G), where the YCA is the 5′-extension beyond the ERE half site 
sequence,  ‘5-AGGTCA-3’ (Fayard et al, 2004; Khorasanizadeh & Rastinejad, 2001).  
 
The LBD of ligand-activated NRs consists of a twelve α-helical structure (H1 to H12) 
that is folded into three layers. Binding of cognate ligand induces a reversible 
conformational change that involves the repositioning of the H12 at the C-terminal 
region, which allowing co-activator recruitment to the AF-2 domain. Initial 
crystallographic studies of the mouse LRH-1 (mLRH-1) LBD revealed an active 
conformation, with a large but empty ligand-binding pocket (Sablin et al, 2003). The 
mLRH-1 LBD has a long extended H2 which folds into an additional forth layer, 
unlike any other NRs. This unique H2 structure was found to stabilise and hold H12 
in a constitutively active position, which contributes to the ligand independent activity 
of the receptor (Sablin et al, 2003). Several independent research groups obtained 
similar structural features for the human LRH-1 LBD (Krylova et al, 2005; Ortlund et 
al, 2005; Wang et al, 2005). However, these studies found phospholipids within the 
hLRH-1 LBD, indicating a possibility of ligand regulation for LRH-1 activity. 
However, the endogenous phospholipid ligands for LRH-1 are yet to be confirmed. In 
addition, the physiological relevance of the interaction between LRH-1 and 
phospholipids still remains to be fully appreciated. !!!!!
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1.21 Modulation of LRH-1 activity by phospholipids 
 
Structural analysis of the hLRH-1 LBD demonstrated the presence of phospholipid in 
the ligand binding pocket. Non-denaturing mass spectrometry identified two common 
phospholipids, phosphatidylglycerol (PG) and phosphatidylethanolamine (PE) in the 
hLRH-1 LBD (Krylova et al, 2005; Ortlund et al, 2005). Quantification revealed a 1:1 
ligand/receptor ratio, indicating nearly all the hLRH-1 purified protein produced in 
bacteria is bound by a phospholipid (Krylova et al, 2005). However, another study 
suggested that only 20% of recombinant hLRH-1 LBD is bound by phospholipids 
(Ortlund et al, 2005). Immobilized hybridization methods showed that LRH-1 can 
also bind to other phospholipids including phosphatidylinositol phosphate (PIP) 
(Krylova et al, 2005). Substitution mutations in the hLRH-1 LBD that void 
phospholipid binding resulted in a decrease in the recruitment of SRC2 and SRC3 and 
a reduction in transcriptional activity (Ortlund et al, 2005). Although mLRH-1 
appears to be constitutively active in the absence of bound phospholipids, 
humanization of mLRH-1 by substitution of a key amino acid residue that is critical 
for phospholipid interactions resulted in phospholipid binding to mLRH-1 and 
enhanced mLRH-1 transcriptional activity, suggesting that phospholipid binding is 
required for the maximal activity of LRH-1 (Krylova et al, 2005), as well as 
indicating that murine LRH-1 LBD may not bind to these phospholipids. A recent 
study screened a series of phospholipid species, using a gene reporter assay and 
discovered the length of fatty acid chains and the head group composition are key 
determinants of LRH-1 transcriptional activation (and presumably binding to the 
LRH-1 LBD). The authors identified that two phosphatidylcholine (PC), 1,2-
dilauroyl-sn-glycero-phosphocholine (DLPC) and 1,2-diundecanoyl-sn-glycero-
phosphocholine (DUPC) are selective agonists for LRH-1 (Lee et al, 2011) (Figure 
1.8). DLPC and DUPC were able to displace pre-bound bacterial phospholipids, PG 
and PE from the hLRH-1 LBD in vitro, whereas longer chain PC such as 1,2-
dipalmitoyl-sn-glycero-phosphocholine (DPPC) are not capable of displacing PG and 
PE and do not stimulate LRH-1 activity (Lee et al, 2011). A follow up study revealed 
that the mode of DLPC binding to LRH-1 is radically different from ligand-receptor 
interaction in typical steroid NRs, suggesting a different mode of mechanism in 
achieving receptor activation (Musille et al, 2012).  
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1.22 Regulation of LRH-1 activities 
1.22.1 Co-regulators 
 
LRH-1 appears to adopt a constitutively active structure in the absence of ligands 
and/or through tight binding to phospholipids. Although the possible role of other 
phospholipids such as PCs remains to be fully unraveled, co-regulator proteins play 
key roles in regulating LRH-1 functions. LRH-1 generally interacts with co-regulator 
proteins that possess LXXLL motifs in a manner similar to that of other NRs. Hence, 
typical NR co-activators, including the p160 (SRC1-3) and the p300/CBP family 
proteins interact with and enhance LRH-1-mediated transcription (Fayard et al, 2004; 
Ortlund et al, 2005). The tissue specific NR co-activator, PPARγ co-activator-1α 
(PGC-1α) colocalises with LRH-1 in adipose tissue, ovary and liver and PGC-1α 
appears to be important for LRH-1 function in these tissues (Safi et al, 2005; Shin & 
Osborne, 2008; Yazawa et al, 2010). LRH-1 does not appear to interact with typical 
co-repressor proteins such as NCoR and SMRT, which require the displacement of 
AF-2 from the active orientation for their binding (Sablin et al, 2003; Xu et al, 2003). 
Important co-repressors of LRH-1 are the atypical NRs, short heterodimer partner 
(SHP) and dosage-sensitive sex reversal adrenal hypoplasia congenita critical region 
on the X chromosome (Dax-1), the interaction being mediated by LXXL motifs in 
these receptors. SHP and Dax-1 inhibit LRH-1 activity by competing with p160 and 
PGC-1α co-activators for binding to LRH-1 at the LBD (Lee & Moore, 2002; Shin & 
Osborne, 2008). Moreover, SHP recruits the histone deacetylase sirtuin 1 (SIRT1) in 
silencing gene transcription (Chanda et al, 2010). LRH-1 directly regulates the 
expression of SHP expression in the liver, indicating that there is an autoregulatory 
feedback loop important in mediating LRH-1 action in the liver (Goodwin et al, 
2000). Dax-1 and LRH-1 are co-expressed in the ovary, where DAX-1 has been 
shown to inhibit LRH-1-mediated transcription of steroidogenic genes (Kim et al, 
2004; Peng et al, 2003; Yu et al, 2005). It has also been demonstrated that LRH-1 
preferentially interacts with PGC-1α, SHP and DAX-1 rather than other co-activator 
protein such as p160 and p300 family proteins. PGC-1α, SHP and DAX-1 possess 
distinctive amino acids sequences around the LXXL interacting motif, which allows 
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an additional hydrophobic interaction between H3 and H4 in the LRH-1 LBD 
(Ortlund et al, 2005).  
In addition to co-activator proteins, LRH-1 has been shown to directly interact with 
other transcriptional factors and synergistically promote gene transcription, including 
GATA transcriptional factors (GATA3/4/6), cAMP response element-binding protein 
(CREB) and β-catenin (Botrugno et al, 2004; Bouchard et al, 2005; Hadizadeh et al, 
2008; Robert et al, 2006; Weck & Mayo, 2006; Yumoto et al, 2012). The co-operation 
between LRH-1 and these transcriptional factors appears to be important in the 
regulation of the expression of steroidogenic genes in gonads and adipose tissue, and 
for expression of proliferative genes in the colon, liver and pancreas. 
 
1.22.2 Post-translational modification 
 
LRH-1 activity is subject to regulation by post-translational modification. Cyclic 
adenosine monophosphate (cAMP)/PKA signals are well known to stimulate 
steroidogeneic gene expression in the ovary. PKA induced phosphorylation of LRH-1 
at ser-469 promotes its interaction with GATA3 and GATA4, and synergistically 
enhances the transcription of aromatase gene reporters (Bouchard et al, 2005). 
Phosphorylation by ERK1/2 MAPK of ser-238 and ser-243 in the hinge region also 
stimulates LRH-1 activity (Lee et al, 2006). LRH-1 is also a target for SUMO 
modification. SUMO-1 conjugation at lysine 173, 224, 289 in the DBD and the hinge 
region results in transcription repression and subnuclear relocalization of LRH-1 
(Chalkiadaki & Talianidis, 2005; Yang et al, 2009). Moreover, PKA signals regulate 
LRH-1 activity by inhibiting sumoylation. Activation of the cAMP pathway by 
forskolin has been shown to suppress nuclear body co-localisation of LRH-1 by 
downregulating the expression of a number of enzymes involved in the SUMO 






1.22.3 LRH-1 synthetic molecules  
 
Using a high-throughput screening (HTS) based on assessment of interaction between 
the LRH-1 LBD and a TIF2 (SRC2) co-activator peptide in a fluorescence resonance 
energy transfer (FRET)-based assay, Whitby et al. identified a series of substituted 
cis-bicyclo[3.3.0]oct-2-enes as LRH-1 agonists (Whitby et al, 2006). The lead 
compound 5a (GSK8470) stimulated LRH-1 activity in reporter gene assays and 
modulated endogenous gene expression mediated by LRH-1, in this case SHP 
expression in liver cells (Whitby et al, 2006). However, the drawbacks of this 
compound series are their poor stability and lack of discrimination between LRH-1 
and SF-1 (Whitby et al, 2006; Whitby et al, 2011). A more recent study reported 
analogues using the same core structure. The new lead, 24-exo, has improved 
stability, hydrophobicity and potency on LRH-1, although no apparent improvement 
in selectivity was seen between LRH-1 and SF-1 (Figure 1.8) (Whitby et al, 2011). 
Recently, two research groups have reported the identification of LRH-1 antagonists. 
The Scripps research institute used a cell-based reporter gene assay in screening of a 
library of 60 compounds to identify two lead compounds, ML180 and ML179. These 
two compounds inhibited LRH-1-mediated transcription of a aromatase gene PII 
promoter based reporter gene (Busby et al, 2010). A more recent screen carried out by 
Benod et al., identified another two LRH-1 inhibitors, named Cpd3 and 3d2 using 
molecular docking screening approaches for commercially available compounds that 
could be accommodated in the LRH-1 LBD (Benod et al, 2013). These compounds 
bind to LRH-1 protein in vitro, and inhibit LRH-1 transcriptional activity in cell-








Figure 1.8 The chemical structure of LRH-1 synthetic compounds 
A) Phospholipids species identified from the mass spectrometry accommodate within 
LRH-1 ligand binding domain (LBD) produced in bacteria. Phosphatidylethanolamine 
(PE) and   phosphatidylglycerol (PE) B) Other phospholipids species identified as 
potential agonists for LRH-1. Phosphatidylinositol-trisphosphate (PIP3), 1,2-
dilauroyl-sn-glycero-3-phosphocholine (DLPC) and 1,2-diundecanoyl-sn-glycero-
phosphocholine  (DUPC) C) Small molecule synthetic agonists identified for LRH-1, 


















1.23 LRH-1 in development 
 
LRH-1 expression can be detected in the early developing epiblast and homozygous 
deletion of LRH-1 (LRH-1-/- mice) causes embryonic lethality at day E6.5-E7.5, with 
impaired node formation and gastrulation (Pare et al, 2004). LRH-1 is essential in 
maintaining the expression of octamer-binding transcription factor 4 (Oct4), which is 
a critical factor in regulating embryonic stem cell (ESC) pluripotency and 
differentiation (Gu et al, 2005). Oct4 is required in the reprogramming of mouse 
somatic cells to induced pluripotent stem cells (iPSCs). Interestingly, LRH‐1 is able to 
replace Oct4 in generating mouse iPSCs, indicating its potentially important role in 
maintenance of stem cell pluripotency via regulation of Oct4 expression (Heng et al, 
2010; Wang et al, 2011). In addition to Oct4, LRH-1 also regulates the expression of 
the homeobox gene Nanog and T-box transcription factor (TBX3), additional factors 
important in maintaining ESC pluripotency (Wagner et al, 2010). In later embryonic 
developmental stages, LRH-1 continues to be expressed in the foregut endoderm 
during liver and pancreatic morphogenesis (Rausa et al, 1999). Here, LRH-1 regulates 
the expression of transcriptional factors that are important in foregut differentiation 
including hepatic nuclear factor-1α (HNF-1α), HNF-3β and HNF4-α (Pare et al, 
2004). LRH-1 also regulates the expression of α1-fetoprotein (AFP), which is an 
endodermal marker of early fetal hepatocyte differentiation (Galarneau et al, 1996). In 
early pancreatic development, pancreatic and duodenal homeobox (PDX-1) regulates 
the expression of LRH-1. PDX-1 is an essential factor for pancreatic development and 
differentiation, indicating that LRH-1 is an important downstream target in the PDX-1 
regulatory cascade (Annicotte et al, 2003). 
 
1.24 LRH-1 in hormone synthesis 
 
SF-1, the LRH-1 related NR5A family member has a well-established role in 
hormone synthesis. SF-1 expression is confined to steroidogenic tissues, such as the 
adrenal cortex, gonadal tissues and pituitary glands and hypothalamus, and it plays a 
central role in steroid hormone synthesis by regulating the expression of steroidogenic 
enzymes (Schimmer & White, 2010; Val et al, 2003). LRH-1 has been shown to 
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stimulate the expression of known SF-1 targets. These genes encode steroidogenic 
enzymes such as the steroidogenic acute regulatory protein (StAR), cholesterol side-
chain cleavage (CYP11A1), 3β-hydroxysteroid dehydrogenase type II (HSD3β2), 
17α-hydroxylase (CYP17A1), 11β-hydroxylase (CYP11B1), 18-hydroxylase 
(CYP11B2) and aromatase (Sirianni et al, 2002). In adults, LRH-1 expression is also 
found in adrenal glands, gonadal tissues (ovary and testis), adipose and colon. In these 
organs, LRH-1 has been shown to play important roles in regulating the production of 
steroid hormones, including estrogen, progesterone, and glucocorticoid (Clyne et al, 
2004; Labelle-Dumais et al, 2007; Mueller et al, 2006; Sierens et al, 2010; Wang et al, 
2001). 
 
1.25 LRH-1 in reproduction 
 
Female reproductive functions are tightly controlled by pituitary gonadotrophins and 
locally produced steroid hormones including estrogen and progesterone for successful 
ovulation and follicular development. Both SF-1 and LRH-1 have been implicated as 
key factors in maintaining normal reproductive physiology by regulating estrogen and 
progesterone production in the ovary (Kim et al, 2005; Kim et al, 2004; Peng et al, 
2003; Saxena et al, 2004). In the ovary, LRH-1 expression was found in granulosa 
cells and corpora luteum (CL), whilst SF-1 is expressed in theca and granulosa cells, 
but is absent from the CL (Boerboom et al, 2000; Falender et al, 2003). LRH-1 
expression in the ovary varies during the menstrual cycle and is regulated by pituitary 
gonadotropins. FSH has been shown to stimulate LRH-1 expression during follicular 
growth, LH during ovulation, and LH and prolactin during luteinization and 
maturation of the CL (Boerboom et al, 2000; Falender et al, 2003). It has been 
suggested that LRH-1 preferentially regulates progesterone production in the ovary as 
high expression of LRH-1 is observed in CL, which is the primary site for 
progesterone production and where SF-1 is absent. Heterozygous LRH-1 knockout 
female mice (LRH-1+/-) have decreased fertility and significantly lowered 
progesterone levels. The decrease in fertility in mice can be rescued by exogenous 
progesterone supplementation, which supports a vital role of LRH-1 in reproduction 
by regulating progesterone synthesis (Labelle-Dumais et al, 2007). In addition, 
granulosa cell-specific LRH-1 knockout (LRH-1gc-/-) mice are sterile due to 
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anovulation and exhibit marked reduction in progesterone levels, indicating LRH-1 
action cannot be compensated for by SF-1 (Duggavathi et al, 2008). This study also 
showed that LRH-1 regulates a number of proteases involved in the ovulatory process 
such as the matrix metalloproteinases (MMP), MMP2, MMP9 and MMP19 
(Duggavathi et al, 2008). A CL and uterus specific LRH-1 knockout demonstrated 
additional roles of LRH-1 in regulating female fertility, including decidualization of 
the endometrium for embryo implantation and formation of the placenta for embryo 
development. Therefore LRH-1 has multiple, indispensible roles in establishing and 
sustaining pregnancy (Zhang et al, 2013). The expression of inhibin α-subunit (INHA) 
in granulosa cells in the ovary and leydig cells in the testes is regulated by LRH-1 
(Robert et al, 2006; Weck & Mayo, 2006). The inhibin α-subunit forms heterodimer 
with either the βA or βB subunit and function as suppressing pituitary FSH secretion. 
Inhibin glycoprotein hormone plays an important role in regulating gonadal functions 
including spermatogenesis, steroid hormone production, follicle development, 
luteinsation and granulosa cell proliferation (Robert et al, 2006; Weck & Mayo, 
2006). In the testes, LRH-1 was shown to regulate aromatase expression in the leydig 
cells, implicating it as a key regulator of rat spermatogenesis (Sierens et al, 2010). 
 
1.26 LRH-1 in cholesterol, bile acid, glucose and lipid metabolism 
 
In adults, LRH-1 is highly expressed in endoderm-derived organs, such as the 
pancreas, liver and colon, where it is implicated in the regulation of cholesterol, bile 
acid and lipid homeostasis. LRH-1 has been shown to regulate key genes involved in 
reverse cholesterol transport, including scavenger receptor type BI (SR-B1), 
cholesteryl-ester-transfer protein (CETP) and apolipoprotein A1 (ApoA1). The 
expression of these genes was shown to be essential for the uptake of cholesterol into 
the liver and the maintenance of normal circulating cholesterol levels (Delerive et al, 
2004; Luo et al, 2001; Schoonjans et al, 2002).  
 
LRH-1 has been implicated in bile acids synthesis in the liver via the regulation of 7α-
hydroxylase (CYP7A1), which governs the rate-limiting steps in converting 
cholesterol to bile acids (Goodwin et al, 2000; Lu et al, 2000). Several in vitro studies 
have suggested that LRH-1 controls hepatic cholesterol and bile acid metabolism 
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through an autoregulatory cascade involving FXR and SHP. These studies suggested 
that LRH-1 can positively regulate and maintain the basal expression of CYP7A1, 
therefore catalyzing the production of bile acids. Increasing levels of bile acids then 
lead to the activation of FXR, which induces SHP expression. In the presence of high 
levels of bile acids, LRH-1 functions as a repressor of CYP7A1 transcription by 
recruiting co-repressor SHP to the gene promoter (Goodwin et al, 2000; Lu et al, 
2000). More recent studies using animal models suggested LRH-1 mainly acts in a 
repressive role in bile acid synthesis, as demonstrated by LRH-1+/- mice, which have 
increased bile production and CYP7A1 expression (del Castillo-Olivares et al, 2004). 
However, LRH-1 knockout in hepatocytes and the intestinal epithelium had no 
significant effect on basal CYP7A1 expression, suggesting that LRH-1 may play a 
minor role in regulating CYP7A1 expression or the presence of redundant factors in 
regulating CYP7A1 expression (Lee et al, 2008; Mataki et al, 2007). However, these 
studies showed that LRH-1 expression is critical for the expression of 12α-
hydroxylase (CYP8B1), which encodes an enzyme that catalyzes the conversion of 
chenodeoxycholic acid to cholic acid.  Silencing LRH-1 expression in mouse liver 
was shown to affect the composition of the bile acid pool (Lee et al, 2008). In 
addition, liver and intestinal specific LRH-1 knockout mice showed a reduction in 
intestinal absorption of lipids and re-uptake of bile acids due to a decrease in 
expression of a number of bile acid and lipid transporters, including bile salt export 
pump (BSEP), multi-drug resistance protein (MRP2 and MRP3), sodium-dependent 
bile acid co-transporter (NTCP) and ATP-binding cassette (ABC) transporters 
(ABCG5 and ABCG8), demonstrating the importance of LRH-1 in bile acid and lipid 
homeostasis (Lee et al, 2008; Mataki et al, 2007).  
 
High levels of bile acids in the liver are known to reduce fatty liver and improve 
glucose metabolism. As LRH-1 has been implicated in bile acid metabolism, a recent 
study attempted to determine if LRH-1 could be targeted for the treatment of type 2 
diabetes caused by fatty liver (Lee et al, 2011). Administration of LRH-1 agonist 
DLPC and DUPC to mice resulted in increased bile acid levels, and a reduction of 
hepatic triglycerides and serum glucose. This study was extended by using two mouse 
models of insulin resistance, the db/db and diet induced obese (DIO) models. DLPC 
administration in these mice increased insulin sensitivity and reduced hepatic 
triglyceride levels and nonesterified fatty acids in their livers. Moreover, a decrease in 
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the expression of sterol regulatory element binding transcription factor 1 (Srebp1) was 
observed in DLPC treated mice, which is required for cholesterol biosynthesis and for 
uptake and fatty acid biosynthesis and is associated with fatty liver. These results 
suggest LRH-1 may play a role in glucose metabolism and hepatic lipogenesis (Lee et 
al, 2011).  
 
1.27 LRH-1 in the colon and colorectal cancer 
 
LRH‐1 is highly expressed in the proliferative cells of the intestinal crypts. It has been 
suggested to play a key role in regulating intestinal cell renewal (Botrugno et al, 
2004). LRH-1+/- mice have reduced intestinal proliferation and decreased crypt depth, 
while over-expression of LRH-1 in murine pancreatic and hepatic cell lines stimulates 
proliferation by promoting G1/S transition by upregulating cyclin D1 and cyclin E1 
via an interaction with β-catenin (Botrugno et al, 2004). As demonstrated by its 
proliferative role in the colon, LRH-1 has been implicated in intestinal tumour 
formation. In mouse models of carcinogen-induced (azoxymethane, AOM) and 
genetically induced (APC heterozygous knockout, APC min/+) intestinal cancer, LRH-
1+/- mice had a reduced incidence of intestinal cancer (Schoonjans et al, 2005). 
Unexpectedly however, a decrease in LRH-1 in was observed in LRH-1+/+ APCMin/+ 
and AOM-induced intestinal tumour, compared to the normal intestine. Interestingly, 
LRH-1 expression was found to negatively correlate with proinflammatory cytokine 
tumour necrosis factor-α (TNF-α) in intestinal tumours (Schoonjans et al, 2005). 
These findings indicate that aberrant LRH-1 expression in the intestine could lead to 
initiation of intestinal tumourigenesis by both affecting cell cycle control as well as 
through its impact on inflammatory pathways (Schoonjans et al, 2005). 
 
1.28 LRH-1 in inflammation 
 
Several independent studies have reported a role for LRH-1 in supressing the 
inflammatory response by regulating local glucocorticoid production. Over-
expression of LRH-1 in murine intestinal epithelial cells has been shown to increase 
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glucocorticoid synthesis via upregulation of CYP11A1 and CYP11B1 expression 
(Mueller et al, 2006). LRH-1+/- mice were predisposed to intestinal inflammation as a 
result of a defect in local glucocorticoid production (Coste et al, 2007; Mueller et al, 
2006). Consistent with these findings, a reduction in LRH-1 mRNA levels was 
observed in patients with inflammatory bowel disease (IBD), together with a decrease 
in CYP11A1 and CYP11B1 expression, suggesting a protective effect of LRH-1 
against the onset of IBD (Coste et al, 2007). In colon cancer, glucocorticoid 
production was found to be significantly greater compared to the normal mucosa, due 
to higher expression levels of CYP11A1 and CYP11B1 (Sidler et al, 2012). It has also 
been demonstrated that LRH-1 can suppress T-cell activation by promoting 
glucocorticoid production in colon cancer cell lines, suggesting that LRH-1 may 
contribute to tumour immune escape (Sidler et al, 2012). In addition, LRH-1 has also 
been shown to have a protective role in hepatic acute phase response. LRH-1 was 
shown to repress the expression of interleukin-1 receptor antagonist (IL-1RA), 
thereby inhibiting inflammatory responses mediated by pro-inflammatory cytokines, 
suggesting the existence of multiple mechanisms contributing to the overall anti-
inflammatory properties of LRH-1 (Venteclef et al, 2006). 
 
1.29 LRH-1 in pancreatic cancer 
 
Genome-wide association studies have linked mutations in the LRH-1 gene and its 
upstream regulatory regions as susceptibility factors in the development of pancreatic 
cancer and disease progression (Li et al, 2012; Rizzato et al, 2011). LRH-1 is 
upregulated in human pancreatic cancer cells compared to the normal pancreatic 
ductal epithelium (Benod et al, 2011). Downregulation of LRH-1 expression in 
pancreatic cancer cells resulted in growth arrest and a decrease in the expression of 





1.30 LRH-1 in breast cancer 
 
The expression of LRH-1 is low in normal breast tissue, but is found to be 
significantly upregulated in breast tumour and tumour associated stromal fibroblasts 
(TAFs) (Miki et al, 2006; Zhou et al, 2005). The expression of LRH-1 was detected in 
40-50% of breast tumours and TAFs, and its expression was shown to be positively 
associated with steroid receptors, ERα and PR, and steroidogenic enzymes including 
StAR, steroidogenic acute regulatory protein, CYP11A1, HSD3β2 (Miki et al, 2006; 
Zhou et al, 2005). 
 
Several studies suggested that LRH-1 contributes to breast cancer development and 
progression through the regulation of aromatase expression in TAFs, thereby 
increasing local estrogen production (Bulun et al, 2009; Chand et al, 2011; Clyne et 
al, 2004; Zhou et al, 2005). Aromatase expression is regulated by different tissue-
specific promoters (Bulun et al, 2005). In the disease-free breast, aromatase 
expression is relatively low and mainly utilizes a weak PI.4 promoter, which is 
regulated by glucocorticoids and cytokines (Bulun et al, 2005). The expression of 
aromatase in TAFs is significantly elevated and involves a switch in promoter usage 
from the PI.4 to the proximal cAMP-dependent promoter PII (Bulun et al, 2005; 
Bulun et al, 2009). Prostaglandin E2 (PGE2), a tumour secretion factor from breast 
tumours stimulates PII expression and the activity of aromatase in adipose stromal 
cells via the activation of protein kinase A (PKA) and protein kinase C (PKC) 
signalling pathways (Bulun et al, 2012; Bulun et al, 2009). LRH-1 expression is found 
in adipocytes and it directly regulates the activity of the aromatase PII promoter, at 
least in reporter gene assays (Chand et al, 2011; Clyne et al, 2002). Moreover, LRH-1 
expression and its activity showed to be regulated by PKA and PKC pathways 
(Bouchard et al, 2005; Clyne et al, 2004; Hadizadeh et al, 2008; Zhou et al, 2005). 
Furthermore, the expression of LRH-1 in TAFs has been shown to be associated with 
aromatase expression (Zhou et al, 2005). It has been suggested that breast tumours 
also secrete antiadipogenic cytokines such as tumour necrosis factor α (TNFα) and 
interleukin 11 (IL-11) that inhibit adipocyte differentiation in promoting local 
estrogen biosynthesis (Figure 1.9) (Bulun et al, 2009). 
 
! 66!
LRH-1 expression was detected mainly in ERα-positive cell lines (Annicotte et al, 
2005; Thiruchelvam et al, 2011). LRH-1 is an ERα direct target gene and important in 
mediating the growth in ERα-positive breast cancer cell lines. Downregulation of 
LRH-1 was shown to inhibit the estrogen-stimulated growth of MCF-7 cells 
(Annicotte et al, 2005; Thiruchelvam et al, 2011). Furthermore, LRH-1 promotes 
motility and cell invasiveness in breast cancer cell lines through the remodeling of 
actin cytoskeleton and E-cadherin cleavage (Chand et al, 2010). The increase in E-
cadherin cleavage as a result of LRH-1 overexpression is possibly via upregulation of 
MMP9 expression, which is LRH-1-regulated in the ovary (Chand et al, 2010; 
Duggavathi et al, 2008). 
 
The expression of LRH-1 in tumour containing stromal compartment has implicated it 
as a key factor in local estrogen production within the tumour microenvironment. 
However, the regulation of gene expression by LRH-1 in breast cancer cells is still 
remaining largely unknown. Therefore, the aim of the current study was to identify 









Figure 1.9 Proposed model for estrogen synthesis in breast tumour–associated 
stromal fibroblasts 
The release of factors from breast cancer cells determine the key biological features of 
this micro-environment. Prostaglandin E2 (PGE2) induces aromatase expression in 
undifferentiated adipose fibroblasts by upregulating LRH-1 expression and 
transcriptional activity via activation of protein kinase A (PKA) and protein kinase C 
(PKC) signalling pathways. LRH-1 regulates the expression of aromatase in pre-
adipocytes. Local estrogen (E2) synthesis from androgens (T) stimulates the 
proliferation and survival of breast cancer cells. Differentiated/mature adipocytes do 
not express aromatase. Breast cancer cells secrete antiadipogenic cytokines such as 
Tumour necrosis factor α (TNFα) and interleukin 11 (IL-11) which inhibit the 






















1.31 Study aims !
Previous studies in our laboratory identified LRH-1 is an estrogen-regulated gene in 
MCF-7 breast cancer cells, and demonstrated its importance in regulating the growth 
of MCF-7 and other LRH-1 positive breast cancer cells (Thiruchelvam et al, 2011). 
These studies also found that the previously described LRH-1 isoforms are poorly 
expressed in breast cancer cell lines. Characterization of the transcriptional start site 
of LRH-1 transcripts in breast cancer cells led to the identification two new LRH-1 
isoforms, with a form called “variant 4” (LRH-1v4) being the predominant form of 
LRH-1 expressed in breast cancer cells. A collaboration with Prof Tony Barrett and 
Prof Alan Spivey (Department of Chemistry, Imperial College) was initiated for the 
identification of LRH-1 antagonists. The aims of my project are  
 
1) to determine the molecular mechanisms by which LRH-1 regulates the growth 
of breast cancer cells,  
2) develop cell-based screening strategies for the identification of LRH-1 
antagonists. 
 
To determine the molecular mechanisms by which LRH-1 regulates breast cancer cell 
growth, I proposed to perform LRH-1 ChIP-seq to identify the direct genomic targets 
of LRH-1 and subsequently evaluate the potential role of LRH-1 in regulation of gene 
expression. LRH-1 ChIP-seq was complicated by the poor enrichment observed using 
commercially available LRH-1 antibodies, necessitating the development of other 
approaches towards this end. The results of these studies are described. 
 
For the second aim, I propose to use a screening cascade, starting with the mammalian 
2-hybrid assay using the LRH-1 LBD and the PGC-1α co-activator. I chose this 
approach because assessment of interaction between the LRH-1 LBD and a co-
activator is more likely to identify compounds that bind to the LRH-1 LBD, rather 
than compounds that influence LRH-1 activity through modulation of other signalling 
pathways, such as protein kinase activities. Having identified hit compounds, I aim to 
carry out further screens to refine the hits, including assessment of inhibition of full-
length LRH-1 in a reporter gene assays and assessment of phenotypic effects, 
primarily growth inhibition, in LRH-1 positive and negative breast cancer cell lines. 
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Together, these studies aim to define the mechanisms by which LRH-1 regulates 
breast cancer cells and identify small molecule inhibitors of LRH-1 that could in the 
future be evaluated for their activity against LRH-1 and for the development of 
potential therapeutic lead compounds, ultimately leading to potential new therapeutic 
agents for breast cancer treatment.   
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Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Reagents and materials 
 
General chemicals and reagents were obtained from Sigma-Aldrich (Gillingham, 
UK), VWR Ltd (Lutterworth, UK) and Fisher Scientific (Loughborough, UK). 
Molecular biology reagents, such as DNA and protein ladders, restriction enzymes 
and PCR enzymes were obtained from Fermentas (York, UK) and Invitrogen (Paisley, 
UK). TaqMan and SYBR Green real-time PCR reagents were from Applied 
Biosystems (Invitrogen, Paisley, UK). Oligonucleotides were synthesised by 
Invitrogen (Paisley, UK). Kits for DNA and RNA preparation were obtained from 
QIAGEN (Crawley, UK). Protease inhibitor cocktail was obtained from Roche 
(Sussex, UK). FuGENE HD transfection reagent and Dual-Glo Luciferase Assay 
System were purchased from Promega (Southampton, UK). Lipofectamine LTX Plus 
and Lipofectamine RNAi MAX transfection reagents were obtained from Invitrogen 
(Paisley, UK). Small interfering RNAs (siRNA) oligos were from Dharmacon and 




1.5ml microcentrifuge tubes and pipette tips were purchased from STARLAB Ltd 
(Milton Keynes, UK). Micro-cuvettes and 250ml centrifuge bottles were obtained 
from VWR Ltd (Leicestershire, UK). Disposable round bottom 30ml centrifuge tubes 
were purchased from SARSTEDT Ltd (Leicester, UK). Tissue culture and 
microbiological grade plastics, serological strippette pipettes and conical centrifuge 





2.1.3 General equipment 
  
Large volume centrifugations were performed with a Sorval RC-5B refrigerated 
centrifuge (Sorval, Leicester, UK). Bench top micro-centrifuges, Sorval Pico and 
Sorval Fresco were obtained from Sorval (Leicester, UK). Incubations were 
performed in a water bath (Techne, Bibby Scientific Ltd, Staffordshire, UK), 
incubator oven (LEEC, Nottingham, UK), shaking incubator (New Brunswick 
Scientific Company Incorporated, Edison, USA) or block heater (Grant-bio, Wolf 
Laboratories, York, UK). Samples were mixed using a Vortex-Genie 2 (Scientific 
Industries, London, UK). Sonication was performed using a Sanyo MSE Soniprep 150 
sonicator (MSE Ltd, London, UK). Polymerase Chain Reaction (PCR) was carried out 
using a GeneAmp PCR system 9700 (Applied Biosystems, Chesire, UK). Real-time 
quantitative PCR was carried out using an Applied Biosystems 7900HT Fast Real-
Time PCR System (Invitrogen). Horizontal agarose gel electrophoresis tanks were 
purchased from Thistle Scientific (Glasgow, UK). Western blotting vertical gel 
electrophoresis tanks and transfer apparatus were from Hoeffer (GE Healthcare Life 
Science, Buckinghamshire, UK) and Bio-Rad (Hertfordshire, UK). Power packs were 
obtained from Bio-Rad (UK). Spectrophotometric measurements were carried out on 
a Shimadzu UV-1201 spectrophotometer (Shimadzu Corporation, Tokyo, Japan), 
Nanodrop ND-1000 (Thermo Scientific) and Tecan infinite M200 microplate reader 
(Tecan Group Ltd., Switzerland). Luminescence measurements were performed using 
a TopCount NXT microplate scintillation and luminescence counter (Packard, 
PerkinElmer, Cambridgeshire, UK). Infrared gel imaging was carried out using an 
Odyssey Fc dual-mode imaging system (LI-OR biotechnology Ltd, Cambridge, UK). 
 
2.1.4 Cell culture equipment and reagents 
 
Cells were maintained in a Galaxy CO2 incubator (New Brunswick, Eppendorf, 
Cambridge, UK) at 37oC in a humidified air atmosphere supplied with 5% CO2. Cell 
culture manipulations were carried out in a NuAIRE class II, ducted laminar flow 
safety cabinet (NUAIRE DH Autoflow, Oxon, UK). Dulbecco’s Modified Eagle’s 
Medium (DMEM), L-Glutamine–Penicillin–Streptomycin solution (200mM L-
glutamine, 10,000 units/ml penicillin, and 10mg/ml streptomycin in 0.9% sodium 
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chloride) (PSG), 0.02% EDTA solution and 10X trypsin solution were supplied by 
Sigma-Aldrich. Phenol red-free DMEM and Opti-MEM were supplied by Invitrogen. 
Fetal calf serum (FCS) and dextran-coated, charcoal-treated FCS (DSS) were 




17β-estradiol (E2) was obtained from Sigma-Aldrich. ICI182,780 and Phorbol 12-
myristate 13-acetate (PMA) were purchased from Tocris Bioscience (Bristol, UK). 
1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC) was obtained from Avanti Polar 
Lipids (USA). LRH-1 synthetic compounds were synthesised and provided by Prof 
Tony Barrett and Prof Alan Spivey (Department of Chemistry, Imperial College).  
 
2.1.6 Bacterial media and plates 
 
L-Broth and L-Broth agar capsules were obtained from MP Biomedical, LLS. 
(France). Ampicillin sodium salt was purchased from Sigma-Aldrich (Gillingham, 
UK). Bacterial media were prepared using double distilled, de-ionised water (ddH2O). 
Media were autoclaved and stored at 4˚C. Selection antibiotics were added freshly to 
the media prior to inoculation of bacteria. 
 
 




10g of tryptone-B, 5g of yeast extract-B, and 10g of NaCl in 1 liter of ddH2O, 
Autoclaved to sterilize and stored at 4°C. 
 
LB plates 10g of tryptone-B, 5g of yeast extract-B, 10g of NaCl, and 15g of Agar-B in 1 liter of 
ddH2O, autoclaved to sterilize, then cooled to 50°C prior to the addition of the selection 
antibiotic. The LB-agar was then poured into Sterilin Petri dishes, allowed to set and 
stored at 4°C for up to a month.  
 
Ampicillin A 100mg/ml working stock was prepared in ddH2O, sterilized by passage through a 





2% Tryptone, 0.5% yeast extract, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, 10mM 





The firefly luciferase reporter vectors pGL3-basic and pGL3-promoter, the renilla 
luciferase reporter vectors pRL-TK and pRL-CMV, and Bluescribe vector (BSM) 
were purchased from Promega. The expression plasmids for LRH-1 (pCI-LRH-1), 
SHP (pCDM8-hSHP) and the LRH-1 responsive luciferase reporter (SF1-Luc) were 
gifts from Dr Donald McDonnell (Duke University, USA) and Dr David Moore 
(Baylor, USA) (Lee et al, 2006; Ortlund et al, 2005). The expression plasmid LRH-
1v4 was generated by Dr Andy Photiou in this laboratory, by carrying out site-
directed mutagenesis of the pCI-LRH-1 plasmid to disrupt the translation start site of 
LRH-1v1 (Thiruchelvam et al, 2011). HA-tagged LRH-1 (pCI-3HA-LRH-1) was 
generated by Miss Holly Callaghan in this laboratory, by inserting a 3xHA coding 
sequence into pCI-LRH-1. The GATA3 and SF-1 expression plasmids were 
purchased from Geneservice (Source BioScience Ltd, Nottingham, UK). The mouse 
PKA catalytic subunit α cDNA has been described previously (Chen et al, 1999). The 
HSD3B2 and StAR promoter luciferase reporter plasmids were provided by Dr 
Jacques Tremblay (Laval University, Canada) (Dube et al, 2009) and the aromatase 
PII (PII-516) luciferase reporter gene was provided by Dr Colin Clyne and Dr Evan 
Simpson (Prince Henry’s Institute of Medical Research, Australia) (Clyne et al, 
2002). The pS2-Luc and pS2-ΔERE-Luc luciferase reporter plasmids were provided 
by Dr Vincent Giguere (McGill University, Canada) (Lu et al, 2001). The GAL4 
responsive luciferase reporter (GAL4-TK-Luc) was provided by Prof Malcolm Parker 
(Imperial College) (Bevan et al, 1999). The expression plasmids GAL4-TIF2 and 
GAL4-PGC-1α were provided by Dr Donald McDonnell (Duke University, USA) 
(Safi et al, 2005). The expression plasmids GAL4-NCoR and GAL4-SMRT were 
provided by Dr Ronald Cohen (University of Chicago, USA) (Cohen et al, 2000). 
GAL4-SHP and pVP16-LRH-1 LBD were generated by Miss Becky Shao in this 
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laboratory by PCR amplification of SHP and the LRH-1 LBD coding sequence from 




2.2.1 Cell culture 
 
All cell lines were purchased from the American Tissue Type Culture Collection 
(ATCC) and the European Collection of Cell Cultures (ECACC). Cells were cultured 
in DMEM medium supplemented with 10% FCS and 1% PSG. Cell lines were 
routinely maintained in a logarithmic phase of growth in T150 tissue culture flasks. 
Cell lines were tested every 3-6 months to ensure mycoplasma negativity. All cell 
lines were tested on a three-monthly basis to ensure they were free from mycoplasma 
infection and were genotyped for authenticity on an annual basis by sending genomic 
DNA to LGC Standards (Cologne, Germany). 
 
Cell cultures were grown to 70-80% confluency. Cell culture medium was removed 
from the culture flask and cells were washed twice with 0.02% EDTA solution 
(Sigma) pre-warmed to 37˚C. Cells were trypsinised by adding 2ml of 1X trypsin 
solution (Sigma), and incubated at 37oC for 3 minutes for cell detachment. After 
trypsinisation, 8ml of pre-warmed culture medium was added to neutralize the action 
of trypsin. The cell suspension was transferred to a 15ml conical tube, and cells 
pelleted by centrifugation at 1300rpm for 3 minutes. Cells were re-suspended in fresh 
medium and transferred to new flasks. Cells were serially passaged in tissue culture 
flasks by “splitting” at a ratio of between 1:5 and 1:10. 
 
Cell lines were frozen down and preserved for long-term storage. Cultured cells 
growing in log-phase (70-80% confluency) were trypsinised following the procedure 
used above for subculturing. Cell pellets were re-suspended in 5ml of freezing 
medium (90% FCS, 10% dimethyl sulfoxide DMSO) (Sigma). 1.5ml of cell 
suspension in the freezing medium was transferred into 2.5ml cryovials. Cryovials 
were placed in an isopropanol chamber (Thermo scientific) and stored at –80°C 
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overnight prior to transferring to liquid nitrogen storage. Cell lines in continuous 
culture were discarded following subculturing for no more than 30 passages. The 
frozen cells were thawed rapidly at 37°C in a water bath and added to a 15ml conical 
tube containing 10ml of pre-warmed (37oC) culture medium. Cells were pelleted by 
centrifugation at 1300 rpm for 3 minutes, re-suspended in 5ml of medium and placed 
in a T25 tissue culture flask. 
 
For cell seeding in culture plates, the number of cells in the suspension was 
determined by cell counting using a haemocytometer. In order to assess viability, cell 
suspensions were mixed with an equal volume of 0.4% trypan blue solution (Sigma). 
10µl of the cell suspension was loaded into a haemocytometer chamber (Sigma). The 
number of cells in 4 squares was counted using a hand tally counter under a 
microscope. If cells had taken up trypan blue, they were considered as non-viable and 
were excluded from the count. The cell concentration (cells/ml) was calculated as the 
average number of cells per square x dilution factor (2) x 104.   
 
For experiments in which the effects of estrogen were determined, cells were cultured 
in phenol red free medium supplemented with 10% DSS and 1% PSG for three days 
prior to the experiment. 17β-estradiol (E2) and ICI182,780 (ICI) were prepared in 
ethanol and used at a final concentration of 10nM and 100nM, respectively. 
Compounds used for testing for activation/inhibition of LRH-1 were prepared in 
DMSO and used at a final concentration of 30µM, unless otherwise stated. 1,2-
dilauroyl-sn-glycero-3-phosphocholine (DLPC) was prepared in ethanol and used at a 
final concentration of 100µM. In general, aqueous ligand stocks were added into 
culture medium at a dilution of 1 in 1000. An equal volume of ethanol or DMSO was 
added to the no ligand (vehicle) controls. 
 
2.2.2 Small interference RNA (siRNA) transfections !
Double-stranded RNA oligos (ON-TARGETplus siRNA or Non-targeting siRNA) 
were purchased from Dharmacon. siRNA was re-suspended in siRNA dilution buffer 
(Invitrogen) at a concentration of 20µM, which is equivalent to 20pmol/µl. 
Transfections of siRNA were carried out using Lipofectamine RNAi MAX 
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(Invitrogen), with the reverse transfection method. For transfection experiments in 
10cm culture dishes, 40µl of 20 µM siRNA oligonucleotides were diluted in 500µl 
Opti-MEM and 40µl of Lipofectamine RNAi MAX was added to the diluted siRNA. 
The complex was gently mixed by vortexing and incubated at room temperature for 
20 minutes. The complex was plated on the culture dishes, and a cell suspension 
(2x107 cells in 10ml of medium) was added on top of the complex to achieve a final 
siRNA concentration of 80nM. Antibiotics were excluded from the culture medium 
during the transfection process. Following 24 hours of transfection, the culture 
medium was replaced with fresh medium containing antibiotics. Cells were harvest at 
48 or 72 hours post-transfection for expression analysis as stated in the figure legends. 
Transfections performed in 96-well plate (cell growth assay) and 15cm dish (ChIP 
assay) were scaled up or down, depending on the surface area of the culture dish. 
 
 
2.2.3 Transient transfection of plasmid DNA 
 
Transient transfection of plasmid DNA was carried out using FuGENE HD (Promega) 
according to the manufacturer’s protocol. For transfection experiments in 10cm 
culture dishes, 2x107 cells were seeded in cell culture dishes the day before 
transfection. On the day of transfection, cell culture medium was replaced with 
medium containing no antibiotics. 10µg of DNA plasmids were diluted in 500µl Opti-
MEM to obtain a final concentration of 0.02µg/µl. 25µl of FuGENE HD was added to 
diluted DNA in a ratio of 2.5 to 1 (2.5µl of FuGENE HD: 1µg of total plasmid DNA). 
The complex was incubated at room temperature for 20 minutes and added to the cell 
monolayer in a drop-wise manner. After 24 hours, culture medium was replaced, and 
cells were further incubated for 24 hours for expression analysis. Transfections 
performed in 15cm dish for ChIP assay were scaled up 2.8 times based on the surface 





2.2.4 Bacterial plasmid transformation 
 
Subcloning efficiency DH5α competent cells (Invitrogen) were used for plasmid 
transformation. Cells were thawed on ice, and 50µl of cell suspension was gently 
transferred into a pre-chilled 1.5 ml microcentrifuge tube. Cells were incubated with 
100ng of plasmid DNA on ice for 30 minutes, heat shocked at 42°C for 45 seconds in 
a water bath, and subsequently cooled on ice for 2 minutes. The cells were then 
allowed to recover by the addition of 600µl of S.O.C medium and incubated at 37°C 
with 200 rpm shaking for 1 hour before spreading on a pre-warmed LB-agar plate 
containing ampicillin (100µg/ml). Plates were incubated upside down in an incubator 
oven at 37°C overnight for bacterial colony formation. 
 
2.2.5 Plasmid Preparation !
A single colony was picked from the bacterial culture plate and transferred into 3ml of 
pre-warmed LB medium containing 100µg/ml ampicillin. The culture was placed in a 
shaking incubator at 37oC with 200 rpm for 6-8 hours. 500µl of the initial bacterial 
culture was added to 200ml of LB medium containing 100µg/ml ampicillin and 
placed in a shaking incubator at 37oC for 18-24hrs. Plasmid DNA was prepared using 
QIAGEN Plasmid Maxi Kits, according to the manufacturer’s instructions. Plasmid 
DNA was quantified and purity was measured at absorbance at 260 and 280 nm, using 
an ND-1000 spectrophotometer (Thermo Scientific).  
 
2.2.6 Agarose gel electrophoresis of DNA 
 
DNA was resolved on 1% to 2% agarose gels prepared in Tris-Borate-EDTA (TBE) 
buffer (89mM Tris-HCl, 89mM Boric acid and 2mM EDTA) (10x concentration from 
Sigma) using a horizontal gel electrophoresis apparatus (Thistle Scientific). Agarose 
gels contained 0.25µl/ml ethidium bromide (Sigma) or 1µl/ml SYBR Safe DNA gel 
stain (Invitrogen). DNA was visualised using an UVIpro Platinum Gel Doc System 
ultraviolet transilluminator (UVItec, UK). The sizes of the plasmids / DNA fragments 
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were determined using DNA ladder markers. The markers used were Low Range/ 
High Range, ready to use, MassRuler DNA ladder (Fermentas).  
 
2.2.7 Generation of ERα  gene promoter luciferase reporter  
 
Human ERα genomic DNA was prepared from bacterial artificial chromosome 
(BAC) clone RP3-443C4 (Geneservice). The genomic region of the ERα gene 
promoter from -5993 to -117 (position relative to the transcription start site of 
promoter A), here called “ERP", was amplified using high fidelity pfu DNA 
polymerase (Fermentas) according to the manufacturer’s instructions. PCR primer 
sequences were as follows: 
 
Forward primer: 5’-GTGGCTCGAGCAGACTTGGGTAAAACTTGATCATG-3’ 
Reverse primer: 5’-ACATCCAGATCTCCAGGCACAACTCGATTTGGAGC-3’ 
 
The PCR product was cloned into the pJET vector using the CloneJET PCR cloning 
kit (Fermentas) according to the manufacturer’s instructions, to give pJET-ERP. 
pJET-ERP was then digested with BglII restriction enzyme (Invitrogen), and the ERP 
fragment was gel purified using the QIAquick Gel Extraction Kit (QIAGEN) and 
cloned into the BglII site of the pGL3-basic and pGL3-promoter luciferase reporters 
(Promega). 
 
The 3’ deletion ERP-Luc constructs were generated by restriction digest of ERP in 
pGL3-promoter, as listed in the table below. The digested insert and vector DNA 
fragments were gel purified, and the insert fragments were re-ligated back into the 
pGL3-promoter by using T4 DNA ligase (Invitrogen). Refer to Figure 3.9. 
 
 
Table 2.2 List of 3’ deletion constructs of ERα  promoter luciferase reporter 
Construct Position relative to 





ERPF1-Luc -5993 to -2341 MluI and EcoRV  MluI and SmaI 
ERPF2-Luc -5993 to -5048 MluI and SwaI MluI and SmaI  
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2.2.8 Site-directed mutagenesis 
 
Site-directed mutagenesis was carried out using the QuikChange Multi-site-directed 
Mutagenesis kit (Agilent Technologies, UK) according to the manufacturer’s 
instructions. The LRH-1 response elements (LRHREs) in ERα promoter (ERP) were 
mutagenised to BamHI restriction enzyme sites. The wild-type ERP gene sequences 
and mutagenic primer sequences are listed in table 2.3. The sequences in bold are the 
putative LRH-1 binding sites, substitutions in the mutants are underlined. The LRH-
1/ER binding motif was mutated in the pS2 promoter luciferase reporter. Wild-type 
and mutant sequences as shown in result figure 3.15. The mutagenesis primer 
sequences are given in table 2.4, with the substituted nucleotides underlined. 
 
 

















2.2.9 Luciferase gene reporter assay 
 
MCF-7 or COS-1 cells were seeded in 24 well plates at a density of 5x104 cells per 
well and incubated for 24 hours prior to transfection. Transfection of plasmid DNA 
was carried out using FuGENE HD reagent (Promega). Cells were transfected with 
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100ng each of the firefly luciferase reporter and renilla luciferase control plasmid 
(pRL-TK). The amount of expression plasmid used was as follows: 10ng for ERα, 
50ng for LRH-1, 50ng for SF1, 10ng for SHP, 100ng for GATA3 and 100ng for PKA 
(unless otherwise stated in the figure legend). An equal amount of the appropriate 
vector (pcDNA3 or pSG5 plasmid) was transfected in the vector controls. Bluescribe 
DNA (BSM) was added to adjust the total amount of DNA to 400ng per well. The 
DNA mix was diluted with Opti-MEM to obtain a final DNA concentration of 
0.02µg/µl. FuGENE HD was added at a 5:2 ratio (FuGENE HD (µl): DNA (µg)). 
20µl of the DNA-FuGENE HD mixture was added to the cells in each well and 
incubated for 5 hours. After 5 hours of transfection, medium was replaced. To 
determine the effect of the ligands, these were included in the fresh medium, as 
appropriate. After 24 hours of incubation, cell lysates were prepared in 100µl passive 
lysis buffer (Promega). The firefly and renilla luciferase activity was determined 
using the DualGlo luciferase assay kit (Promega) according to manufacturer’s 
instructions. In brief, the cell lysates were transferred into 96-well opti-plate 
(PerkinElmer). 50µl of luciferase reagent was added to each well. Following 
incubation for 10 minutes, firefly luciferase activity was determined by the TopCount 
NXT microplate scintillation and luminescence counter (PerkinElmer). This was 
followed by the addition of 50µl of Stop and Glo reagent and incubation for 10 
minutes before measurement of renilla luciferase activity. The renilla luciferase 
activity served as control for transfection efficiency, so the firefly luciferase reading 
was normalized to the reading for renilla luciferase. 
 
2.2.10 Mammalian two hybrid (M2H) Assay 
 
COS-1 cells were seeded in 96 well plates at a density of 8x103 cells per well. Cells 
were transfected with Lipofectamine LTX plus (Invitrogen), according to 
manufacturer’s protocol. For each well, 150ng of GAL4-TK-Luc, 5ng of pRL-CMV, 
47.5ng of pVP16-LRH-1-LBD (or pVP16), and 47.5ng of GAL4/co-regulator fusion 
constructs were used. DNA mixes were diluted with Opti-MEM to obtain a final DNA 
concentration of 12.5ng/µl. Lipofectamine Plus reagent was added to the diluted DNA 
in a ratio of 1:1 (Lipofectamine Plus (µl): DNA (µg)) and incubated for 5 minutes at 
room temperature. Lipofectamine LTX was added in a ratio of 3:1 (Lipofectamine 
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LTX (µl): DNA (µg)) and the mixes were incubated for a further 30 minutes. 
Lipofectamine-DNA complexes were diluted 5 times in Opti-MEM. Culture medium 
in the 96-wells plate was removed by aspiration and 100µl of the diluted 
lipofectamine/DNA/Opti-MEM complex was added into each well with the aid of a 
multi-dispenser. Following 5 hours of transfection, the medium in each well was 
replaced with culture medium, which included compounds being tested. The same 
volume of DMSO was added to the vehicle control. Cells were further incubated for 
24 hours, and the cell lysates were assayed for luciferase activity, as in section 2.2.9.  
 
2.2.11 Cell growth assay 
 
The Sulphorhodamine B (SRB) growth assay was used to assay cell growth based on 
the measurement of cellular protein content. Cells were seeded at a density of 3x103 
cells per well, in 96-well plates. On the day of measurement, cells were fixed by 
adding 100µl ice-cold 40% trichloroacetic acid (TCA) to each well on top of the 
culture medium and incubated at 4°C for 1 hour. The plates were washed 5 times in 
ddH2O after fixation, and 100µl of 0.4% SRB (Sigma) in 1% acetic acid was added to 
each well and incubated for 30 minutes at room temperature. Following SRB staining, 
the plates were washed 5 times with 1% acetic acid to remove unbound dye and 
allowed to air-dry overnight. The bound dye was then solubilised by adding 100µl of 
10mM Tris-base and placed on a shaker for 15 minutes at room temperature. The 
absorbance was read at 492nm using a Tecan Infinite M200 plate reader. 
 
To determine 50% growth inhibition (GI50) values for compounds, the test compounds 
were prepared in culture medium in two-fold serial dilutions. 100µl of diluted 
compound was added to the cells containing 100µl of culture medium. The final 
concentration was obtained at two-fold serial dilution from 100µM to 0.39 µM (9 
points). Cell growth was assessed using the SRB assay 48 hours after addition of the 
compounds. The percentage cell growth was calculated using the equation below, and 





Equation for percentage cell growth calculation: 
% Cell growth = (Mean OD sample - Mean OD day0) / (Mean OD DMSO control – Mean OD 
day0) X 100% 
 
2.2.12 Extraction of total RNA 
 
For RNA preparation, cells were washed twice with ice-cold PBS and collected by 
scraping into RLT buffer (QIAGEN), containing (1% v/v) β-Mercaptoethanol 
(Sigma). Cells were homogenised by centrifugation through a QIAShredder spin 
column (QIAGEN) at 13,000 rpm for 2 minutes. RNA extraction was carried out 
using the RNeasy Mini Preparation kit (QIAGEN) according to manufacturer’s 
protocol. Prior to elution, columns were treated with DNase using the RNase-Free 
DNase Set (QIAGEN) to remove residual DNA. RNA was eluted in 50µl of RNase-
free water. RNA concentration and purity were determined by measuring absorbance 
at 260 and 280 nm. 
 
2.2.13 Complementary DNA (cDNA) preparation by reverse 
transcription 
 
cDNA was prepared from total RNA using thin-walled PCR tubes, reagents from 
Fermentas. 
Reactions were prepared as below: 
• 4µl of 5x RT buffer  (Pre-warmed prior to use)  
• 2µl of 10mM dNTP stock  
• 1µl of random hexamer primer 100µM (0.2µg/µl)  
• 2µg of total RNA  
• RNase free water to a total volume of 19µl  
• 1µl of Reverse transcriptase (200U/µl)  
 
The reaction was carried out in the GeneAmp 9700 PCR machine (Invitrogen) at 
42°C for 1 hour, followed by 5 minutes at 95°C to heat inactivate the reverse 
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transcriptase. The cDNA was then diluted 1 in 10 with DNase-free sterile ddH2O and 
2µl of diluted cDNA was used for each PCR reaction. 
2.2.14 TaqMan quantitative real-time PCR 
 
Gene expression analysis was carried out using TaqMan assays purchased from 
Applied Biosystems (ABI) on a 7900HT fast Real-time PCR machine. Each sample 
for PCR was assayed in triplicate, in a MicroampTM fast optical 96-well reaction 
plate (ABI). 
 
Each reaction mixture consisted of the following components: 
• 10 µl of TaqMan fast universal PCR master mix  
• 1µl of TaqMan assay probe  
• 2µl of cDNA  
• 7µl of DNase/RNase free water  
 
The thermal cycle profile: 
• Stage 1 
! 95˚C for 20 seconds  
• Stage 2 (cycle x 40)  
! 95˚C for 3 seconds 
! 60˚C for 30 seconds 
 
In each case the expression of the test gene was normalised to the GAPDH 
housekeeping gene and relative to the appropriate control using the 2-ΔΔCT method. 
 
 
Table 2.5 List of TaqMan real-time RT-PCR assays 
 

















2.2.15 Protein lysate preparation 
2.2.15.1 Hot lysis buffer extraction 
 
Cells in culture plates were washed twice with ice-cold PBS and hot lysis buffer 
(0.12M Tris-HCl pH6.8, 4% w/v SDS, 20% v/v glycerol, 0.2M DTT, 0.008%w/v 
bromophenol blue) pre-heated to 100˚C was added to the plates (500µl per 10cm 
dish). Cell lysates were collected by scraping and transferred into 1.5ml screw-capped 
microcentrifuge tubes. Samples were then heated at 95˚C for 5 minutes and stored at -
80°C until further use.  
 
2.2.15.2 Radioimmune Precipitation Buffer (RIPA) buffer extraction 
 
Cells were washed twice with ice-cold PBS and ice-cold RIPA buffer (50 mM Tris-
HCl at pH 8.0, with 150 mM sodium chloride, 1.0% Igepal CA-630 (NP-40), 0.5% 
sodium deoxycholate, and 0.1% sodium dodecyl sulfate) (Sigma), supplemented with 
protease inhibitor cocktail (Roche) was added to the cell monolayer (400µl per 10cm 
dish). Cell lysate was collected by scrapping and transferred into a pre-chilled 1.5ml 
microcentrifuge tube. Samples were incubated at 4˚C for 30 minutes, with vortexing 
every 5 minutes. Cell lysates were then centrifuged at 13,000 rpm for 10 minutes at 
4˚C. The supernatants were transferred to new 1.5ml microcentrifuge tube and the 
pellets were discarded. Protein content was quantified using a BCA protein assay kit 
(Thermo Fisher Scientific). For western blotting, RIPA samples were mixed with 2X 
sample buffer (0.125 M Tris-HCl at pH 6.8, 4% SDS, 20% glycerol, 10% β-
mercaptoethanol and 0.004% bromophenol blue) (Sigma) and heated at 95˚C prior to 
loading. 
 
2.2.15.3 Protein quantification 
 
Protein concentrations was determined using the Pierce BCA Protein Assay Kit 
(Thermo Fisher Scientific), according to the manufacturer’s protocol. In brief, bovine 
serum albumin (BSA) standards were generated (1 to 30µg) in a 50µl volume. 5µl 
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protein lysates were diluted 10x in ddH2O to obtain a 50µl volume. BCA reagents A 
and B were mixed with a ratio of 50 to 1, and 1ml of mixed BCA reagent were added 
to each sample and standard. The samples were mixed and incubated at 37˚C for 30 
minutes. The reactions were then transferred into a micro-cuvette and the optical 
density (OD) was measured at absorbance reading of 562 nm. Protein concentration 
of the samples was determined from the standard curve generated for BSA. 
 
2.2.16 Western blotting 
 
Cell lysates were heated to 95°C for 5 minutes and cooled on ice prior to loading. 
10µl of protein lysate from hot lysis buffer extracts or 20µg of RIPA lysates buffer 
were loaded onto an SDS-polyacrylamide resolving gel (8 to 12%), with a 5% 
stacking gel. A SE250 mini-gel system from Hoefer (GE Healthcare) was used for 
electrophoresis. Electrophoresis was carried out at 80V for 30 minutes to allow 
proteins to go through the stack and then at 100V for 1 to 2 hours, until the 
bromophenol blue dye front reached the bottom of the gels. The gels were transferred 
onto Hybond ECL Nitrocellulose membrane (Amersham Biosciences) using a TE-22 
transfer unit (Hoefer, GE Healthcare) at 100V for 90 minutes. The membrane was 
incubated in blocking buffer for 1 hour at room temperature to reduce non-specific 
binding of primary antibody. The membrane was then incubated with the diluted 
primary antibody in blocking buffer at 4°C with gentle shaking overnight. After 
primary antibody incubation, the membrane was washed three times in PBST (15 
minutes per wash on a rocking platform) and then incubated for 1 hour with the HRP-
conjugated secondary antibody, which was diluted in blocking buffer. The membrane 
was washed three times in PBST. The SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Fisher Scientific) was added to the membrane and incubated for 5 
minutes followed by autoradiography using Hyperfilm ECL (GE Healthcare) on a X-
ray developer (Konica Minolta). The molecular weights of the proteins were 






Table 2.6 List of solutions for western blotting 
Solution Recipe 
Upper buffer  
 
0.5M Tris-HCl (pH 6.8), 0.4% w/v SDS 
Lower buffer 
 
1.5M Tris-HCl (pH8.8), 0.4% w/v SDS 
Running buffer 
 
25mM Tris-Base, 192mM glycine, 0.1% SDS 
Transfer buffer 
 
5mM Tris-Base; 38mM glycine, 20% methanol 
 
PBST buffer (PBS/Tween-20) 
 
PBS, 0.05% (v/v) Tween 20 
Blocking buffer 
 





Table 2.7 List of SDS-PAGE Acrylamide gel solutions 
Gel solutions Recipe 
8% resolving gel 8ml lower buffer, 8.5ml 30% acrylamide: bis-acrylamide, 
62.5µl TEMED, 250µl 10% APS, 15.3ml ddH2O 
 
10% resolving gel 8ml lower buffer, 10.6ml 30% acrylamide: bis-acrylamide, 
50µl TEMED, 200µl 10% APS, 13.4ml ddH2O 
 
12% resolving gel 
 
 
8ml lower buffer, 12.7ml 30% acrylamide: bis-acrylamide, 
41.7µl TEMED, 166.7µl 10% APS, 11.2ml ddH2O  
5% stacking gel 2.5ml upper buffer, 1.5ml 30% acrylamide: bis acrylamide, 




Table 2.8 List of antibodies for western blotting 
Primary Antibody Cat. No. Dilution Company 





















Perseus Proteomicss, Japan 
Novocastra Laboratory, UK 
Santa Cruz, UK 
Santa Cruz, UK 
Prof Malcolm  
Parker (Imperial College) 
Abcam, UK 
 
Secondary Antibody Cat. No. Dilution Company 
 
HRP-Goat anti-mouse IgG  












2.2.17 Co-immunoprecipitation (Co-IP) 
 
For each IP reaction, 1mg of whole cell extract prepared in RIPA buffer were used. 
Lysates were incubated with 50µl of agarose beads (Santa Cruz, UK) at 4˚C with 
rotation for 2 hours for pre-clearing. Lysates were then centrifuged at 3,000 rpm for 3 
minutes at 4˚C. The pre-cleared supernatant was transferred to a fresh microcentrifuge 
tube and the remaining beads were discarded. For each IP reaction, 50µl of agarose 
beads were incubated with 2µg of antibody at 4˚C with rotation for 2 hours in 1ml of 
volume in ice-cold PBS. Agarose beads conjugated with antibodies were washed three 
times with ice-cold PBS, re-suspended in 100µl of PBS and transferred to the pre-
cleared lysate. IP was allowed incubation at 4˚C with rotation for overnight. 
Following IP, the beads were washed 3 times with ice-cold PBS. Supernatants were 
removed and the beads were re-suspended in 80µl of 2X sample buffer (0.125 M Tris-
HCl at pH 6.8, 4% SDS, 20% glycerol, 10% β-mercaptoethanol and 0.004% 
bromophenol blue) (Sigma). The samples were heated at 95˚C for 10 minutes, and 
10µl of immunoprecipitated complex was used for western blotting analysis. 
 
2.2.18 Electrophoretic mobility shift assay (EMSA) 
 
The TNT coupled reticulocyte lysate system (Promega) was used to produce LRH-1 
and ERα protein. Reactions as prepared as follow: 
 
• 25µl of TNT rabbit Reticulocyte lysate 
• 2µl of TNT reaction buffer 
• 1µl of RNA polymerase 
• 0.5µl of amino acid mixture lacking Leucine (1mM) 
• 0.5µM of amino acid mixture lacking Methionine (1mM) 
• 2µl of expression plasmid of LRH-1 or ERα (1µg/µl) 
• 19µl of ddH2O 
 
The IVTT reactions were incubated at 30˚C in a heat block for 90 minutes, and stored 
at -80˚C until further use. The complimentary oligonucleotides, one of which was 
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labeled with the infrared DY782 dye (Eurofins, Germany), were mixed (1µM each in 
100µl of TE buffer) in a 1.5ml microcentrifuge tube, and placed in a 2-litre beaker 
containing boiling water. The beaker was taken off the heat and allowed to cool 
overnight to room temperature. The hybridised oligonucleotides were diluted 1 in 10 
in water. For EMSA, 4µl of IVTT protein was pre-incubated with 5µl of 2x DNA 
binding buffer (DBB) for 10 minutes. 1µl of diluted hybridized oligonucleotides were 
added to the reaction and the samples were incubated for 30 minutes at room 
temperature. 1µl of 10x Odyssey orange loading dye (LI-COR) was added to the 
samples, and the samples were resolved by electrophoresis in 8% polyacrylamide gel 
containing 0.5x TBE (Sigma) at 100V for 1 hour, until the dye front was 2-3 cm from 
the bottom of the gel. The infrared signal was visualised using the Odyssey Fc dual-
mode imaging system (LI-COR). 
 
 
Table 2.9 List of solutions for EMSA 
Gel solutions Recipe 
2X DNA binding buffer (DBB) 20mM Tris-HCl at pH 8, 200mM NaCl, 10mM MgCl2, 2mM 
EDTA, 5mM DTT, 0.2µg/µl poly dI-dC (Sigma), and 0.2µg/µl 
acetylated BSA (New England BioLabs). 
 
0.5x TBE buffer 44.5mM Tris-HCl, 44.5mM Boric acid and 1mM EDTA (10x 
concentrated obtained from Sigma) 
 
8% resolving gel 
 
 
37.78ml 0.5x TBE buffer, 11.67ml 30% acrylamide: bis-
acrylamide, 50µl TEMED, and 500µl 10% APS  






















































2.2.19 Chromatin immunoprecipitation (ChIP) assay 
 
MCF-7 cells were seeded in 15cm culture dishes at a density of 6x106 cells per dish. 
For LRH-1 ChIP analysis, cells were co-transfected with 4µg of pCI-3HA-LRH-1 or 
the empty vector with 24µg of BSM plasmid, using FuGENE HD reagent, as 
described in section 2.2.3. Cells were harvested 48 hours post-transfection. To 
determine the effects of estrogen on LRH-1 and ERα recruitment, MCF-7 cells were 
cultured in phenol red free DMEM containing 10% DSS for three days prior to 
transfection 10nM 17β-estradiol or an equal volume of vehicle (ethanol) was added 
45 minutes before cell harvesting. Prior to harvesting, the cell number was determined 
by cell counting on a single dish. Cells were processed for ChIP, essentially as 
described (Schmidt et al, 2009). Cell fixation was performed by replacing the culture 
medium with 30ml of fixation buffer on each dish and incubation at 37˚C for 10 
minutes. To quench the fixation, 2.5M glycine was added to a final volume 1/20 of 
the volume of the fixation buffer (1.5 ml for 15 cm plates). The cells were washed 
twice with ice-cold PBS, and collected by scraping in 2ml of PBS containing protease 
inhibitor cocktail (Roche). Cells from individual dishes for the same experimental 
condition were pooled into a 50ml centrifuge tube, and pelleted by centrifugation at 
2,000 rpm for 5 minutes at 4˚C. The cell pellets were re-suspended in 10 ml lysis 
buffer 1 (LB1) per 5x107 cells and placed on a rotating wheel at 4˚C for 10 minutes. 
Cells were pelleted and re-suspended in the same volume of lysis buffer 2 (LB2) and 
placed on a rotating wheel at 4˚C for 10 minutes. Samples were then centrifuged at 
2,000 rpm for 5 minutes at 4˚C and the resulting pellets re-suspended in 1ml of lysis 
buffer 3 (LB3) per 5x107 cells. Cell lysates were divided into 400µl aliquots, and 
sonication was carried out using a Sanyo MSE Soniprep 150 sonicator (MSE Ltd). 
Each sample was subjected to 4 rounds of sonication at 12.5 amplitude for 18 
seconds. Samples were kept on ice during sonication and incubated on ice for at least 
5 minutes in between each round of sonication to reduce samples heating. Cell lysates 
were then centrifuged at 13,000 rpm for 10 minutes at 4˚C. The supernatants were 
collected and pooled in 15ml centrifuge tubes and insoluble debris was discarded. 
10% (v/v) Triton X-100 was added to the supernatants to obtain a final concentration 
of 1% Triton X-100.  
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For each ChIP reaction, 100µl of Dynal beads (Invitrogen, UK) and 5µg of antibody 
were used. Dynal beads were washed 3 times with blocking solution, and re-
suspended in 250µl of blocking solution containing 5µg of antibody. The Dynal beads 
were incubated with antibody at 4˚C with rotation overnight. After antibody 
conjugation, the beads were washed three times with blocking solution to wash away 
unbound antibody. For each ChIP reaction, 500µl of lysate (equivalent to 2.5x107 
cells) was used. 500µl of LB3 buffer with 1% Triton X-100 was added to each sample 
to obtain a total volume of 1ml for immunoprecipitation. 100µl of antibody-
conjugated Dynal beads were added to the diluted lysate and incubated at 4˚C with 
rotation overnight. The beads were washed 6 times with 1 ml of RIPA wash buffer (5 
minutes on rotator at 4˚C for each wash), followed by a final wash with 1ml TBS. The 
bound chromatin from the beads was eluted in 200µl of elution buffer, and incubated 
on a shaker at room temperature for 30 minutes. DNA was recovered by reverse 
cross-linking by incubation at 65˚C for 6 hours. After reverse cross-linking, the 
supernatant was collected and transferred to a fresh 1.5ml microcentrifuge tube. 200µl 
of TE buffer and 8µl of 1mg/ml RNase A (Sigma) were added to each sample and 
incubated at 37˚C for 30 minutes. 4µl of 20mg/ml proteinase K (Invitrogen) was 
added to the samples and further incubated at 55˚C for 2 hours. DNA was purified by 
adding 400µl of phenol-chloroform-isoamyl alcohol (P:C:IA) (Sigma) and mixed by 
vortexing. Samples were centrifuged at 13,000 rpm for 5 minutes, and the aqueous 
layer (top layer) was transferred to a new 1.5ml microcentrifuge tube. 16µl of 5M 
NaCl (Sigma, UK), 1µl of glycoblue DNA carrier (Invitrogen) and 800µl of 100% 
ethanol were added to each sample. Samples were incubated at -80˚C for 30 minutes 
to assist DNA precipitation. DNA was pelleted under centrifugation at 13,000 rpm at 
4˚C for 15 minutes. The DNA pellets were washed with 80% ethanol and dried in a 
speedvac for 20 minutes. The resulting DNA pellet was re-suspended in 50µl of 
10mM Tris-HCl at pH 8. 10 µl of lysate, equivalent to 5% of lysate used in ChIP, was 
added to 190 µl of the elution buffer and processed for DNA recovery as above. This 
DNA served as input DNA control for the ChIP samples. For real-time PCR, input 
DNA equivalent to 0.1% of ChIP lysate (1/50th of the recovered input DNA, 
representing 5% of the lysate used in ChIP) was used. 2µl of the purified ChIP DNA 
was used for SYBR Green qPCR analysis. Signals obtained from the ChIP sample 
were normalised to the input sample, % input = 100*2^(adjusted input as 100% – Ct 
(IP)).  
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Table 2.11 List of solutions for ChIP assay 








Lysis Buffer 2 (LB2) 
 
 















50 mM HEPES-KOH pH 7.5, 100 mM NaCl, 1 mM EDTA, 
0.5 mM EGTA, 1% formaldehyde 
 
50 mM HEPES-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA, 
10% Glycerol, 0.5% Igepal CA-630 and 0.25% Triton X-100 
(Supplement with PIC prior use) 
 
10 mM Tris-HCL pH 8, 200 mM NaCl, 1 mM EDTA and 0.5 
mM EGTA (Supplement with PIC prior use) 
 
10 mM Tris-HCL pH 8, 100 mM NaCl, 1 mM EDTA, 0.5 
mM EGTA, 0.1% sodium deoxycholate and 0.5% N-
lauroylsarcosine (Supplement with PIC prior use) 
 
0.5% BSA in PBS 
 
50 mM HEPES-KOH pH 7.5, 500 mM LiCl, 1 mM EDTA, 
1% Igepal CA-630 and 0.7% sodium deoxycholate 
 
20 mM Tris-HCL pH 7.6 and 150 mM NaCl 
 
50 mM Tris-HCL pH 8, 10 mM EDTA and 1% SDS 
 




Table 2.12 List of antibodies for ChIP 
















ab9110 and 04-902 
sc-268 









Cell Signaling, UK 
Santa Cruz, UK 
Abcam, UK and Millipore, UK 
Santa Cruz, UK 
Abcam, UK 
BD Biosciences, UK 
Santa Cruz, UK 








2.2.20 SYBR Green quantitative PCR for ChIP analysis 
 
Real-time PCR was carried out on an ABI 7900HT fast Real-time PCR system using 
SYBR Green PCR Master Mix (ABI). Each sample was analysed in triplicate, in a 
Microamp™ fast optical 96-well reaction plate sealed using the MicroAmp™ Optical 
Adhesive Film (ABI). Each reaction mixture was prepared as below: 
• 10µl of SYBR® Green PCR Master Mix 
• 1µl of forward primer (10µM) 
• 1µl of reverse primer (10µM) 
• 6µl of nuclease free water 
• 2µl of ChIP DNA or 0.1% input DNA 
 
Thermo cycles for SYBR green reactions: 
• Stage 1 
! 50˚C for 2 minutes and 95˚C for 10 minutes 
• Stage 2 (40 cycles) 
! 95°C for 15 seconds 
! 60°C for 1 minute 
! 94!
Table 2.13 Lists of primers used for ChIP assay 
Primer Sequences 
ERα promoter LRHRE1 Forward: 5’-CTAGCCCAAGTGAACCGAGA-3’ 
Reverse: 5’-ACCTCAGGTCACGAACCAAA-3’ 
ERα promoter LRHRE2 Forward: 5’-GAATGGGACACAAAGGGAAA-3’ 
Reverse: 5’-GGTTTTTGATTAGCTCCTGGAC-3’ 
ERα promoter LRHRE3 Forward: 5’-CCCTTGCAGACTTGGGTAAA-3’ 
Reverse: 5’-TGCATGTACCGCATTTCCTA-3’ 
pS2 ERE  Forward: 5’-TATGAATCACTTCTGCAGTGAG-3’ 
Reverse: 5’-GAGCGTTAGATAACATTTGCC-3’ 




NRIP1 ERE Forward: 5’-CTGCCCCATTCTTTGTGATT-3’ 
Reverse: 5’-TAGCAGGATCTGTGCCAGTG-3’ 
AGR3 Forward: 5’-TTTGAGCTGCCCTGTGCTAA-3’ 
Reverse: 5’-GCTGATGGCATTTTGGCCTC-3’ 
PDZK1 Forward: 5’-AGGCCCAGCAAAGACAAATG-3’ 
Reverse: 5’-AAACCACAGGCTGAGGACTG-3’ 
RET Forward: 5’-CTGAGGGCGCAGAGATACAG-3’ 
Reverse: 5’-TGACTCAGCCAGTCTCACCT-3’ 






Chapter 3 Results 
3.1 Comparison of the activities of the major LRH-1 isoforms 
expressed in breast cancer cells 
3.1.1 LRH-1v4 and LRH-1v1 have similar activities in gene reporter 
assays  
 
The newly identified LRH-1v4 appears to be the predominant LRH-1 isoform 
expressed in most LRH-1 expressing tissues examined, including normal breast tissue 
and breast cancer cells (Thiruchelvam et al, 2011). LRH-1v4 lacks 40 amino acids at 
the N-terminal compared to LRH-1v1, which is the longest form of the protein. As 
this results in a significant truncation of the AF1 domain of LRH-1v1, it is possible 
that LRH-1v4 would be less transcriptionally active. Therefore, I carried out studies to 
compare the transcriptional activity of LRH-1v4 and LRH-1v1 on different LRH-1-
responsive reporter genes. 
 
To determine the transcriptional activities of LRH-1v4 and LRH-1v1, I firstly 
assessed LRH-1 activity on the SF1-Luc. SF1-Luc is a SF-1/LRH-1-responsive 
luciferase reporter, which encodes five copies of the SF-1/LRH-1-responsive elements 
fused to the firefly luciferase gene (Lee et al, 1999). By transfecting increasing 
amounts of the LRH-1 expression plasmids into COS-1 cells, the SF1-Luc activity 
was significantly stimulated by LRH-1 constructs in a dose-dependent manner. 
Maximal stimulation by 9-fold of the reporter activity was observed by both LRH-1 
variants, with no significant difference between the activities of LRH-1v4 and LRH-
1v1 (Figure 3.1A and B). Western blotting was carried out in order to confirm the 
expression of both forms of LRH-1, using an antibody that recognises the DNA 
binding domain of LRH-1 (targeting 181-280 amino acids of LRH-1), enabling 
detection of both LRH-1v1 and LRH-1v4. Similar dose-dependent increased in levels 
of LRH-1v1 (61kDa) and LRH-1v4 (55kDa) was observed (Figure 3.1A and B). 
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To further confirm these results, gene reporter studies were performed using other 
LRH-1 reporter genes. These included 3β-hydroxysteroid dehydrogenase type II 
(HSD3β2), steroidogenic acute regulatory protein (StAR) and aromatase PII 
promoters driving firefly luciferase (Saxena et al, 2004; Sirianni et al, 2002; 
Taniguchi et al, 2009). LRH-1 stimulated the luciferase reporter activity driven by 
HSD3β2 and StAR promoter in a dose-dependent manner. As with the SF1-Luc 
reporter, LRH-1v1 and LRH-1v4 activities were very similar (Figure 3.2A and B). 
For the aromatase PII promoter, transfection of LRH-1 alone was not sufficient to 
drive the promoter activity (Figure 3.2C). This is in agreement with previous reports 
showing that LRH-1-mediated aromatase PII promoter regulation is dependent on co-
expression of GATA transcriptional factors and involves cAMP activity (Bouchard et 
al, 2005). From our studies, we observed that both LRH-1v1 and LRH-1v4 are able to 
synergise with GATA3 and activate the aromatase PII promoter by 5-fold (Figure 
3.2D). This is consistent with the observation that LRH-1 interacts with GATA3 
through the C-terminal region of the protein (Bouchard et al, 2005). As with the other 
reporters, there was no significant difference between activities of the two variants. 
 
3.1.2 LRH-1v1 and LRH-1v4 activities do not differ in response to 
activation of PKA and PKC  
 
The transcriptional activity of LRH-1 can be modulated by phosphorylation. The 
protein kinase A (PKA) mediated phosphorylation of LRH-1 at ser-469 in the ligand 
binding domain (LBD) has been shown to be important in maintaining the interaction 
with GATA3, to enhance activation of the aromatase PII promoter (Bouchard et al, 
2005). In addition, activation of the protein kinase C (PKC) pathway leads to the 
phosphorylation of LRH-1 in the hinge region at ser-238 and ser-243 by ERK1/2 
MAPK, again stimulating LRH-1 activity (Lee et al, 2006). LRH-1v1 and LRH-1v4 
contain the ser-238, ser-243 and ser-469 phosphorylation sites. However, analysis of 
the N-terminal protein sequences of LRH-1 using the web based phosphorylation site 
prediction software, NetPhos 2.0 (Blom et al, 1999), identified a potential PKA 
phosphorylation site at ser-31, which is absent in LRH-1v4 (Figure 3.3A). Therefore, 





Figure 3.1 LRH-1v1 and LRH-1v4 variants activate a LRH-1 reporter gene to 
similar extents 
A) COS-1 cells were co-transfected with a LRH-1 responsive reporter (SF1-Luc) 
together with increasing amounts of LRH-1v1 or LRH-1v4 expression plasmids. SF1-
Luc reporter gene activities were corrected for transfection efficiency by normalisation 
to renilla luciferase activity. Protein lysates were prepared and western blotting was 
performed to determine the expression of LRH-1 variants. B) Similar experiments 
were carried out using 50ng of LRH-1v1 or LRH-1v4 expression plasmid. In each case 
reporter gene activity for the vector control was taken as 1 and all other activities are 
shown relative to this. The data shown are the means of three independent experiments 
and the error bars represent the standard error of the mean (SEM). Paired t-test was 
















































































































Figure 3.2 LRH-1v1 and LRH-1v4 activities are similar for LRH-1 responsive 
reporter genes 
COS-1 cells were co-transfected with the steroidogenic acute regulatory protein 
(StAR) (A) 3β-hydroxysteroid dehydrogenase type II (HSD3β2) (B) or the aromatase 
PII promoter (C) luciferase reporter genes, together with increasing amounts of LRH-
1v1 or LRH-1v4 expression plasmids, as indicated. D) The aromatase PII promoter 
reporter (PII-516-Luc) was co-transfected in COS-1 cells with GATA3, LRH-1v1 or 
LRH-1v4, as shown. In each case, reporter gene activity for the vector control was 
taken as 1 and all other activities are shown relative to this. The data shown are the 
means of three independent experiments and the error bars represent the SEM. Paired 





























































































































































































































Gene reporter assay were carried out to access the activities of LRH-1v1 and LRH-
1v4 in response to PKA and PKC signals. The PKA or PKC pathways were 
stimulated either by co-transfection of the PKA catalytic subunit expression plasmid 
or addition of the PKC activator, phorbol 12-myristate 13-acetate (PMA). We 
observed that LRH-1 induced SF1-Luc activity was stimulated by 3.5-fold by PKA 
(Figure 3.3B), while, PMA stimulated LRH-1 activity by 80-fold (Figure 3.3C). 
However, no significant differences in activity were found between LRH-1v1 and 
LRH-1v4 in response to PKA or PKC activation (Figure 3.3B and C). Taken together, 
these findings indicate that the first 40 amino acids in the N-terminal sequence that 
are absent in LRH-1v4 are not regulated by these signalling pathways and indicate 
that these 40 amino acids do not have a significant impact on LRH-1 transcriptional 
activity, at least in reporter gene assays in COS-1 cells. 
 
3.1.3 LRH-1v1 and LRH-1v4 can be regulated by synthetic agonists 
 
A series of synthetic LRH-1 agonists, exemplified by compounds 5A and 5B have 
been shown to promote LRH-1 activity (Whitby et al, 2006), and compounds 5A has 
been shown to bind to the LRH-1 LBD, to displace phospholipids (Whitby et al, 
2011). Luciferase reporter studies were carried out to determine the responsiveness of 
LRH- 1v1 and LRH-1v4 to these synthetic agonists. SF1-Luc was co-transfected in 
COS-1 cells with either LRH-1v1 or LRH-1v4. Following transfection, cells were 
treated with compound 5A or 5B for 24 hours. The results showed that compound 5A 
and 5B were able to stimulate LRH-1v1 and LRH-1v4 to a similar degree (Figure 
3.4). This suggests that the activities of LRH-1 agonists are mainly mediated through 
the LBD of LRH-1 and suggest that the AF-1 domain in the N-terminal is not required 





Figure 3.3 PKA and MAPK pathways stimulate LRH-1v1 and LRH-1v4 variants 
to similar levels 
A) A diagram showing the serine phosphorylation sites that have been previously 
identified in LRH-1, and a potential PKA phosphorylation site at Ser 31 identified 
using NetPhos 2.0 phosphorylation site analysis software. B) The SF-1-Luc reporter 
gene was co-transfected in COS-1 cells together with LRH-1v1, LRH-1v4 or vector 
control, together with a mouse PKA catalytic subunit expression plasmid. C) 
Transfections were carried out as above. Phorbol 12-myristate 13-acetate (PMA) was 
added at a final concentration of 1µM for 8 hours prior to harvesting for luciferase 
assay. The data shown are the means of three independent experiments and the error 
bars represent the SEM. Reporter gene activity for the vector control was taken as 1 
and all other activities are shown relative to this. Paired t-test was used to compare the 




























































































































Figure 3.4 LRH-1v1 and LRH-1v4 respond in a similar manner to LRH-1 
agonists in reporter gene assays 
COS-1 cells were transfected with the SF-1-Luc reporter gene, together with LRH-
1v1 or LRH-1v4. LRH-1 agonists, compounds 5A or 5B were solubilised in DMSO 
and added to a final concentration of 30 µM. The data shown are the means of three 
independent experiments, in which SF1-Luc activity was normalised to the activity of 
the renilla luciferase. The reporter gene activity with vehicle treatment (DMSO) was 
taken as 1 and all other activities are shown relative to this. The data shown are the 
means of three independent experiments and the error bars represent the SEM. Paired 
t-test was used to compared the activities, n.s. represents not significant with p>0.05. 







































3.2 LRH-1 mediates the growth of breast cancer cells by regulating 
ERα expression 
3.2.1 LRH-1 is important in mediating MCF-7 breast cancer cell 
growth 
 
ERα plays a primary role in regulating breast cancer cell proliferation by regulating 
the expression of estrogen-responsive genes. Previous work in this laboratory 
identified the expression of LRH-1 in breast cancer cells is directly regulated by ERα 
in an estrogen-dependent manner (Thiruchelvam et al, 2011), which has also been 
shown by others (Annicotte et al, 2005). In addition, LRH-1 expression in breast 
tumours is associated with ERα status (Miki et al, 2006), providing support for ERα 
regulation of LRH-1 expression. In order to determine if LRH-1 plays a role in the 
growth of ERα-positive breast cancer cells, I measured the growth of MCF-7 cell 
following siRNA-mediated knockdown of LRH-1. 
 
MCF-7 cells were transfected with three LRH-1 siRNAs. Real-time RT-PCR analysis 
showed that siLRH-1#2 and #3 effectively inhibited the expression of LRH-1 mRNA 
by 90% in MCF-7 cells when compared to the siControl. However, no reduction in 
LRH-1 expression was observed for siLRH-1#1 (Figure 3.5A). This is consistent with 
Western blotting results showing that LRH-1 protein was almost completely lost 
when MCF-7 cells were transfected with siLRH-1#2 and #3, but there was no 
reduction in LRH-1 protein levels for siLRH-1#1 (Figure 3.5B). The growth of MCF-
7 cells was assessed using the sulphorhodamine B (SRB) assay following LRH-1 
silencing. At day 5, cells transfected with siLRH-1#2 and #3 exhibited a significant 
growth reduction by 40% and 20% respectively (Figure 3.5C). These results 
demonstrated that downregulation of LRH-1 inhibits the growth of MCF-7 cells, 









Figure 3.5 LRH-1 regulates MCF-7 cell growth 
MCF-7 cells were transfected with siRNA for LRH-1 or with a control siRNA 
(siControl). Total mRNA and protein were prepared 72 hours post-transfection. qRT-
PCR (A) and western blotting (B) are shown. C) MCF-7 cell growth was measured by 
sulforhodamine B (SRB) assay over a 5 day period. The data shown are the means of 
three independent experiments and the error bars represent the SEM. Asterisks 
indicate p<0.05 using the paired t-test; n.s. represents no statistically significant 
difference. 





































































3.2.2 siRNA mediated knockdown of LRH-1 downregulates the 
expression of ERα and ERα target genes in MCF-7 cells. 
 
A number of nuclear receptors and transcription factors have been shown to be 
involved in estrogen signalling by regulating the expression ERα or mediating ERα 
transcriptional activity, and include FOXA1, FOXO3A, FOXM1, GATA3, and RARα 
(Carroll et al, 2005; Eeckhoute et al, 2007; Millour et al, 2010; Ross-Innes et al, 2010; 
Theodorou et al, 2013). These factors are essential for ERα-regulated growth of breast 
cancer cells. The expression of these factors is also estrogen-regulated, providing 
evidence for the importance of positive regulatory loops for ERα function in breast 
cancer cells. To determine if LRH-1 regulates breast cancer cell growth though 
affecting ERα signalling, the expression of a panel of well-studied estrogen-regulated 
genes in MCF-7 was assessed following siRNA-mediated knockdown of LRH-1. 
 
Real-time RT-PCR analysis showed that expression of several ERα target genes, 
including PR, pS2, NRIP1 and GREB1 was significantly reduced following LRH-1 
silencing (Figure 3.6A). A reduction in pS2 and NRIP1 in protein level was also 
observed following LRH-1 silencing (Figure 3.6B). The reduction in expression of 
estrogen-responsive genes suggested the possibility that LRH-1 knockdown might 
affect ERα levels. Indeed, qRT-PCR and western blotting demonstrated that LRH-1 
silencing resulted in a significant reduction in ERα mRNA and protein levels (Figure 
3.6A and B).  
 
 3.2.3 LRH-1 regulates the activity of ERα gene promoter 
 
To determine if LRH-1 directly regulates the expression of ERα, we analysed the ERα 
gene promoter to search for the presence of potential LRH-1 binding sites. The human 
ERα gene is transcribed from at least seven promoters (A to F) and generates multiple 
transcripts that differ in their 5’ untranslated regions (5’ UTR) (Kos et al, 2001)  
(Figure 3.7). Search across a 150kb region encoding promoters A to F, identified 11 
sequences on either strand, which conformed to consensus LRH-1 binding site 
(5’YCAAGGYCR-3’), as well as a palindromic sequence (5’-CCAAAGCTTTGG- 
3’) which shared sequence similarity with a LRH-1 binding motif identified in the 
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mouse bile salt export pump (BSEP) gene (5’TTCCCAAAGCTTGTT-3’) (Song et al, 
2008) (Figure 3.7). The expression of different ERα transcripts has been previously 
examined in our laboratory and showed that the majority of ERα expression in breast 
cancer cells is initiated at promoter A (Thiruchelvam et al, 2011). Given the presence 
of three putative LRH-1 binding sites that map close to promoter A, we generated an 
ERα promoter luciferase reporter (ERP-Luc) by cloning a 6kb region which contains 
promoters A-D, into a promoter-less luciferase reporter plasmid (pGL3-basic) (Figure 
3.7 and 3.8A). 
 
To determine if LRH-1 could transactivate ERP-Luc, MCF-7 cells were transfected 
with ERP-Luc, together with LRH-1. pGL3-Basic luciferase reporter was included as 
a negative control. Transfection of LRH-1 stimulated ERP-Luc by 20-fold but did not 
affect the pGL3 control vector (Figure 3.8B). This supports the hypothesis that LRH-1 
directly regulates ERα expression in MCF-7 cells. 
 
Short heterodimer partner (SHP) was shown interacts with LRH-1 and serves as a 
potent co-repressor for LRH-1. In addition, the activities of several LRH-1 dependent 
gene promoters are repressed by SHP (Goodwin et al, 2000; Kovacic et al, 2004). To 
further investigate the LRH-1 regulation of the ERα promoter, SHP was co-
transfected with LRH-1. The LRH-1-stimulated activity of ERP-Luc was completely 
blocked by SHP (Figure 3.8C). Given the mode of action of SHP, this experiment 






Figure 3.6 LRH-1 regulates the expression of ERα and ERα target genes in 
MCF-7 cells 
MCF-7 cells were transfected with siRNA for LRH-1 or with a control siRNA (siCtrl). 
Total mRNA and protein were prepared 72 hours post-transfection. A) qRT-PCR 
analysis was performed, as shown. The gene expression was normalised to GAPDH 
control and relative to the siCtrl. The data shown are the means of three independent 
experiments and the error bars represent the SEM. B) Immunoblotting for LRH-1 










































































































































Figure 3.7 Identification of putative LRH-1 response elements (LRHREs) in the 
ERα gene promoter 
A diagrammatic representation of ERα gene promoter region with positions of ERα 
promoters A through F highlighted. Sequences on either the sense or the anti-sense 
strand that conform to LRH-1 consensus binding site (5’-YCAAGGYCR-3’) (Fayard 
et al 2004) are shown, together with a LRHRE sequence (5’TTCCCAAAGCTTGTT-
3’) similar to an unsual LRH-1 binding sites identified in the mouse BSEP gene (Song 
et al 2008). The region of the ERα gene used to generate the ERα promoter luciferase 












































Figure 3.8 LRH-1 stimulates the activity of the ERα gene promoter 
A) A schematic representation of the 6.0 kb ERα gene promoter containing three 
putative LRH-1 regulatory elements. This region was cloned into pGL3 luciferase 
reporter (ERP-Luc). B) MCF-7 cells were co-transfected with the ERα promoter 
reporter (ERP-Luc) or a control reporter plasmid (pGL3-Basic), together with LRH-1. 
C) MCF-7 cells were co-transfected with ERP-Luc and LRH-1, together with SHP. 
Reporter gene activity in the absence of LRH-1 was taken as 1 and all other activities 
are shown relative to this. The data shown are the means of three independent 

























































































3.2.4 Functional analysis of LRH-1 response elements (LRHREs) in 
the proximal ERα promoter region 
 
As highlighted above, the 6 kb region of the ERα promoter used in ERP-Luc contains 
three putative LRH-1 responsive elements (LRHRE). I generated 3’ deletion 
constructs in a luciferase reporter plasmid encoding a minimal promoter element 
(pGL3-promoter) (Figure 3.9A). Deletion of ERα promoter from -2341 to -117 
(ERPF1) showed a small, but significant reduction in LRH-1 stimulated activity. 
However, LRH-1 did not stimulate the activity of the shorter fragment (ERPF2), 
which contains two sequences conforming to the LRH-1 binding motif, suggesting 
that LRHRE2 and LRHRE3 are not involved in the regulation of ERα by LRH-1 
(Figure 3.9B). This finding was confirmed by site-directed mutagenesis of each of the 
three putative LRHREs (Figure 3.10A). Mutation of LRHRE2 (ERPm2), LRHRE3 
(ERPm3) or both sites, did not affect LRH-1 activity, whereas mutation of LRHRE1 
(ERPm1) significantly reduced reporter gene activation by LRH-1, suggesting that 
LRHRE1 is required for the binding of LRH-1 to mediate ERα gene transcription 
(Figure 3.10B). 
 
Chromatin immunoprecipitation (ChIP) assay was next performed to determine if 
LRH-1 is recruited to the ERα gene promoter. Due to insufficient enrichment of LRH-
1 pull-down using commercial antibodies, an epitope-tagged LRH-1 construct (HA-
LRH-1) was transfected into MCF-7 cells. Primers that flank each of the LRHREs 
were used in qPCR to determine LRH-1 binding (Figure 3.11A). In agreement with 
the deletion and site-directed mutagenesis experiments described above, no LRH-1 
binding was evident for LRHRE2 or LRHRE3 (Figure 3.11B). However, LRH-1 
binding at LRHRE1 was observed. Collectively, these data demonstrated ERα is a 
direct transcriptional target of LRH-1 and identify a LRH-1 binding site located in the 






Figure 3.9 Regulation of the 6kb ERα gene promoter by LRH-1 requires 
sequences that include LRHRE1 
A) A diagram representing the ERα promoter reporter, together with constructs 
containing smaller regions of the ERα promoter. B) Reporter activities were assessed 
in MCF-7 cells by co-transfection of LRH-1. The activity of the reporter constructs is 
shown relative to the vector control. The data shown are the means of three 
independent experiments and the error bars represent the SEM. Asterisks indicate 
































































   
 
    
Figure 3.10 LRHRE1 is required for activation of the ERα promoter luciferase 
reporter gene by LRH-1 
A) A diagram representing the ERα promoter reporter and the mutants with disruption 
of the putative LRHREs. B) Reporter activities were accessed in MCF-7 cells by co-
transfecting ERP-Luc or mutant reporters with LRH-1. Reporter gene activity in the 
absence of LRH-1 was taken as 1 and all other activities are shown relative to this. 
The data shown are the means of three independent experiments and the error bars 
represent the SEM. Asterisk show the mutants whose activities were significantly 
























































































Figure 3.11 LRH-1 binds to LRHRE1 in the ERα gene promoter 
A) A diagram of ERα gene promoter with putative LRH-1 binding sites is shown. 
Arrows indicate the positions of primers used for qPCR in the ChIP assay. B) MCF-7 
cells were transfected with HA-LRH-1 expression plasmid. ChIP was performed 
using an HA antibody and control ChIP was carried out using mouse IgG. qPCR was 
carried out using primers flanking each putative LRH-1 binding site. Bar charts show 
the means of three independent experiments; error bars represent the SEM. An 



































3.2.5 LRH-1 and GATA3 can regulate the ERα promoter activity 
synergistically 
 
Previous studies showed that LRH-1 cooperates with GATA3 in mediating gene 
transcription on several gene promoters, including the aromatase PII promoter 
(Bouchard et al, 2005; Martin et al, 2005b; Robert et al, 2006). In addition, GATA3 
positively regulates ERα expression in breast cancer cells (Eeckhoute et al, 2007). 
Therefore, I investigated whether LRH-1 and GATA3 cooperate in the regulation of 
ERα expression. As shown above (Figure 3.2D), LRH-1 and GATA3 synergistically 
stimulate aromatase PII reporter gene activity (Figure 3.12A). Interestingly, a similar 
co-operativity between LRH-1 and GATA3 was also observed in the case of ERP-Luc 
(Figure 3.12B). 
 
PKA has previously been shown to promote synergism between GATA3 and LRH-1 
on the aromatase PII promoter (Bouchard et al, 2005) and see Figure 3.2. PKA 
stimulates the synergism between LRH-1 and GATA3 in MCF-7 cells for the 
aromatase PII promoter luciferase reporter (Figure 3.13A). Interestingly, PKA did not 
promote synergism between LRH-1 and GATA3 (Figure 3.13B). Indeed, PKA 
inhibited LRH-1/GATA3 activation of ERP-Luc, suggestive of PKA independence of 
LRH-1 and GATA3 in the regulation of ERα expression. In fact, the results raise the 
possibility that PKA inhibits LRH-1 and GATA3 activity in the regulation of ERα 
expression, which may be important in their regulation of aromatase and ERα 







Figure 3.12 LRH-1 and GATA3 act synergistically to stimulate the aromatase 
PII and ERα reporter genes 
The aromatase PII promoter luciferase reporter (PII-516-Luc) (A) or the ERα 
promoter reporter (ERP-Luc) (B) were co-transfected into MCF-7 cells together with 
GATA3 and LRH-1. Reporter gene activity for the vector control was taken as 1 and 
all other activities are shown relative to this. The data shown are the means of three 































































































Figure 3.13 Protein Kinase A promotes the synergism between LRH-1 and 
GATA3 on the aromatase PII promoter, not on the ERα promoter 
MCF-7 cells were transfected with the aromatase PII promoter luciferase reporter 
(PII-516-Luc) (A) or the ERα promoter reporter (ERP-Luc) (B), together with GATA3 
and LRH-1 and increasing amounts of the mouse PKA catalytic subunit expression 
plasmid. Reporter gene activity for the vector control was taken as 1 and all other 
activities are shown relative to this. The data shown are the means of three 
















































































3.3 Identification of LRH-1-regulated gene in breast cancer cells 
3.3.1 Gene expression microarray analysis following siRNA-mediated 
LRH-1 silencing 
 
Having established that LRH-1 regulates breast cancer cell growth and that it acts, in 
part, by regulating ERα expression, we wanted to identify other LRH-1 target genes. 
Towards this aim, we performed a gene expression microarray in MCF-7 cells 
following siRNA-mediated LRH-1 downregulation. The two siRNAs (siLRH-1#2 and 
#3) that strongly reduced LRH-1 expression in MCF-7 cells were transfected in MCF-
7 cells and RNAs prepared from four biological replicates were used with the Human 
HT-12 v 3.0 Expression BeadChIP from Illumina. The microarray study was carried 
out under contract with the service offered by the Dept. of Pathology at Cambridge 
University. 
 
Hierarchical cluster analysis identified 222 genes, the expression of which was 
significantly altered (p<0.01, fold change >1.5) by both LRH-1 siRNAs when 
compared to the control siRNA. Ninety-one of these genes are upregulated and 131 
genes are downregulated following LRH-1 silencing. In order to define the functional 
roles of LRH-1-regulated genes in MCF-7 cells, gene ontology (GO) enrichment 
analysis was carried out. This analysis showed enrichment for genes involved in 
estrogen and steroid hormonal signalling and metabolic processes. The most 
significantly enriched genes are those associated with “response to estrogen stimulus” 
(Lai et al, 2013). As we have already demonstrated LRH-1 regulates the expression of 
ERα, these further confirmed that LRH-1 played a central role in estrogen signalling. 
  
3.3.2 LRH-1 genome binding is enriched at ERα binding sites in 
breast cancer cells 
 
Given that LRH-1 regulates ERα expression, it is possible that the ERα-regulated 
genes whose expression was reduced in the microarray analysis following LRH-1 
knockdown are simply indirect targets of LRH-1. To address this, we decided to carry 
out ChIP-seq for LRH-1 in MCF-7 cells. Due to the lack of sufficient enrichment 
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achieved for ChIP at the ERα promoter (see section 3.2.4), we decided to perform 
ChIP-seq following ectopic expression of HA-tagged LRH-1 in MCF-7 cells. MCF-7 
cells were transiently transfected with LRH-1 and protein lysates were prepared for 
Western blotting and ChIP lysates after 48 hours. The fixed cell pellets were sent to 
Dr Wilbert Zwart in the laboratory of Dr Jason Carroll (CRUK Cambridge Research 
Institute). Dr Wilbert Zwart performed ChIP using antibodies for the HA tag, as 
described (Schmidt et al, 2009). The ChIP DNA was amplified and sequences were 
generated on an Illumina HiSeq 2000 gene analyser. ChIP-seq of two biological 
replicates resulted in the identification of 4,876 high-confidence LRH-1 binding sites 
(Lai et al, 2013).  
 
Interestingly, of the 4,876 LRH-1 binding sites, 35% (1,723) binding sites overlapped 
with ERα binding sites. Motif enrichment analysis identified a sequence 5’-
YCARGGYCA-3’ (Y=C/T; R=A/G), consistent with the previously identified LRH-1 
binding sequence consensus 5’-YCAAGGYCR-3’ (Fayard et al, 2004), present in the 
LRH-1 binding sites that did not overlap with ERα binding sites, as well as in the 
LRH-1/ERα shared sites. A motif consistent with the ERE consensus sites was the top 
hit in the ERα unique sites. Binding of LRH-1 at estrogen-responsive elements in ERα 
target was observed in a number of well-defined estrogen-regulated genes, including 
the pS2 (TFF1) and NRIP1 genes (Lai et al, 2013). These findings raise the possibility 
that LRH-1 directly regulates the expression of many ERα target genes. 
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3.3.3 LRH-1 activates an estrogen-responsive pS2 reporter gene 
 
To explore the potential link between LRH-1 and ERα in the regulation of common 
target genes, we focused on the pS2 gene, as the regulation of its expression by ERα 
has been extremely well studied. The pS2 gene was originally identified in MCF-7 
cells following a differential hybridisation strategy for identifying estrogen-regulated 
genes (Jakowlew et al, 1984; Masiakowski et al, 1982) and is expressed in about 50% 
of ERα-positive breast cancers (Foekens et al, 1990). Estrogen regulation is mediated 
by an estrogen response element (ERE) located 407bp upstream of the transcriptional 
start site (Berry et al, 1989; Lu et al, 2001) and the mechanisms of ERα and co-
activator recruitment, as well as histone modification have been defined in great detail 
(Metivier et al, 2003). LRH-1 ChIP-seq demonstrated its recruitment to the ERα 
binding region. Examination of the ERE sequence showed that the pS2 ERE is also a 
consensus LRH-1 binding motif (Figure 3.14A).  
 
In order to validate the pS2 gene as a direct LRH-1 target gene, reporter gene studies 
were used to determine if LRH-1 activates the pS2 gene and if the LRH-1 regulation 
is mediated by the already defined ERE at -407. COS-1 cells were co-transfected with 
a pS2 promoter luciferase reporter (kind gift of Prof Vincent Giguere, Montreal) (Lu 
et al, 2001), together with LRH-1 or ERα. As expected, ERα stimulated the pS2 
reporter gene. Interestingly, LRH-1 also stimulated the pS2 reporter gene. The pS2 
reporter activity was further enhanced by LRH-1 in the presence of the LRH-1 
synthetic agonist, compound 5A (Figure 3.14B).  
 
A pS2 reporter gene in which the ERE has been deleted (pS2ΔERE-Luc) was not 
activated by ERα (Figure 3.14C). Deletion of the ERE also reduced LRH-1 activation 
by 80%, demonstrating the importance of the ERE for LRH-1 activation of this 
reporter gene. There was some activation of the mutant reporter by LRH-1, which 
may be due to the presence of another potential LRH-1 binding site, 5’-
TTAAGGTCA-‘3 (-269/-260), which is a binding site for estrogen receptor-related 
receptors (ERRs) (Lu et al, 2000). ChIP-seq provided no direct evidence for LRH-1 









Figure 3.14 LRH-1 binds at the estrogen-responsive element in pS2 promoter 
and regulates promoter activity 
A) Shown are the consensus ERE and LRH-1 binding sequences, together with the 
sequence of the estrogen-responsive element (ERE) in the pS2 gene promoter. COS-1 
cells were grown in estrogen-depleted medium for 72 hours. Cells were then 
transfected with a pS2 luciferase reporter gene (B and C) or a pS2 promoter reporter 
with deletion of the ERE sequence (pS2ΔERE-Luc) (C), together with ERα or LRH-
1. Cells were treated with 17β-estradiol (E2) at 10nM or the LRH-1 synthetic agonist 
compound 5A at 25µM for 24 hours. The data shown are the means of three 










































ERα consensus:             AGGTCANNNTGACCT 
LRH-1 consensus:        YCAAGGYCR 


















































































To further examine the functionality of the overlapping hormone responsive elements 
for LRH-1 and ERα in the pS2 promoter, we assessed the binding of LRH-1 and ERα 
using the electrophoretic mobility shift assay (EMSA) with in vitro transcription/ 
translation (IVTT) LRH-1 and ERα (Figure 3.15A). DNA oligo probes with specific 
mutations at binding motif were used in EMSA to define binding sequence 
requirements for LRH-1 and ERα (Figure 3.15B). As expected, ERα bound to the pS2 
ERE (Figure 3.15C). Substitution of sequences 5’ to sequences conforming to the 
ERE consensus did not prevent ERα binding (pS2 EREm1), whereas substitutions in 
either arm of the palindromic ERE sequence drastically reduced ERα binding (pS2 
EREm2, m3, m4). LRH-1 bound to the pS2 ERE, confirming the ChIP-seq and 
reporter gene results. Moreover, substitution of sequences 5’ to the ERE, known to be 
required for LRH-1 binding (pS2 EREm1), prevented LRH-1 binding to the pS2 
sequence, as did substitutions in the 5’ ERE half-site (pS2 EREm2, m4), whereas 
mutation of the 3’ ERE half-site did not affect LRH-1 binding (EREm3).  
 
Introduction of these mutations in the pS2-Luc reporter by site directed mutagenesis 
had the expected effect on reporter gene activation by ERα and LRH-1. Thus, 
mutations that prevented ERα or LRH-1 binding in EMSA also prevented pS2-luc 
activation by ERα and LRH-1 (Figure 3.15E, F). This demonstrates that LRH-1 can 
be recruited to the pS2 ERE to promote pS2 gene expression.  
 
To further demonstrate the specificity of LRH-1 and ERα binding to DNA, EMSA 
was carried out using the well characterised ERE in the chicken vitellogenin gene 
(vit-ERE) (Galarneau et al, 1996). The vit-ERE does not contain the 5’ extension 
required for LRH-1 binding and as expected LRH-1 did not bind this sequence in 
EMSA. Substitution of the GTC trinucleotide 5’ to the ERE, by TCA, generates a 
good consensus LRH-1 binding site (vit EREm3), to which LRH-1 did indeed bind 
(Figure 3.15D). Substitution of the GTC trinucleotide by GCA, present in the pS2 
gene, also allowed LRH-1 binding. Neither of these mutations prevented ERα binding 
to the vit ERE (Figure 3.15C). ERα binding was prevented by mutation of the 5’ ERE 
half-site (vit EREm1).      
 
The LRH-1 binding site that has been mapped in the mouse alpha foetal protein (AFP) 
gene promoter (Galarneau et al, 1996) served as another control for this experiment. 
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As expected, ERα did not bind the AFP LRH-1 binding site, whereas LRH-1 bound to 
the wild-type but not mutant binding site.   
 
As described above, a considerable proportion (35%) of LRH-1 binding sites 
overlapped with ERα binding sites, including the pS2 promoter proximal ERE. EMSA 
was performed for another ER α binding site, mapping to intron 1 (chr 21:15299682-
15299703 in the hg18 genome build (http://genome.ucsc.edu)) of the NRIP1 gene, a 
region to which ChIP-seq demonstrated LRH-1 recruitment. As in the case of the pS2 
ERE, LRH-1 bound the NRIP1 ERE, binding being blocked by mutations in the 5’ 










ER consensus             AGGTCANNNTGACCT 
LRH-1 consensus       YCAAGGYCR 
pS2 ERE        GATCCCTGCAAGGTCACGGTGGCCACCCCGTGA 
pS2 EREm1      GATCCCTGgtAGGTCACGGTGGCCACCCCGTGA 
pS2 EREm2      GATCCCTGCAAccTCACGGTGGCCACCCCGTGA 
pS2 EREm3      GATCCCTGCAAGGTCACGGTGGggACCCCGTGA 
pS2 EREm4      GATCCCTGCAAccTCACGGTGGggACCCCGTGA 
 
NRIP1 ERE      ATGCAGCTCAAGGTCACACACTAACCCGCCCTGTG 
NRIP1 EREm1    ATGCAGCTgtAGGTCACACACTAACCCGCCCTGTG 
NRIP1 EREm2    ATGCAGCTCAAccTCACACACTAACCCGCCCTGTG 
 
Vit ERE        GATCCAAAGTCAGGTCACAGTGACCTGATCAAAGA 
Vit EREm1      GATCCAAAGTCAccTCACAGTGACCTGATCAAAGA 
Vit EREm2      GATCCAAAGcaAGGTCACAGTGACCTGATCAAAGA 
Vit EREm3      GATCCAAAtcaAGGTCACAGTGACCTGATCAAAGA 
 
AFP         CTATCTTATGTTCAAGGACAAAGACCACTTC 













































































Figure 3.15 LRH-1 binds to estrogen-responsive elements in estrogen-regulated 
gene promoters 
A) Western blotting of IVTT reactions used for EMSA. (B) Shown are the consensus 
ERα and LRH-1 binding site sequences. Also shown are the human pS2, NRIP1 and 
chicken vitellogenin (vit) gene ERE sequences, as well as the sequence of the LRH-1 
binding site in the mouse alpha-fetoprotein (AFP) gene. Mutations introduced in the 
different binding sites are shown, with changes from wild-type sequences highlighted 
in red, lower case lettering. EMSA was carried out using double-stranded labelled 
oligonucleotides with the sequences as defined in (B), using IVTT for ERα (C, G) or 
LRH-1 (D, G). COS-1 cells cultured in estrogen-depleted medium were transfected 
with the pS2 promoter luciferase reporter (pS2-Luc) or the mutant pS2 reporter genes 
that contain the mutations as shown in (B). Shown are the reporter activities induced 
by ERα (D) or LRH-1 (F). Following normalisation for the renilla luciferase 
activities, pS2 promoter activities are shown relative to the activities obtained for wt 
pS2-luc. The data shown are the means of three independent experiments and the 




3.4 Synergistic recruitment of LRH-1 and ERα to estrogen response 
elements at ERα binding regions 
3.4.1 LRH-1 promotes ERα binding at estrogen-responsive 
promoters 
 
LRH-1 ChIP-seq analysis in MCF-7 cells demonstrated that binding of LRH-1 is 
enriched at a subset of ERα binding sites. In addition, I showed that LRH-1 binds to 
an overlapping LRH-1 and ERα response element and that LRH-1 can promote 
luciferase activity of a pS2-luc reporter gene through binding to the overlapping 
binding site. To confirm the above findings, I performed LRH-1 ChIP analysis 
following transfection of HA-LRH-1 in MCF-7 cells, under conditions which did not 
lead to an increase in ERα protein levels (Figure 3.16D). ChIP followed by qPCR 
demonstrated recruitment of LRH-1 to the pS2 ERE region (Figure 3.16A), as well as 
the NRIP1, PDZK1, RET and AGR3 ERα binding regions, but not to an ERα binding 
region in the ELOVL2 gene, for which no LRH-1 binding was observed for LRH-1 
ChIP-seq.  
 
ChIP for ERα confirmed its binding to these regions (Figure 3.16B). Interestingly, I 
observed an increase in ERα recruitment at all of the ERα binding regions to which 
LRH-1 is recruited, but not at the ERα binding region in the ELOVL2 gene (Figure 
3.19B, C). These findings suggest that LRH-1 enhances ERα recruitment at ERα 
binding regions. To confirm a role for LRH-1 in promoting ERα recruitment to DNA, 
I carried out ChIP for ERα following siRNA-mediated LRH-1 knockdown. LRH-1 
knockdown resulted in a 50% reduction in ERα binding at sites to which the LRH-1 
binds, including pS2, NRIP1, PDZK1, RET and AGR3, but not at the ELOVL2 gene 
(Figure 3.17). Taken together, these data show that LRH-1 promotes the recruitment 





Figure 3.16 LRH-1 is recruited to ERα binding regions and promotes ERα 
recruitment 
MCF-7 cells were transiently transfected with HA-LRH-1 or vector control. Cells 
were fixed and harvested 48 hours post-transfection and ChIP was performed using a 
HA (A) or an ERα (B) antibody. The bar charts represent the mean of the qPCR 
results from three independent experiments, presented as fold enrichment relative to 
the enrichment obtained for the IgG control. Error bars represent the SEM. C) ERα 
ChIP qPCR results from (B) are shown relative to the vector transfected control. The 
results are the means of three independent experiments and the error bars represent 
the SEM. Asterisks show p<0.05. Difference in ERa binding to the ELOVL2 region 





















































































































































































































Figure 3.17 siRNA-mediated knockdown of LRH-1 leads to a reduction of ERα 
binding to estrogen-responsive promoter 
A) MCF-7 cells were transfected with LRH-1 siRNA or a control siRNA (siCtrl). 
Cells were fixed and harvested for ChIP 48 hours post-transfection and ChIP-qPCR 
for ERα was carried out as in Figure 3.19 (B) The results in (A) are shown relative to 
the siCtrl transfection. The data shown are the means of three independent 
experiments and the error bars represent the SEM. Asterisks represent p<0.05, n. s. 


















































































































3.4.2 LRH-1 and ERα do not bind to pS2 ERE simultaneously and do 
not interact with each other 
 
The data above indicated the co-operative action between LRH-1 and ERα on 
estrogen-responsive gene promoters. Given the overlapping DNA binding motifs 
occurring in these sites, I examined whether both receptors simultaneously bind to the 
pS2 ERE sequence. In EMSA studies, I detected the binding of ERα and LRH-1 to the 
pS2 ERE sequence as have been shown in figure 3.15. However, no additional 
migrating complex was observed when both proteins were mixed compared to LRH-1 
or ERα alone (Figure 3.18A), indicating LRH-1 and ERα do not co-occupant at the 
pS2 ERE. In addition, the interaction between LRH-1 and ERα was examined. Co-
immunoprecipitations of ERα and LRH-1 were performed from protein extracts 
prepared from in COS-1 cells following the ectopic expression of HA-LRH-1 and 
ERα. These results showed no evidence of interaction between LRH-1 and ERα 
(Figure 3.18B). Taken together, these results indicated that co-operative function 
between LRH-1 and ERα does not involve the co-occupancy at the binding sites, 
suggesting a mechanism involving a cyclical binding of ERα and LRH-1 to the 









Figure 3.18 LRH-1 and ERα do not interact and binds to pS2 sequence 
simultaneously 
A) EMSA was carried out using pS2 and AFP labelled oligonucleotides incubated 
with IVTT products of ERα or LRH-1 alone or in a mixture. B) COS-1 cells were 
transiently transfected with pSG5-ERα and HA-LRH-1. Cell extracts were prepared 













































3.4.3 LRH-1 is required for the recruitment of ERα cofactors and co-
activators to modulate chromatin structure 
 
Chromatin remodelling is critical for transcription initiation and ERα binding has 
been shown to promote the recruitment of transcriptional co-activator proteins, 
including the p160 (SRC1/TIF2/AIB1) co-activators that facilitate the recruitment of 
histone acetyltransferases such as p300 and CBP histone acetyltransferase (HAT) 
transferases. HATs such as p300/CBP acetylate core histones, to enhance chromatin 
accessibility (Shang et al., 2000). Additional modifications required for transcription 
initiation by ERα and other transcription factors include histone lysine and arginine 
methylation (Metivier et al, 2003; Metivier et al, 2006). Additionally, recent ChIP-seq 
studies have demonstrated the importance of other transcription factors, particularly 
pioneer factors FOXA1 and GATA3, for the recruitment of ERα to DNA (Carroll et 
al, 2005; Laganiere et al, 2005b; Theodorou et al, 2013). Since LRH-1 stimulates the 
recruitment of ERα to DNA, I hypothesised that LRH-1 may promote ERα 
recruitment by promoting pioneer factor recruitment and/or by facilitating chromatin 
remodelling by promoting the recruitment of co-activators and consequent histone 
modification. 
 
ChIP assays were performed to assess the binding of co-activators following LRH-1 
siRNA transfection in MCF-7 cells (Figure 3.19A). There was a significant decrease 
in AIB1, p300 and CBP recruitment to pS2 promoter ERE region following LRH-1 
silencing. In addition, a marked reduction in levels of histone H3 lysine 9 and 27 
acetylation (H3K9Ac and H3K27Ac) was evident. Furthermore, markers of 
transcriptional activity including H3K4Me3 and the recruitment of RNA polymerase 
II  (RNA PolII) were also reduced upon silencing of LRH-1. Note that levels of these 
proteins were not reduced following LRH-1 knockdown (Figure 3.19B). Taken 
together, these findings demonstrate the importance of LRH-1 in augmenting the 
recruitment of co-activator proteins, which may aid ERα recruitment and gene 
transcription. 
 
FOXA1 and GATA3 transcription factors are known for mediating ERα binding by 
recruiting co-regulatory complex in modulating chromatin accessibility, so-called 
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pioneer factors for ERα (Carroll et al, 2005; Laganiere et al, 2005b; Theodorou et al, 
2013). Silencing of LRH-1 did not affect FOXA1 binding to pS2 ERE promoter 
region, reflecting the fact that FOXA1 is reportedly bound to DNA prior to the 
recruitment of ERα. However, the binding of GATA3 was significantly reduced 
following downregulation of LRH-1 (Figure 3.19A). The inhibition of GATA3 
recruitment is not due to a reduction in GATA3 levels (Figure 3.19B). Synergism 
between GATA3 and LRH-1 has been described for a number of genes (Bouchard et 
al, 2005; Robert et al, 2006), as exemplified by the aromatase PII promoter (Figure 
3.2D and 3.12). Since GATA3 aids ERα recruitment to DNA, promotion of GATA3 
recruitment to ERα-regulated gene promoters may therefore provide a mechanism by 







Figure 3.19 LRH-1 is required for the recruitment of co-activators and ERα 
cofactors to modulate chromatin structure 
A) MCF-7 cells were transfected with siRNA for LRH-1 or a control siRNA. ChIP 
followed by qPCR was performed as in Figure 3.16. The data shown are representing 
as relative to IgG control, except in the case of ChIP for acetylated and methylated 
H3, where the enrichment is shown relative to the ChIP for total H3. The bar charts 
represent the means of three independent experiments and error bars represent as 
SEM. Asterisks show statistically significant differences (p<0.05). n.s. represents not 


















































































































































































3.4.4 ERα regulates LRH-1 recruitment to ERα binding regions 
 
The data so far presented highlight the importance of LRH-1 in facilitating 
recruitment of ERα to estrogen-responsive promoters in breast cancer cells. To further 
examine LRH-1 and ERα co-operativity at the co-binding regions I assessed the 
impact of the ERα ligands 17β-estradiol (E2) and ICI182,780 (ICI) on LRH-1 
binding. Treatment of MCF-7 cells transiently transfected with HA-LRH-1 with E2 
stimulated LRH-1 binding (Figure 3.20). Conversely, ERα downregulation by the 
addition of the selective estrogen receptor downregulator (SERD) ICI182,780 (ICI) 
led to reduced LRH-1 binding (Figure 3.21). These results suggest that ERα promotes 
LRH-1 binding to DNA. In the absence of evidence for a physical interaction between 
LRH-1 and ERα, or for co-occupancy of LRH-1 and ERα at shared LRH-1/ER 
binding sites, these results provide evidence for a model in which LRH-1 binding 
promotes ERα binding and ERα binding promotes LRH-1 binding, perhaps involving 
sequential recruitment and dissociation of the two factors, as proposed in the “assisted 









Figure 3.20 Recruitment of LRH-1 to the estrogen-responsive promoters can be 
modulated by ERα activity 
MCF-7 cells were cultured in hormone-depleted media for 3 days followed by 
transient transfection of HA-LRH-1 or vector control. LRH-1 and ERα binding on 
estrogen-responsive promoters was assessed following the addition of 10nM E2 for 
45mins. ChIP was performed using an ERα (A) or a HA (B) antibody and qPCR 
analysis was performed as previously. The bar charts represent the means of three 
independent experiments, enrichment is relative to IgG control, the error bars 
represent the SEM. Asterisks show statistically significant differences (p<0.05). n.s. 
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Figure 3.21 Downregulation of ERα by ICI treatment reduces LRH-1 
recruitment to estrogen-responsive promoters 
MCF-7 cells were transfected with HA-LRH-1, followed by the addition of 100nM 
ICI182, 780 for 24 hours. ChIP for ERα (A) or HA (B) and qPCR were carried out as 
before. The bar charts represent the means of three independent experiments, 
enrichment is relative to IgG control, and the error bars represent the SEM. Asterisks 
show statistically significant differences (p<0.05). n.s. represents not significant. C) 
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3.5 Towards the development of small molecule inhibitors of LRH-1. 
 
Key to the inhibition of ERα activity in breast cancer has been the development and 
use of drugs, primarily tamoxifen, that block estrogen signalling by competing with 
estrogen for binding to the ERα LBD, to prevent its activation. The work described in 
this thesis clearly identifies LRH-1 as an important regulator of ERα action in breast 
cancer cells. Drugs that can inhibit LRH-1 action may provide a novel strategy for the 
treatment of ERα-positive breast cancer. Towards this end, a collaboration was 
initiated with Prof Tony Barrett and Prof Alan Spivey in the Department of 
Chemistry, Imperial College, together with the computer assisted drug design group 
led by Prof J Snyder, Emory University. The aim was to use a computer-based de 
novo drug design approach to develop novel LRH-1 antagonists. The approach used 
was to model known nuclear receptor antagonists, primarily tamoxifen and raloxifene, 
both selective estrogen receptor modulators (SERMs) in the LRH-1 LBD and 
introduce modifications that would allow binding within the LRH-1 LBD, but cause 
movement of helix 12 (AF2) out of the active position and thereby inhibit LRH-1 
activity. Although this approach yielded some interesting compounds that inhibited 
LRH-1 activity, they inhibited LRH-1 activity only at high concentrations and 
appeared to have off target effects. Nonetheless, these compounds represent the first 
described potential LRH-1 antagonists (Rey et al, 2012). These compounds are not 
described here as other team members carried out the major part of the work on these 
compounds. In carrying out screening with these compounds, however, I included a 
number of compounds developed using a novel chemistry approach for facile 
synthesis of complex resorcylate compounds, some of which have activity for nuclear 
receptors, for example zearalenone, identified as an ERα agonist over 30 years ago 
(Kiang et al, 1978; Martin & Keen, 1978; Patel et al, 2011). The characterization of a 





3.5.1 Development of a mammalian two-hybrid assay to access the 
interactions between LRH-1 and co-regulators 
 
The mammalian two-hybrid assay (M2H) was developed as a tool to screen for novel 
LRH-1 antagonists. The M2H approach provides a method for detecting protein-
protein interactions. It is well established that LRH-1 interacts with a number of co-
activator proteins including p160 family members, p300/CBP and PGC-1α (Safi et al., 
2005). Many of these co-activator proteins possess α-helical motifs containing 
LXXLL sequences (named the NR box) that interact with a charge clamp generated in 
ligand-bound NR LBDs, involving α-helices H3, H4, H5 and H12 (Heery et al, 1997; 
Nagy & Schwabe, 2004; Nettles & Greene, 2005; Shiau et al, 1998). Transcriptional 
co-repressors often interact with antagonist bound LBD, or to the unliganded LBD 
through a more extended α-helical motif, known as a CoRNR box conforming to the 
consensus sequence, (I/L)XX(I/V)I (Hu & Lazar, 1999). For the M2H assay, I co-
transfected cells with constructs that express the LRH-1 LBD as a fusion protein with 
the VP16 activation domain, and a second construct that encodes co-regulator 
peptides that contain the NR interacting motifs as fusion proteins with the GAL4 
DBD. This allows the quantitative measurement of the interaction between the LRH-1 
LBD and co-regulator peptides using a GAL4 responsive luciferase reporter gene. 
 
The synthetic LRH-1 agonist, compound 5A, stimulated interaction of the LRH-1 
LBD with PGC-1α and TIF2 (Figure 3.22A, B). Interaction of the LRH-1 LBD with 
SHP, the NR that acts as a LRH-1 repressor was detected, but was not influenced by 
compound 5A (Figure 3.22C). However, there was no detectable interaction of the 
LRH-1 LBD with the NCoR and SMRT CoRNR motifs (Figure 3.22D-E). This is in 
agreement with the structural finding that LRH-1 LBD adopts a constitutively active 
conformation that preferentially favours co-activator recruitment (Sablin et al, 2003). 
This active LBD structure results in an inability of LRH-1 to recruit conventional co-
repressors NCoR and SMRT. The recruitments of atypical co-repressors, SHP and 
DAX-1, are mediated through the presence of LXXLL motifs in these NRs, hence the 
interaction with SHP that is observed here. The lack of stimulation of LRH-1 LBD 
interaction with SHP by compound 5A is interesting and unexplained, but may be due 
to likelihood that SHP interacts with the LRH-1 LBD through the conventional 
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LXXLL motif mediated interaction but has additional contacts with the LRH-1 LBD, 
as has been described for the interaction of the LRH-1 LBD with DAX1 (Sablin et al, 
2008). Other synthetic LRH-1 agonists (Whitby et al, 2006; Whitby et al, 2011) 
similarly stimulated the LRH-1 LBD interaction with PGC-1α, but did not greatly 
influence its interaction with SHP (Figure 3.23).  
 
3.5.2 Screening the resorcylate compound library discovered 
potential LRH-1 antagonists that inhibit LRH-1 and co-activator 
interactions 
 
A library of 45 resorcylate compounds provided by Barrett laboratory was initially 
screened using M2H with the VP-16 fused to the LRH-1 LBD and GAL4-PGC-1α, at 
concentrations ranging from 0.1 - 25 µM (Figure 3.24).  Sixteen compounds inhibited 
the recruitment of PGC-1α to LRH-1 LBD in a dose dependent manner (Figure 
3.24A-C). However, at high concentrations (25µM) nine of these compounds also 
appeared to affect the renilla luciferase transfection control, suggestive of non-
specific transcriptional effects by these compounds. These compounds were therefore 
not further evaluated. On this basis, 7 compounds selectively inhibited the LRH-
1/PGC-1α interaction, namely compounds ICNR007, ICNR010, ICNR014, ICNR016, 
ICNR026, ICNR029, ICNR031 (chemical structures as shown in figure 3.25A).  
 
The M2H assay was repeated for the seven compounds and confirmed the findings of 
the initial screen (Figure 3.25B). Compounds ICNR014 and ICNR16 showed 80% 
inhibition of LRH-1/PGC-1α interaction at 25 µM, whilst compounds ICNR007, 
ICNR010, ICNR026, ICNR029 and ICNR031 showed ≥50% inhibition at a 
concentration of 25µM (Figure 3.25B).  
 
A LRH-1 reporter gene assay was used to further evaluate the effects of these 
potential antagonists on LRH-1 transcriptional activity. Four out of the seven 
compounds inhibited LRH-1 transcriptional activity in a dose dependent manner. At 
25µM ICNR016, ICNR007, ICNR014 and ICNR010 inhibited LRH-1 transcriptional 
activity by 81%, 58%, 58% and 35% respectively. However, ICNR026, ICNR029 and 
ICNR031 did not inhibit LRH-1 activity in the reporter gene assay (Figure 3.25C). 
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Moreover, the four most potent compounds were able to inhibit the agonistic effects 
of compound 5A (Figure 3.26A). The most profound effects were observed for 
compounds ICNR007 and ICNR016, which completely abrogated the agonistic 
activity of 5A. A recent publication identified specific phosphatidylcholines, in 
particular 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC) as potent activators of 
LRH-1 (Lee et al, 2011) and binding of DLPC in the LRH-1 LBD has been 
demonstrated by X-ray crystallography (Musille et al, 2012). Indeed, DLPC 
stimulates the LRH-1 activity in gene reporter assay (Figure 3.28B). ICNR016, 
ICNR007, ICNR014 and ICNR010 all inhibit the DLPC-stimulated LRH-1 activity 
(Figure 3.26B). Taken together, these findings show that several resorcylate 
compounds tested here inhibit LRH-1 activity in a mammalian 2-hybrid assay, as well 







Figure 3.22 LRH-1 synthetic agonist, 5A, stimulates co-activator interactions 
with LRH-1 
Cells were co-transfected with a GAL4 responsive reporter gene (GAL4-tk-Luc) and 
VP-16-LRH-1 (LBD), together with GAL4-PGC-1α (A), GAL4-TIF2 (B), GAL4-
SHP (C), GAL4-NCOR (D) or GAL4-SMRT (E). Cells were treated with 30µM 5A 
or vehicle (DMSO) for 24 hours. GAL4 reporter activities were normalised to the 
activities of the renilla luciferase. The data shown are the means of three independent 
experiments; error bars represent the SEM. Asterisks indicate p<0.05 using paired t-





















































































































Figure 3.23 LRH-1 synthetic agonists stimulate LRH-1 transcriptional activity 
by promoting the recruitment of co-activator PGC-1α 
A) COS-1 cells were co-transfected with the LRH-1 responsive promoter reporter 
(SF1-Luc) and LRH-1. Cells were treated with increasing concentrations of LRH-1 
agonists for 24 hours following transfection. (B, C) Cells were co-transfected with a 
GAL4 responsive reporter gene (GAL4-tk-Luc) and VP-16-LRH-1 (LBD), together 
with GAL4-PGC-1α (B) or GAL4-SHP (C). Reporter activities were normalised with 
renilla luciferase activity and shown as relative to vehicle control (DMSO). The data 








































































































































































Figure 3.24 Screening of a resorcylate-based compound library identifies 
compounds that inhibit the interaction of the LRH-1 LBD with PGC-1α 
A-C) COS-1 cells were co-transfected with the GAL4 responsive promoter (GAL4-
tk-Luc), VP16-LRH-1 (LBD), and GAL4-PGC-1α. Also transfected was a renilla 
luciferase reporter genes (RLTK), as a control for transfection efficiency.  Following 
transfection, cells were treated with increasing concentrations of the compounds for 
24 hours. GAL4 reporter activities were normalised to the activities of the renilla 
luciferase and are shown relative to the activity obtained for the vehicle (DMSO) 
control. Data shown are the mean of three replicates from a single experiment. 
Asterisks highlight the compounds that inhibited GAL4-tk-luc activity in a dose 
dependent manner with by ≥40% at the highest concentration of compound. # shows 













































































































































































































































































































*# *# *# *# *# *#
*# *# *#
*# *# *# *#
*# *#
*#
## ## ## ## ##







Figure 3.25 Confirmation of the LRH-1 inhibitory activity of resorcylate 
compounds 
A) Chemical structures of selected compounds is shown. B) COS-1 cells were 
transfected as in figure 3.24, LRH-1 and PGC-1α interaction was reassessed for 
selected compounds in three independent experiments. C) COS-1 cells were co-
transfected with the LRH-1 responsive reporter (SF1-Luc) and LRH-1. Cells were 
treated with compounds for 24 hours post-transfection. Reporter gene activities were 
normalised with renilla luciferase activity and shown as relative to vehicle control 
(DMSO). The data shown are the mean obtained from three independent experiments 
and the error bars represent the SEM. 
  











































































































































Figure 3.26 Resorcylate compounds inhibit the LRH-1 activity stimulated by 
LRH-1 agonists 
COS-1 cells were co-transfected with the LRH-1 responsive reporter (SF1-Luc) and 
the LRH-1 expression plasmid. Cells were treated with compounds at 25µM with or 
without LRH-1 agonists, 5A at 25µM (A) or 1,2-dilauroyl-sn-glycero-3-
phosphocholine (DLPC) at 100µM (B). Reporter activities were normalised with 
renilla luciferase activity and shown as relative to vehicle control (DMSO). The data 
shown are the mean obtained from three independent experiments and the error bars 
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3.5.3 The identified LRH-1 inhibitors are not specific for LRH-1  
 
LRH-1 is a member of the nuclear receptor superfamily of transcription factors that 
share homology in the DBD and LBD. In particular, LRH-1 is very closely related to 
SF-1, with 65% amino acid sequence homology in the LBD (Fayard et al, 2004). 
DLPC and the synthetic agonists (Lee et al, 2011; Whitby et al, 2006; Whitby et al, 
2011) that stimulate LRH-1 activities also activate SF-1. To investigate the selectivity 
of our resorcylate hits on related proteins, I tested the effects of these compounds on 
SF-1 activity in a gene reporter assay. SF1-Luc luciferase reporter was used because 
both LRH-1 and SF-1 recognise the same responsive elements. As has been reported 
previously, compound 5A stimulates LRH-1 and SF-1 to a similar extent (Whitby et 
al, 2006). Moreover, the most potent of our resorcylate hits also inhibit SF-1 activity. 
Indeed, the degree of SF-1 inhibition by these compounds is similar to the inhibition 
observed for LRH-1 (Figure 3.27A). 
 
As described above, at least one resorcylate compound, zearalenone, is an ERα 
agonist. Therefore, I also assessed these compounds for their activity in an ERα 
reporter gene assay to test if the activities of these compounds are specific for the 
NR5A (LRH-1, SF-1) subfamily of nuclear receptors. Estrogen stimulated ERα 
activity by 12-fold (Figure 3.27B). Unexpectedly, a 6-fold increase in ERα activity 
was observed with cells treated with compound 5A. ICNR010, ICNR014 and 
ICNR016 also stimulated ERα activity by 3, 6 and 3.5-fold respectively at 25µM. 
However, ICNR007 did not affect ERα activity (Figure 3.27B). To examine if these 
compounds directly bind to ERα, an ERα ligand-binding assay was carried out under 
contract with Cerep (France). For this, the affinity of the compounds to ERα was 
assessed by their ability to displace a fluorescently labelled estrogen ligand 
(Fluormone ES2) from the full-length ERα recombinant protein. In agreement with 
the reporter gene assay, ICNR010, ICNR014 and ICNR016 competed with the 
labelled ligand, indicating direct binding of these compounds to ERα. The degree of 
binding to ERα in order is ICNR014>ICNR016>ICNR010, again in agreement with 
their activities in the reporter gene assay. The binding of these compounds to ERα is 
relatively weak (IC50: 7 to 25µM) in comparison 17β-estradiol (IC50: 19nM) (Figure 
3.27C). However, ICNR007 was unable to displace labelled-estrogen at 
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concentrations up to 25µM, which is consistent with the lack of activity observed in 
the gene reporter assay.  Taken together, evaluation of the four LRH-1 inhibitors for 
their activities against SF-1, and ERα transcriptional activity indicates that it should 
be possible to obtain compounds that are selective for LRH-1/SF1, as shown with 
ICNR007. However, the current compounds do not show selectivity between LRH-1 
and SF-1. Nevertheless, these studies have identified novel LRH-1 inhibitors, which 
will permit rational design for further refinement towards the identification of more 
potent and selective LRH-1 inhibitors. It should be noted that the cell-based M2H and 
reporter gene assays used to identify the LRH-1 inhibitors suggest, but do not 
demonstrate that these compounds act by binding to the LRH-1 LBD. However, the 
fact that some of the compounds bind to the ERα LBD, this indicate the possibility 
that they may bind to LRH-1 LBD.  
 
3.5.4 LRH-1 antagonists inhibit the growth of breast cancer cells 
 
Downregulation of LRH-1 using siRNA inhibits the growth of LRH-1 positive breast 
cancer cell lines. To assess the biological activity of our novel LRH-1 inhibitors, I 
determined the effect of these compounds on the growth of breast cancer cells. In 
order to determine if the effects of these compounds are mediated through LRH-1, I 
investigated growth in MCF-7 cells, as well as the LRH-1 negative SKBR3 breast 
cancer cell line. MCF-7 cells express ERα and LRH-1, but do not express SF-1 
(Figure 3.28A and B). None of the three NRs was expressed in SKBR3 cells. The 
absence of SF-1 expression is in agreement with previous studies reporting the 
absence of SF-1 expression in breast cancer cells and breast tissue (Clyne et al, 2002; 
Yang et al, 2002). 
 
The four LRH-1 inhibitors reduced MCF-7 cell growth, with GI50 ranging from 12-56 
µM, with growth inhibition being in the order ICNR007> ICNR014> ICNR016> 
ICNR010 (Figure 3.28C). In SKBR3 cells, ICNR010, ICNR014 and ICNR016 also 
inhibited growth with similar GI50 values. This suggests that the growth inhibition by 
ICNR010, ICNR014 and ICNR016 is non-specific and is not mediated by effects of 
these compounds on LRH-1 or ERα. In this context it is important to note that some 
resorcylate compounds inhibit protein kinases such as cyclin-dependent kinases 
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(aigialomycin), whilst radicicol is a Hsp90 inhibitor (Patel et al, 2011). Thus, it is 
possible that inhibition of MCF-7 and SKBR3 growth by these compounds is due to 
additional activities.  
 
In the case of ICNR007, however, SKBR3 growth was not inhibited, whereas it was 
the most potent inhibitor of MCF-7 cell growth, with GI50 of 12µM. Given that 
ICNR007 inhibits LRH-1 activity, but does not bind ERα or affect ERα activity, it is 
likely that its action in MCF-7 cells is due to inhibition of LRH-1 activity. To 
determine if ICNR007 is able to inhibit the expression of LRH-1 target genes in 
MCF-7 cells, RNA was prepared following treatment of MCF-7 cells with ICNR007 
for 24 hours. ICNR007 did not affect LRH-1 expression in MCF-7 cells (Figure 
3.28D). A small reduction in ERα expression was observed although this was not 
statistically significant. Expression of pS2 and NRIP1 was significantly reduced 
(Figure 3.28D). These results show that ICNR007 is a LRH-1 inhibitor that can 
modulate its activity in breast cancer cells. As such ICNR007 is a novel small 
molecule inhibitor of LRH-1 that should form the basis for refinement to identify 





Figure 3.27 Evaluation of test compounds for action on SF-1 and ERα 
A) COS-1 cells were co-transfected with SF1-Luc and the expression plasmid for 
LRH-1 or SF-1. Cells were treated with the compounds at a final concentration of 
25µM. B) COS-1 cells cultured in steroid-depleted medium for 72 hours were 
transfected with an estrogen-responsive luciferase reporter gene (ERE3-Luc), together 
with ERα. Cells were treated with compounds at 25µM or 17β-estradiol (E2) at 
10nM. Reporter activities were normalised with renilla luciferase activity and shown 
as relative to vehicle control (DMSO). Data shown are the means of three replicates, 
error bars represent the SEM. Asterisks indicate p<0.05 using paired t-test; n.s. 
represents no statistically significant difference. C) In vitro ERα fluoligand binding 
assay conducted by Cerep (France) to determine binding of compounds to ERα. 
Recombinant ERα protein were incubated with fluorescent ERα ligand (Fluormone 
ES2) together with a two-fold serial dilution of the unlabeled compounds. The IC50 
values were determined by non-linear regression analysis. N.C. represents no binding 
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Figure 3.28 ICNR007 specifically inhibits the growth of breast cancer cells 
Expression analysis of LRH-1, SF-1 and ERα in MCF-7 and SKBR3 breast cancer 
cells, by qRT-PCR (A) and western blotting (B). C) MCF-7 and SKBR3 breast cancer 
cells were treated with a two-fold serial dilution of compounds with the highest final 
concentration of 100µM for 48 hours. Cell number was estimated using the SRB 
assay and 50% growth inhibition (GI50) values were determined using Prism 5.0 
Graphpad Software. D) RNA was prepared from MCF-7 cells treated with 25µM 
ICNR007 or vehicle (DMSO) for 24 hours. qRT-PCR was perform to determine the 
expression of ERα, pS2 and NRIP1 as shown. Expression were normalised to 
GAPDH expression and the relative expression level in the vehicle control is taken as 
1. The data shown are the means of three independent experiments and the error bars 
represent the SEM. Asterisks indicate p<0.05 using the paired t-test; n.s. represents no 
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Chapter 4 Discussion  
4.1 LRH-1 as novel target in the treatment of breast cancer !
Estrogens play critical roles in the initiation and progression of breast cancer. 
Biological functions of estrogen are mainly mediated by ERα, which regulates genes 
that promote breast cancer cell proliferation and survival (Foster et al, 2001; Frasor et 
al, 2003). Endocrine therapies aimed at inhibiting ERα action provide significant 
improvement in disease free and overall survival in women with ERα-positive breast 
cancer. However, a substantial proportion of patients do not respond to these agents, 
and those patients who initially respond may eventually develop resistance to therapy 
(Ali & Coombes, 2002; Ring & Dowsett, 2004). All patients with advanced or 
metastatic disease eventually relapse on these therapies. Therefore, there is an urgent 
need to identify novel targets in combating endocrine-resistant disease. 
LRH-1 is an important regulator in development, steroidogenesis and bile 
acid/cholesterol homeostasis (Fayard et al, 2004). LRH-1 has also recently been 
implicated to play a proliferative role in cancers, including those of the colon, 
pancreas and breast (Annicotte et al, 2005; Benod et al, 2011; Schoonjans et al, 2005). 
It has been shown to control the expression of cell cycle regulators, including cyclin 
D1, cyclin E1 and c-myc. In breast cancer, LRH-1 expression has been positively 
correlated with ERα expression (Miki et al, 2006), and was found to be significantly 
elevated in both breast tumour and tumour-associated stromal fibroblasts (TAFs) 
compartments (Zhou et al, 2005). A positive correlation of LRH-1 and aromatase 
expression was found in TAFs, suggesting its role in promoting breast cancer cell 
growth by regulating local estrogen biosynthesis in breast stromal tissue (Zhou et al, 
2005), whilst direct evidence for regulation of aromatase expression by LRH-1 has 
also been reported (Bouchard et al, 2005; Clyne et al, 2004; Clyne et al, 2002).  
Previous work from our laboratory identified LRH-1 as an estrogen-responsive gene 
in a gene expression microarray study in MCF-7 breast cancer cells. We confirmed 
that LRH-1 is a direct ERα target gene and showed that it is important in mediating 
breast cancer cell growth (Thiruchelvam et al, 2011), findings that have also been 
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reported by other groups (Annicotte et al, 2005). Importantly, we observed that 
siRNA-mediated knockdown of LRH-1 was associated with reduced ERα and 
estrogen-regulated gene expression in breast cancer cell lines (Thiruchelvam et al, 
2011). In an attempt to define direct LRH-1 target genes in breast cancer cells, we 
carried out gene expression microarray and ChIP-seq analysis in MCF-7 breast cancer 
cells. LRH-1 regulated genes identified from the gene expression microarray 
following LRH-1 silencing showed a significant enrichment in estrogen signalling 
pathways. Meanwhile, LRH-1 ChIP-seq analysis showed that a substantial proportion 
of LRH-1 binding sites map to ERα binding sites, suggesting that LRH-1 directly 
regulates a proportion of ERα target genes (Lai et al, 2013). 
In the work presented in this thesis, I showed that LRH-1 directly regulates the 
expression of ERα. Additionally, I have demonstrated that LRH-1 co-operates with 
ERα in regulating ERα target gene expression, hence uncovering a key role for LRH-
1 in mediating estrogen responses in breast cancer cells. The results of my work 
indicate that LRH-1 is a novel therapeutic target in breast cancer. Towards further 
evaluation of the importance of LRH-1 in breast cancer, we initiated a study to 
identify small molecule inhibitors of LRH-1. I describe here novel hit compounds, 
some of which selectively inhibit LRH-1, paving the way for the discovery of small 
molecules that inhibit LRH-1 activity and which may ultimately provide new 
therapeutic drugs for the treatment of endocrine resistant breast cancer.  
 
4.2 LRH-1 isoforms  !
While performing immunoblotting, we noted that commercial antibodies failed to 
detect LRH-1 in breast cancer cell lines, despite the presence of LRH-1 mRNA. 
Several different LRH-1 isoforms result from alternative splicing, including LRH-
1v1, hLRH-1 and LRH-1v2 previously described (Fayard et al, 2004). Previous work 
in our laboratory used 5’-RACE to determine LRH-1 isoforms in breast cancer cells. 
These studies identified a new LRH-1 variant, LRH-1v4, that arises from alternative 
promoter usage and is the major form of LRH-1 expressed in breast cancer cells 
(Thiruchelvam et al, 2011). LRH-1v4 lacks the first 40 amino acids at the N-terminus 
encoding the LRH-1 exon 1. To determine if LRH-1v4 demonstrates differences in 
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activity compared to the other isoforms expressed in breast cancer cells, although at 
lower levels than LRH-1v4, I undertook reporter gene assays. The results from the 
reporter gene studies did not show any significant difference in activity between 
LRH-1v1 and LRH-1v4 on all the tested LRH-1-inducible gene promoters. It has been 
reported that LRH-1 transcriptional activity is stimulated by PKA and 
PKC/MAPK/ERK (Bouchard et al, 2005; Lee et al, 2006), as well as by synthetic 
agonists of LRH-1 (Whitby et al, 2006). I failed to identify any significant differences 
in the activities of the two major LRH-1 isoforms, LRH-1v4 and LRH-1v1. Both 
variants were activated by inducers of PKA or MAPK signalling to similar extents 
and were indistinguishable in their activities in the presence of synthetic LRH-1 
agonists. It remains unclear, therefore, as to whether different LRH-1 isoforms have 
different activities. Differences in the isoforms may be due to differential regulation 
of their expression. Although LRH-1v4 was the predominant variant expressed in 
breast cancer cells, LRH-1v1 appears to be the major isoform in tissues classically 
associated with high-level LRH-1 expression, namely liver, small intestine and colon 
(Thiruchelvam et al, 2011). I carried out reporter gene studies in which I 
overexpressed LRH-1v1 and LRH-1v4 in cells that do not typically express LRH-1, 
so it is possible that at physiological levels in relevant tissues the differences in the N-
terminal regions of LRH-1 variants may indeed display differences in activity. This 
could be due perhaps to differential recruitment of interacting co-regulator proteins. In 
addition, many NRs encode N-terminal transcription activation functions, AF-1, 
which are subject to post-translational modification, especially phosphorylation 
(Anbalagan et al, 2012; Rochette-Egly, 2003), as well as ubiquitylation, which 
regulates receptor degradation (Nawaz et al, 1999; Preisler-Mashek et al, 2002; 
Valley et al, 2005). These possibilities would need to be explored in detail in order to 
determine whether differences in amino acid sequences for the N-terminal region of 
LRH-1 have functional relevance.    
 
A previous study evaluating LRH-1 expression in invasive ductal carcinoma showed 
that 43% of breast tumours are LRH-1 positive, with LRH-1 expression being 
positively associated with steroid receptor status (ERα and PR) and better prognosis 
(Miki et al, 2006). Importantly, the authors utilized an antibody that recognises the 
first 30 amino acids at the N-terminus of LRH-1 (K8801, Perseus Proteomics Inc.), 
and as such would not have detected LRH-1v4. Therefore, it is likely that LRH-1 
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expression has been underestimated in breast cancers to date. It will be important to 
utilise antibodies that recognise LRH-1v4 in future immunohistochemical analysis of 
breast tumours. In measuring LRH-1 expression by western blotting, I used an 
antibody that recognises an epitope in LRH-1 containing amino acids 161-280 
(H2325, Perseus Proteomics Inc.), which would detect all isoforms of LRH-1 
identified to date. This antibody may have better utility for immunohistochemical 
studies. It must be noted, however, that this antibody together with many other 
commercially available LRH-1 antibodies were found to be inadequate for other 
experimental techniques, for example ChIP-seq.  
 
4.3 LRH-1 regulates ERα expression !
The regulation of ERα transcription is mediated by multiple promoters, with 
expression from some promoters being highly tissue-specific (Kos et al, 2001). 
Evaluation of ER transcripts in breast caner cell lines and normal breast tissue 
demonstrated that the majority of the transcripts utilize the proximal gene promoter A. 
Transcripts initiated from other promoters (B, C, D, E and F) were also observed, 
however at much lower levels (Flouriot et al, 1998; Thiruchelvam et al, 2011; Weigel 
et al, 1995). 
LRH-1 knockdown using siRNA inhibited breast cancer cell growth and was 
accompanied by a reduction in ERα expression at both the mRNA and protein level. 
In order to investigate the LRH-1 regulation of ERα expression, an ERα promoter 
luciferase reporter constructs (ERP-Luc), encoding a 6kb region of the ERα promoter, 
was generated which included ERα gene promoters A-D that are responsible for the 
majority of ERα expression in breast cancer cells. By carrying out reporter gene 
studies and mutation analysis, I demonstrated that a LRH-1 binding site (LRHRE1) 
located near ERα promoter A is essential for the LRH-1 stimulation of gene promoter 
activity. The LRHRE1 sequence differs from the LRH-1 consensus sequence, but is 
similar to the LRH-1 binding site identified in the LRH-1 target gene in the mouse 
bile salt export pump (BSEP) gene (Song et al, 2008). We were also able to 
demonstrate that LRH-1 is able to bind to the LRHRE1 sequence in vitro by using a 
fluorescence polarization assay (Thiruchelvam et al, 2011). Furthermore, I confirmed 
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the recruitment of LRH-1 to the ERα promoter region containing the LRHRE1 motif 
using a ChIP assay in MCF-7 breast cancer cells. Together these results demonstrate 
that LRH-1 can directly regulate the expression of ERα in breast cancer cells. 
However, although the LRHRE1 motif was important for the regulation of ERα 
reporter genes, mutation of LRHRE1 motif did not completely abolish LRH-1 
mediated activation. Further deletion analysis of the 6 kb region identified sequences 
located between bp -2341 to -5048, possibly containing additional LRH-1 responsive 
sequences. However, no motifs consistent with LRH-1 binding are present within this 
region, suggestive of indirect effects of LRH-1 at this region. Nor was any binding to 
this region evident from the LRH-1 ChIP-seq analysis. Rather, interrogation of the 
ChIP-seq data identified LRH-1 binding sites 25 kb and 35 kb upstream of the 5’ most 
ERα exon, corresponding to promoter F, which corresponds to the enhancer region to 
which binding of ERα and GATA3 has previously been reported (Eeckhoute et al, 
2007). Thus, in addition to LRH-1 binding to regions proximal to promoter A, ChIP-
seq identified LRH-1 binding in the ERα enhancer region (Figure 4.1). The lack of 
detectable LRH-1 binding near promoter A may imply weak binding to this region, 
with strong LRH-1 binding to the enhancer region. Taken together, these data clearly 
demonstrate that LRH-1 regulates ERα expression in breast cancer cells, with direct 
regulation being evident in MCF-7 cells.   
 
4.4 Aromatase PII and ERα gene promoters respond differently to 
LRH-1 and protein kinase A activation !
The aromatase gene is transcribed from a number of different promoters, with 
promoter usage being highly tissue selective (Bulun et al, 2005; Bulun et al, 2009; 
Simpson et al, 2002). In gonadal tissues, the majority of aromatase transcripts are 
initiated at the aromatase promoter PII and the LRH-1 related SF-1 can bind to PII 
and regulate aromatase expression (Simpson, 2003). Aromatase expression in breast 
tumours and adjacent adipose tissue is markedly elevated compared to normal breast 
tissue (Harada, 1997; Zhou et al, 1997; Zhou et al, 2005). The elevated aromatase 
expression in breast cancer is associated with a switch in promoter usage from the 
normal adipose specific promoter I.4 to the gonadal-type PII promoter in breast 
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cancer-associated stroma (Bulun et al, 2005; Bulun et al, 2009). While SF-1 is absent 
in breast tissue (Clyne et al, 2002; Yang et al, 2002), LRH-1 expression has been 
implicated as a key factor in regulating aromatase expression by stimulating the 
aromatase PII promoter activity in breast cancer (Clyne et al, 2002), and LRH-1 
expression is positively correlated with aromatase expression in pre-adipocytes in the 
breast cancer associated stroma (Zhou et al, 2005). One of the major stimulators of 
aromatase expression in breast adipose tissue is prostaglandin E2 (PGE2) derived 
from tumour epithelial cells, which subsequently leads to an increase in intratumoural 
estrogen production (Bulun et al, 2005). Interestingly, PKA signalling downstream of 
PGE2 potentiates LRH-1 mediated PII activity in preadipocytes and breast cancer 
cells (Bouchard et al, 2005; Clyne et al, 2004). It has been proposed that PKA 
mediated phosphorylation of LRH-1 at ser-469 is crucial in maintaining the 
interaction between LRH-1 and GATA3, which synergistically stimulate PII. 
In agreement with these findings, reporter gene assays demonstrated synergism 
between LRH-1 and GATA3, with further stimulation of reporter gene activity by 
PKA. Interestingly, although a similar co-operativity between LRH-1 and GATA3 
was also observed for the ERα reporter gene, PKA did not potentiate the ERα 
promoter activity mediated by LRH-1 alone or in combination with GATA3. In fact 
PKA inhibited the ERα reporter gene activation by LRH-1 and GATA3. LRH-1 and 
GATA3 expression has been reported in both breast cancer and intratumoural stromal 
compartments. Interestingly, however, aromatase expression is low or absent in breast 
cancer cells and high in the stromal compartment (Miki et al, 2007), whilst ERα 
expression is confined to the breast cancer cells (Speirs et al, 2002). The reporter gene 
data presented here provide a functional basis for the difference in aromatase and ERα 
expression in the cancer and stromal cells, indicating the importance of both LRH-1 
and GATA3 in the regulation of ERα and aromatase expression, with cell-specificity 
being provided by potential differences in cellular response to PKA activity.  
Possible reasons for the differences in PKA responses at these gene promoters may be 
due to transcription factors acting downstream of PKA. A number of transcription 
factors are reported to regulate aromatase PII promoter activity, including the cAMP–
responsive element binding protein (CREB), activating transcription factor-2 (ATF-2) 
and CCAAT/enhancer binding proteins (C/EBP), all of which are downstream targets 
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of the PKA pathway (Bulun et al, 2005; Bulun et al, 2009). It is possible that these 
factors are involved in the regulation of aromatase PII promoter, but are perhaps not 
required for transcription regulation of the ERα gene. Moreover, SHP, the NR that is a 
well-known repressor of LRH-1, is expressed in preadipocytes (Kovacic et al, 2004). 
SHP is potentially also able to inhibit ERα promoter activity, as shown by ectopic 
expression of SHP in MCF-7 cells. Interestingly, however, we have found that SHP 
expression is very low or absent in breast cancer cell lines (Thiruchelvam et al, 2011) 
(Lin et al., unpublished). Therefore, the presence or absence of other transcription 
factors and co-regulator proteins of LRH-1 may be important in defining promoter 
and cell-type specific activity of LRH-1, as well as in responding to other signalling 
pathways. Given the possibility of inhibiting LRH-1 activity as a therapeutic avenue 
in breast cancer, these differential activities of LRH-1 in breast cancer and breast 
cancer associated stroma require further study. 
 
4.5 LRH-1 directly regulates the expression of a subset of estrogen-
responsive genes in breast cancer cells !
In order to identify genes that mediate LRH-1 action in breast cancer cells, a gene 
expression microarray study was performed in MCF-7 cells following down-
regulation of LRH-1 using siRNA. Pathway analysis of genes whose expression was 
altered upon LRH-1 knockdown showed that there was a strong enrichment for genes 
that are involved in estrogen signalling, including, as expected, ERα itself (Lai et al, 
2013). Given our demonstration that LRH-1 regulates ERα expression, it is possible 
that the genes associated with estrogen signalling are simply ERα target genes. The 
most obvious method for identifying LRH-1 target genes was therefore to carry out 
ChIP-seq using antibodies for LRH-1. I prepared MCF-7 cell lysates and performed 
ChIP using commercial LRH-1 antibodies. The best enrichment in ChIP assays (3-5 
fold) was obtained for the H2325 (Perseus Proteomics Inc.) antibody. Library 
preparation and Illumina sequencing was carried out by Dr Jason Carroll’s laboratory. 
Unfortunately, but unsurprisingly, given the poor enrichment achieved with this 
antibody, analysis of the sequence information did not give sufficient enrichment to 
allow robust peak calling (data not shown). Since ectopic expression of HA-tagged 
LRH-1 has previously been used to identify LRH-1 target genes in stem cells (Heng et 
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al, 2010), we decided to carry out ChIP-seq for HA-LRH-1 following transfection in 
MCF-7 cells. ChIP lysates were prepared and validated by performing ChIP for ERα 
and subsequent library preparation and Illumina sequencing was carried out in Dr 
Wilbert Zwart’s laboratory. As described in Chapter 3 and discussed below, this 
approach served to identify direct targets of LRH-1 that were validated in an 
extensive series of experiments employing siRNA and ectopic expression of LRH-1. 
It should nevertheless be noted that ectopic expression of LRH-1 may have 
highlighted some binding sites that are not representative of endogenous LRH-1 
targets and I briefly highlight here potential approaches for improving ChIP-seq 
studies where appropriate antibodies are not available. Firstly, in contrast to the 
transient transfection employed here, it should be possible to generate lines stably 
expressing epitope-tagged LRH-1, so as to achieve expression in cells at levels similar 
to and not exceeding those of endogenous LRH-1. However, given that transient or 
stable expression utilize regulatory sequences that are not those regulating expression 
of the endogenous gene, such as the use of viral promoters, this approach may also 
provide some non-relevant targets. Another approach would be to use bacterial 
artificial chromosomes (BAC) encoding an epitope-tagged protein of interest in its 
genomic context, as has been described for ChIP-seq of RARα and other NRs in 
MCF-7 cells (Hua et al, 2009; Kittler et al, 2013). Even with this approach, however, 
there are important caveats. For example, ChIP-seq for EGFP-tagged RARα from a 
BAC in MCF-7 cells demonstrated that RARα is recruited to many ERα binding sites, 
as has been confirmed by ChIP-seq for endogenous RARα in MCF-7 cells using a 
RARα antibody. However, other studies with the BAC line led to the conclusion that 
RARα competes with ERα for binding at or near ERα binding sites (Hua et al, 2009), 
whereas ChIP-seq using a RARα antibody reached the conclusion that RARα and 
ERα bind co-operatively (Ross-Innes et al, 2010).  Of course, different antibodies to 
the same protein may also generate different binding profiles in ChIP-seq, depending 
on the accessibility of the epitope.  
Given the provisos highlighted above, it was particularly important that our ChIP-seq 
data were extensively validated. ChIP-seq was carried out following transfection with 
HA-tagged LRH-1 in two independent replicate experiments. Stringent peak calling, 
in which only peaks seen in both experiments were taken as LRH-1 binding sites, was 
also employed. Interestingly, a substantial proportion (35%) of LRH-1 binding sites 
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mapped to ERα binding sites in the ChIP-seq analysis in MCF-7 cells, suggesting a 
transcriptional crosstalk between LRH-1 and ERα in breast cancer cells. LRH-1 binds 
to a consensus DNA sequence consisting of an ERE half site with a 3 bp 5’ extension 
(5’-YCAAGGTCA-3). A motif consistent with the LRH-1 binding site sequence was 
consistently enriched in LRH-1 only and LRH-1/ERα shared binding regions (Lai et 
al 2013), suggesting that LRH-1 may be recruited to the ERα binding site in a subset 
of ERα target genes to regulate their expression. A previous study which mapped ERα 
genomic targets in MCF-7 cells using ChIP-PET revealed a significant enrichment for 
other transcription factor (TF) binding motifs within ER binding regions, including 
forkhead and GATA motifs as mentioned in Chapter 1. Indeed, in defining the 
distribution of ERE and TF binding motifs within these ERα binding regions, this 
revealed a number of TF motifs that are non-randomly distributed and centralised 
with the ERE motif, with the most frequently observed site being LRH-1 binding 
motifs (Lin et al, 2007). These findings, together with our ChIP-seq data, suggested 
that LRH-1 could bind to a substantial proportion of ERα genomic targets through the 
recognition of overlapping binding motifs, possibly in a competitive manner, given 
that such overlapping sites would not be expected to accommodate LRH-1 and ERα at 
the same time. 
In support of the idea that LRH-1 and ERα regulate common targets, we have 
examined the regulation of the pS2 promoter by LRH-1 and ERα, as a prototypical 
estrogen-regulated gene and one that contains an overlapping LRH-1/ERα binding 
site. EMSA and reporter gene studies demonstrated that LRH-1 stimulates pS2 
expression via binding to the overlapping LRH-1/ERE binding motif. This is 
consistent with the findings in a recent report showing that LRH-1 binds to the three 
EREs within the GREB1 promoter and regulates the expression of GREB1 in breast 
cancer cells (Chand et al, 2012). Together with our present study, this work supports a 
mechanism by which two nuclear receptors can regulate gene expression by 
occupying overlapping binding sites. 
 
! 158!
4.6 Co-operative action between LRH-1 and ERα in regulating gene 
expression !
Our ChIP-seq findings raised the question of how LRH-1 and ERα are recruited to 
overlapping binding sites. There is no evidence in the literature for dimerization 
between LRH-1 and ERα. Nor were we able to demonstrate co-occupancy or 
heterodimer formation between LRH-1 and ERα in EMSA. LRH-1 and ERα also did 
not co-immunoprecipitate. Furthermore, we were unable to demonstrate co-occupancy 
in ChIP-reChIP experiments. This is in contrast to the findings for RARα, where 
demonstrated co-occupancy of ERα and RARα at specific binding sites (Ross-Innes et 
al, 2010), although an independent study concluded that RARα competes with ERα 
for binding (Hua et al, 2009). Taken together, these results are indicative of an 
altogether different mechanism of interaction between LRH-1 and ERα at binding 
sites. Interestingly, we found that ectopic expression of LRH-1 stimulated ERα 
recruitment to ERα binding sites. Note that these experiments were performed under 
transfection conditions in which there was no increase in ERα levels. Conversely, 
ChIP studies performed under conditions of shorter duration of siRNA treatment, 
which enables efficient down-regulation of LRH-1 expression without significantly 
altering the expression of ERα, resulted in reduced ERα recruitment to the LRH-
1/ERα co-bound region. This finding was confirmed globally with ERα ChIP-seq 
following LRH-1 knockdown (Lai et al., 2013).  
 
The lack of evidence for a direct interaction between LRH-1 and ERα, together with 
absence of evidence for co-occupancy at ERα binding sites, raised the possibility of 
sequential binding of LRH-1 and ERα. Indeed, detailed ChIP analysis of ERα and 
numerous ERα co-regulators has demonstrated that ERα recruitment to EREs involves 
rapid cycling of association followed by dissociation, with dissociation being 
mediated by proteasomal ERα degradation and subsequent recruitment of fresh ERα 
(Metivier et al, 2003; Reid et al, 2003; Shang et al, 2000). Interestingly, ERα 
recruitment is accompanied by co-activator recruitment and subsequent histone 
acetylation, histone methylation and nucleosome remodelling, leading to RNA 
polymerase II recruitment and consequent transcription initiation. ERα dissociation is 
accompanied by co-activator dissociation and histone deacetylation, demethylation 
and nucleosome remodelling to a more closed state. Re-association of ERα allows the 
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cycle of co-activator recruitment, histone modification and RNA polymerase II 
recruitment to be reinitiated. It is therefore possible that ERα recruitment is followed 
by LRH-1 recruitment, and its subsequent dissociation then promotes ERα re-
association (or vice versa). Evidence for such a model has recently been reported in a 
study using glucocorticoid receptor (GR) and a mutant form of ERα that can bind to a 
GR response element (GRE) (Voss et al, 2011). Remarkably, steady-state levels of the 
two receptors on the GRE were similar, with no apparent competition for binding to 
the GRE. In fact, binding of one NR enabled subsequent binding of the second NR by 
promoting chromatin accessibility, leading to steady state levels of the two NRs at the 
same response element. This study was carried out by transfection of an ERα mutant 
that binds GREs and as such is an artificial system. Nevertheless, this mechanism, 
which the authors termed the “assisted loading mechanism”, provides a ready 
explanation for my findings, in which LRH-1 promotes ERα recruitment to ERα 
binding sites and conversely, ERα promotes LRH-1 recruitment. This is as evidenced 
by inhibition of LRH-1 binding following ERα down-regulation with the anti-
estrogen ICI182, 780. In agreement with this possibility, LRH-1 silencing reduced co-
activator recruitment and histone modifications associated with active chromatin as 
well as RNA PolII binding. The presence of GATA3 at ERα binding regions is 
important for ERα recruitment and its knockdown results in significant modulation in 
ERα recruitment genome-wide (Theodorou et al, 2013). LRH-1 knockdown also 
showed reduced GATA3 at ERα binding regions, suggesting that LRH-1 is an 
important mediator of the early chromatin events required for ERα binding. These 
results suggest that LRH-1 promotes cofactor recruitment and chromatin changes that 
facilitate ERα recruitment. Additionally, stimulation of ERα recruitment by estrogen 
promoted LRH-1 recruitment, while down-regulation of ERα by ICI182,780 treatment 
inhibited LRH-1 binding, suggesting a mechanism involving cyclical binding of ERα 
and LRH-1 to the regulatory regions of estrogen-responsive genes.  
 
In agreement with our results for LRH-1 and ERα, a recent publication described the 
genome-wide binding profiles of ERα and GR in a mouse mammary cell line upon 
activation with their cognate ligands, dexamethasone (Dex) and estrogen (E2) 
respectively (Miranda et al, 2013). Comparing ERα and GR binding profiles with 
either single or dual hormone treatments revealed that dual hormone treatments could 
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promote binding of the other factor at their sites observed in the presence of the single 
treatment, but that the dual treatment led to binding at novel binding sites that are not 
seen with the single treatment. The authors showed that these regions are associated 
with “open” chromatin structure, supporting the “assisted loading model”, in which a 
given factor with chromatin access at specific sites recruits transcriptional co-
regulators to the region to create a transient window for the access of secondary 
factors within the “open” region. The crosstalk between LRH-1 and ERα therefore fits 
into this model of transcription factor action, at least for binding sites with LRH-
1/ERα overlapping binding sites. A model outlining the scheme through which LRH-
1 and ERα might be recruited to overlapping sites is shown in Figure 4.2. Although 
not investigated in detail in this study, it is also likely that LRH-1 binding to nearby 
ERα sites might similarly regulate ERα binding, and vice versa. A potential example 
of such a binding event, which I did not explore, is that identified in the ERα gene 
enhancer (Figure 4.1).  
 
Our studies demonstrate that LRH-1 plays a key role in mediating ERα binding and 
consequent regulation of estrogen-responsive gene expression. As described in 
Chapter 1, dysregulation of the ERα transcription programme is associated with breast 
cancer progression, prognosis and endocrine resistance. Firstly, in the normal breast 
ERα is expressed in non-proliferating epithelial cells, its role being to promote growth 
of surrounding ERα-negative cells (Clarke et al, 1997). Through changes that remain 
unclear, in breast cancer cells ERα is expressed in proliferating cells. It would be 
interesting to determine the possible role of LRH-1, if any, in the switch in ERα-
positive breast epithelial cells from non-proliferative to proliferative cells. Secondly, 
many patients become resistant to endocrine therapies, with the resistant breast cancer 
remaining, in the majority of cases, ERα-positive. Often patients with ERα-positive 
resistant breast cancer respond, albeit briefly, to second line endocrine agent, 
indicating continued importance of ERα in resistant breast cancer. At least in cell line 
models of endocrine resistance, ERα expression is generally maintained and the 
regulation of ERα target genes and growth of the cell lines is ERα dependent (Brunner 
et al, 1993; Lykkesfeldt et al, 1994; Martin et al, 2005a; Tolhurst et al, 2011). The 
potential role of LRH-1 in endocrine resistance should be explored in more detail, 
given the findings I present in this thesis. Finally, a proportion of ERα-positive breast 
cancers become ERα-negative following emergence of endocrine resistance. The 
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potential role of LRH-1 in these patients would be interesting, particularly given 
recent reports on AR function in breast cancer. AR expression is strongly associated 
with ERα-positivity in breast cancer. However, a proportion of ERα-negative breast 
cancer, the so-called apocrine breast cancer, is AR-positive. AR ChIP-seq in a cell 
line model of apocrine breast cancer showed that in these cells AR regulates 
expression of genes that are ERα targets in ERα-positive breast cancer (Robinson et al 
2011). It would be interesting to determine whether LRH-1 might similarly regulate 
the expression of key estrogen-regulated genes in ERα-negative, but LRH-1 positive 
breast cancer. In this context, our laboratory performed real-time RT-PCR profiling of 
120 breast tumours demonstrated high-level of LRH-1 expression in ERα-positive 
tumours, but also in about half of all ERα-negative/HER2-positive tumours (Lin et al., 
unpublished). Investigation of the role of LRH-1 in these tumours might provide 
important insights in ERα-negative breast cancer, as well as highlighting a new 

























Figure 4.2 A model for sequential binding of LRH-1 and ERα at regulatory 
regions of genes sharing overlapping binding sites. 
Binding of LRH-1 to chromatin facilitates co-regulator binding and consequent 
histone modification (orange and purple elipses) and nucleosome remodeling. This 
facilitates LRH-1 dissociation and ERα recruitment. Taking the model of cyclical 
recruitment of ERα and co-regulators into account (Metivier et al, 2006), it is possible 
to propose subsequent ERα promoted chromatin changes, ERα dissociation and re-
recruitment of LRH-1. Note that ERα recruitment could occur prior to LRH-1 
recruitment, ERα binding resulting in chromatin changes that promote LRH-1 





4.7 Development of LRH-1 inhibitors towards use in the treatment of 
breast cancer patients !
The studies described above implicate LRH-1 as a key mediator in the estrogen 
response in breast cancer cells by directly regulating the expression of ERα and also 
in co-operating with ERα to regulate the expression of estrogen-responsive genes. 
Other studies have uncovered an important role for LRH-1 in mediating local estrogen 
biosynthesis in breast cancer associated stromal tissue (Clyne et al, 2004; Zhou et al, 
2005). These findings point to the importance of developing synthetic inhibitors of 
LRH-1, as tools for further dissection of LRH-1 function in breast cancer cells, as 
well as in breast cancer-associated stroma and ultimately, perhaps in treating breast 
cancer patients. 
LRH-1 was also found to regulate the proliferation of other cancer types such as 
colon, liver and pancreas (Benod et al, 2011; Schoonjans et al, 2005; Wang et al, 
2008). Therefore, the development of LRH-1 inhibitors may also useful in the 
treatment of other cancers. Owning to its role in reproduction, the possible use of 
LRH-1 inhibitors as contraceptive agents may also be considered (Sierens et al, 2010; 
Zhang et al, 2013). However, LRH-1 has been implicated in cholesterol, bile acids, 
lipid and glucose metabolism in the liver (Lee et al, 2011; Lee et al, 2008; Mataki et 
al, 2007), as well as its protective role in inflammatory bowl disease and hepatic acute 
phase response (Coste et al, 2007; Venteclef et al, 2006). Therefore, inhibition of 
LRH-1 may have negative effects on these functions. These issues need to be 
addressed in the future if LRH-1 inhibitors are to be used in a clinical setting. 
 
4.8 LRH-1 ligands and structural relationship !
Although LRH-1 belongs to the orphan NR family, several lines of evidence lead to 
the conclusion that its activity is regulated by small molecule binding in the LBD. 
These includes phospholipids, whose function as LRH-1 ligands was first identified 
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by X-ray crystallography, although these studies suggested the possibility that the 
phospholipids may act simply to maintain the active ligand binding pocket, perhaps 
being incorporated into the LBD at the time of protein folding (Krylova et al, 2005; 
Ortlund et al, 2005; Wang et al, 2005). However, a recent study suggests that the 
phosphatidylcholines, DLPC and DUPC, are potent and selective ligands for LRH-1 
(Lee et al, 2011). DLPC was also shown to displace pre-bound bacterial 
phospholipids in the LRH-1 LBD produced in E. coli, suggesting that phospholipid 
binding to LRH-1 may be a dynamic process (Lee et al, 2011). Crystallisation of 
DLPC in the LRH-1 LBD shows that the mode of DLPC binding is radically different 
from other classical NRs (Musille et al, 2012). In contrast to other NR ligands that 
bind deep within the LBP, DLPC bound to LRH-1 near the opening of the LBP and 
left the space that is usually used to coordinate ligands with most NRs left almost 
completely unfilled, therefore suggesting a different mode of receptor activation upon 
binding of phospholipid compare to other classical NRs (Musille et al, 2012). 
Comparing apo- and DLPC-bound LRH-1 structure to LRH-1 bound to bacterial 
phospholipids indicates that the binding of phospholipids to LRH-1 stimulates 
structural changes within LRH-1 LBD, which refuted the previous idea that the helix 
12 of LRH-1 is rigid and insensitive to ligand status (Sablin et al, 2003). Indeed, apo- 
and DLPC-bound LRH-1 display differential co-regulatory protein recruitment. 
DLPC-bound LRH-1 favoured co-activator peptide recruitment (PGC-1α, SRC1 and 
TIF2), whilst apo-LRH-1 binds to co-repressor peptide SHP and SMRT, and does not 
bind to PGC-1α (Musille et al, 2012). Synthetic LRH-1 agonists also appear to be able 
to displace phospholipids (Whitby et al 2010), indicating again that it is possible to 
displace phospholipids from the LRH-1 LBD.   
It was with these findings in mind that we collaborated with Prof Tony Barrett and 
Prof Alan Spivey in initiating a small molecule discovery project to identify LRH-1 
inhibitors. Several screening approaches were attempted. Firstly, synthetic agonists 
related to compound 5A (Whitby et al, 2006) were used to computationally screen for 
compounds that have similar space filling profiles. A second approach was to perform 
computer assisted modeling of the LRH-1 LBD with antagonists for other nuclear 
receptors and develop compound structures that would be predicted to fit into the 
LRH-1 LBD to displace helix 12. Several hundred compounds from these series were 
screened in vitro and in reporter gene assays, identifying several compounds that 
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inhibited LRH-1 activity at IC50 in the range 25-100 µM (Kyle et al, unpublished). 
The low activities of these compounds, together with observed cell toxicities have 
made these compounds difficult to work with. On the other hand, a small library of 
compounds in the resorcylic acid lactone family of natural products originally 
identified from fungal extracts was more promising. This family of compounds was 
chosen because of new chemical approaches developed by Prof Tony Barrett for rapid 
synthesis of what is a chemically difficult group of compounds to synthesise, and 
because this family includes many biologically active compounds, including 
zearalenone, an ERα agonist (Patel et al, 2011). Notably, small structural differences 
in this group of compounds can result in diverse biological effects. Therefore, 
synthesis of a list of new compounds from the resorcylate core could provide 
templates for novel drug-like molecules. 
 
4.9 The identification of resorcylate related compounds in inhibiting 
LRH-1 activity !
Screening of 45 resorcylates, initially using a mammalian two hybrid assay and 
subsequently a LRH-1 reporter gene assay, was carried out. This screening approach 
has identified 4 compounds that inhibit LRH-1 activity, with IC50 values ranging 
between 1-10 µM. As such, these compounds are the most potent LRH-1 antagonists 
described to date. Moreover, at least one of the compounds (ICRN007) inhibited the 
growth of a LRH-1 positive (MCF-7), but not a LRH-1 negative (SKBR3) cells. 
Moreover, ICNR007 inhibited the expression of LRH-1 target genes including pS2 
and NRIP1 genes in MCF-7 cells. Collectively, with the employment of different 
functional assays, this study identified 4 compounds that inhibit LRH-1 activity, with 
the top hit compound ICNR007 showing efficacy in inhibiting endogenous LRH-1. A 
great deal of additional work is required before a suitable lead compound is identified. 
Firstly, and most importantly, is to determine if these hit compounds bind LRH-1 or 
whether they may act through an indirect mechanism. It is conceivable that the 
compounds inhibit LRH-1 action by targeting other signalling pathways, such as 
protein kinase cascades. For example, the resorcylate radicicol is a HSP90 inhibitor, 
aigialomycin D is a cyclin-dependent kinase inhibitor (Schulte et al, 1998) and 
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hypothemycin is an inhibitor of the ERK pathway (Schirmer et al, 2006). Indeed, 
several compounds that inhibit LRH-1 in reporter gene assays with IC50 values in the 
0.1-5.0 µM range have been described (Busby et al, 2010). However, these 
compounds do not bind to LRH-1 (Prof Eric Ortlund, personal communication), so 
their mechanism of action is likely to be indirect. It is potentially significant that not 
all the compounds that inhibited LRH-1 had activity for ERα, suggesting that thy do 
not act on signalling pathways common to both receptors, e.g. hsp90 and the ERK 
pathway. Moreover, several of the most potent LRH-1 inhibitors in our series that 
activate ERα also bind to it in a ligand binding assay, suggesting that these 
compounds may act on LRH-1 by binding to the LBD. Nevertheless, an assay that 
enables the demonstration of direct binding to LRH-1 would clearly validate our hit 
compounds as LRH-1 inhibitors. We have established an in vitro alphascreen assay in 
which interaction between the LRH-1 LBD and PGC1-α (co-activator peptide) was 
used in the screening of other compound series (Rey et al, 2012). This assay should be 
used to further screen the resorcylate compounds. In many ways, the most sensitive 
assays for ligand binding are those in which a radioactively or fluorescently labelled 
ligand is used in a displacement assay. Such an assay would allow direct 
determination of compound binding to the LRH-1 LBD. Co-crystallisation of 
compounds with the LRH-1 LBD would not only confirm direct binding to the LBD, 
but by providing high resolution spatial information about the mode of compound 
binding and critical interactions between compound and the LBD, it would facilitate 
further, rational compound design. 
Another important aspect of inhibitor development is to achieve selectivity, in order 
to avoid off-target effects. As described in Chapter 3, some of the LRH-1 inhibitory 
compounds also modulate ERα activity, where they stimulate, rather than inhibit, its 
activity. Indeed, ligand binding assays established direct binding to ERα for a number 
of the compounds. Such poor selectivity needs to be addressed, although it should be 
noted that the most active LRH-1 inhibitor does not bind ERα and does not affect its 
activity, clearly demonstrating that it is possible to generate compounds that inhibit 
LRH-1 but do not affect ERα. Given these results, however, it would be desirable to 
screen the most interesting compounds for activity against other nuclear receptors. 
Most problematic is the fact that all of the compounds identified here also inhibit SF-
1. LRH-1 and SF-1 are 65% homologous in the LBD (Fayard et al, 2004), so the fact 
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that these compounds are ligands for both receptors is not surprising. For example, 
AR, GR, PR and MR, which share 50-60% amino acid sequence identity in the LBD, 
frequently bind the same ligands and synthetic compounds, including the androgen 
R1881 and the antiprogestin (Moore et al, 2012). ERα and ERβ share 58% amino acid 
sequence identity in the LBD and display very similar ligand binding profiles, 
including very similar affinities for estrogen, tamoxifen and fulvestrant (Kuiper et al, 
1997). However, in each case, it has been possible to develop receptor selective 
synthetic ligands, such as the ERα-selective agonist propyl-pyrazole-triol (PPT) and 
the ERβ-selective agonist diarylpropionitrile (DPN) (Harrington et al, 2003). Isoform 
selective agonist/antagonists have also been developed for peroxisome proliferator 
activated receptors (PPARs) (Michalik et al, 2006; Willson et al, 2000). These NRs 
share 68-70% amino acid sequence identity in their LBDs. Therefore, it is reasonable 
to suppose that it should ultimately be possible to generate LRH-1 inhibitors that do 
not inhibit SF-1. Indeed, a recent publication identified LRH-1 binding small 
molecule inhibitors with IC50 values of 5-6 µM, which appear not to inhibit SF-1 
activity (Benod et al, 2013), which demonstrates that it should be possible to generate 
LRH-1 selective inhibitors. 
The third and most difficult problem in generating clinically viable LRH-1 inhibitors 
is the fact that LRH-1 plays important roles in other tissues in as mentioned above in 
Section 4.1 and Chapter 1. Therefore, inhibition of LRH-1 may have negative effects 
on these functions. A possible way around this problem is the development of tissue-
selective LRH-1 inhibitors. This has been successfully achieved for estrogen 
receptors. For example, tamoxifen is an anti-estrogen in breast cancer cells, but has 
estrogen-like action in bone, cardiovascular system and the uterus, while the related 
drug raloxifene is estrogen-like in bone and the cardiovascular system, but does not 
have estrogenic properties in the uterus (Ali et al, 2011). Selective androgen receptor 
modulators have also been described (Gao & Dalton, 2007). In this context, our 
laboratory has determined that the LRH-1 agonist compound 5A, which is active in 
the liver cells (Whitby et al., 2006), does not activate LRH-1 in kidney cells (HEK-
293), while it moderately activates it in breast. DLPC, which is active in the liver (Lee 
et al, 2011), did not affect LRH-1 in breast cancer cells. Nor was DLPC active in the 
colon cancer cell line HCT-116, but it strongly activated LRH-1 in HEK-293 
(Callaghan et al, unpublished). These results provide evidence that it should be 
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possible to generate selective LRH-1 modulators.  
Taken together, the LRH-1 inhibitor compounds described in this thesis provide hit 
compounds for further development with the aim of therapeutic potential in breast 
cancer. It should be noted that LRH-1 has also been found to regulate cell 
proliferation in other cancer type such as colon, liver and pancreas (Benod et al, 2011; 
Schoonjans et al, 2005; Wang et al, 2008), so LRH-1 inhibitors may ultimately prove 




Through the work presented in this thesis, I have provided evidence for the 
importance of LRH-1 in regulation of gene expression in breast cancer cells, 
particularly through a novel mode of co-operative action of LRH-1 and ERα. I also 
describe future directions, in particular the evaluation of the role of LRH-1 in 
endocrine resistant breast cancer. As outlined above, LRH-1 may have a potential role 
in ERα-negative breast cancer, which deserves further study.  
Secondly, I have also carried out work that has identified compounds that inhibit 
LRH-1 action. These deserve further refinement into more potent LRH-1 inhibitors, 
as thses would be useful as tools for further dissecting the importance of LRH-1 in 
ERα-negative, as well as ERα-positive breast cancer. As discussed above, the 
development of potent LRH-1 inhibitors could also have potential for the treatment of 
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Abstract Estrogen receptor-a (ER) is expressed in the
great majority of breast cancers, and the inhibition of ER
action is a key part of breast cancer treatment. The inhibition
of ER action is achieved using anti-estrogens, primarily
tamoxifen, and with aromatase inhibitors that inhibit estro-
gen biosynthesis, thereby preventing ER activation. How-
ever, resistance to these therapies is common. With the aim
of identifying new molecular targets for breast cancer
therapy, we have identified the liver receptor homolog-1
(LRH-1) as an estrogen-regulated gene. RNA interference
and over-expression studies were used to investigate the role
of the LRH-1 in regulating breast cancer growth and to
identify the targets of an LRH-1 action. Promoter recruit-
ment was determined using reporter gene and chromatin
immunoprecipitation (ChIP) assays. We show that LRH-1
regulates breast cancer cell growth by regulating the ER
expression. Reporter gene and in vitro DNA-binding assays
identified an LRH-1-binding site in the ER gene promoter,
and ChIP assays have demonstrated in vivo binding at this
site. We also provide evidence for new LRH-1 variants in
breast cancer cells arising from the use of alternative pro-
moters. Previous studies have shown that LRH-1 functions
in estrogen biosynthesis by regulating aromatase expres-
sion. Our findings extend this by highlighting LRH-1 as a
key regulator of the estrogen response in breast cancer cells
through the regulation of ER expression. Hence, inhibition
of LRH-1 could provide a powerful new approach for the
treatment of endocrine-resistant breast cancer.
Keywords Estrogen ! Estrogen receptor !
Gene regulation ! LRH-1
Introduction
Estrogen plays a critical role in the development and pro-
gression of breast cancer. Its actions are mediated by
estrogen receptors, with estrogen receptor-a (ER) being
expressed in the majority of breast cancers. ER is a member
of the nuclear receptor (NR) superfamily of transcription
factors, which acts by regulating specific gene expression
upon binding estrogen. Inhibition of ER activity is achieved
clinically through the use of selective estrogen receptor
modulators (SERMs), such as tamoxifen, that compete with
estrogen for binding to ER, to inhibit its activity [1, 2].
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Aromatase inhibitors act by inhibiting the conversion of
androgens into estrogen, and provide an alternative and
effective approach for inhibiting ER activity, with newly
introduced aromatase inhibitors, such as Anastrozole and
Letrozole, already proving to be have greater efficacy than
tamoxifen [3, 4].
The regulation of ER gene expression has been sub-
jected to intense study due to its important role in the
regulation of breast cancer and in other important physio-
logical processes, such as cardiovascular protection, bone
homeostasis, and osteoporosis, and sexual development in
males and females [5]. The coding region of the ER gene is
located within eight exons spanning 140 kb on chromo-
some 6q25 [6, 7]. Regulation of an ER gene expression is
complex, with transcription being initiated within multiple
promoters spanning 150 kb [8]. Several of these promoters
show tissue specificity [9], which has further complicated
studies to define the transcriptional regulators of ER gene
expression.
The liver receptor homolog (LRH-1), like ER, is a
member of the NR superfamily. It belongs to the Ftz-f1 or
NR5A subfamily that includes steroidogenic factor-1 (SF-1),
members of which are characterised by the presence of
an extended DNA-binding domain (DBD), the so-called
Ftz-F1 box located at the C-terminus of the DBD [10].
Most NRs bind to DNA sequences conforming to the
consensus NR-binding sequence, AGGTCA, either as
homodimers (e.g., ER) to palindromes of the AGGTCA
motif or to direct repeats of the AGGTCA motif as het-
erodimers with retinoid X receptor-a (RXRa) [11]. By
contrast, members of the Ftz-F1 subfamily bind to
sequences having a 50 extension to the NR DNA-binding
motif as monomers, with the Ftz-F1 box targeting the
50-YCA extension to the NR DNA-binding motif [12],
where Y is C or T. Until recently classified as orphan
receptors, structural studies have shown that LRH-1 and
SF-1 bind phosphatidyl inositols, with their binding being
required for maximal activity [13–15]. LRH-1 plays
important roles in metabolism, being involved in the reg-
ulation of reverse cholesterol transport, lipid and choles-
terol absorption, bile acid homeostasis, and steroidogenesis
[10]. In particular, the LRH-1 has been implicated in the
regulation of aromatase (CYP19) expression in the ovary
[16]. Interestingly, in adipose tissue from normal women,
CYP19 expression is low and mainly originates from the use
of promoter I.4. By contrast, in breast cancer adipose tissue,
activation of additional CYP19 gene promoters is seen,
including importantly, the gonadal PII promoter. In the latter
context, LRH-1 regulates CYP19 expression through bind-
ing to a response element in the PII promoter [17–20].
In this study, we show that in breast cancer cells, LRH-1
is co-expressed with ER in breast cancer cell lines and that
RNAi-mediated LRH-1 knock-down inhibits breast cancer
cell growth. We demonstrate that this is due, at least in
part, to the regulation of ER expression by LRH-1 through
direct binding to the ER gene promoter. These studies
show, for the first time, that ER is an LRH-1 target gene, a
finding that is potentially relevant for the development of
new therapies for breast cancer.
Materials and methods
Cell lines
COS-1, MCF-7, T47D, ZR75-1, BT474, and MDA-MB-
231 cells were routinely cultured in DMEM containing
10% FCS. For estrogen-depletion experiments, the cells
were transferred to DMEM lacking phenol red and con-
taining 5% dextran-coated charcoal-stripped FCS for 72 h,
as described previously [21]. 17b-Estradiol (estrogen),
4-hydroxytamoxifen, and ICI 182, 780 were prepared in
ethanol and added to the medium at a final concentration of
10 nM (estrogen) or 100 nM (4-hydroxytamoxifen, ICI
182, 780). Compounds 5A, 5B, and 5L, which have pre-
viously been described [22], were prepared in DMSO and
added to a final concentration of 10 lM.
Plasmids
The renilla luciferase reporter gene was RLTK (Promega,
UK). LRH-1 and SHP expression plasmids were pCI-LRH-
1, pCDM8-hSHP, and the LRH-1; the firefly luciferase
reporter gene was SF-1-luc (gifts from Dr. Donald Mc-
Donnell and Dr. David Moore) [14]. The F342W/I416W
LRH-1 mutant was generated by site-directed mutagenesis
of pCI-LRH-1, using primers having the sequences 50-CA
AGCACGAAAAGCTGAGCACCTGGGGGCTTATGTG-
CAAAA-30 and 50-ACTGGGCAACAAGTGGACTATTC
CATATGGGCATCACAAGCCGG-30. The PII-516 aro-
matase reporter gene was kindly provided by Drs. Colin
Clyne and Evan Simpson. ERP-Luc was generated by
amplifying the genomic region covering the ER gene
promoter A to LRHRE3 (-5993/-117) using high fidelity
pfu DNA polymerase (Fermentas, UK) with DNA prepared
from the human ER gene Bacterial Artificial Chromosome
clone RP3-443C4 (Geneservice Ltd, UK). The PCR prod-
uct was cloned into pJET (Fermentas, UK) (pJET-ERP)
and re-cloned into the pGL3-Basic luciferase reporter
vector (Invitrogen), following digestion with BglII
restriction enzyme. The three putative LRH-1 response
elements in this region, LRHRE1-3, were mutated by site-
directed mutagenesis (Quickchange; Stratagene), changing
the LRH-1-binding site to a BamHI restriction site in each
case (details available on request).
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Transfections
MCF-7 and BT474 cells were transiently transfected with
100 ng of SHP or 50 ng of LRH-1, and the total RNA and
protein lysates were prepared 48 h later, as previously
described [21]. For reporter gene assays, COS-1 cells were
transiently transfected in 96-well plates, using FuGene HD
(Roche), according to manufacturer’s protocols. The cells
were transfected with 25 ng of the pGL3-Promoter-based
reporter plasmids or 100 ng of the pGL3-Basic, SF-1 Luc,
and RLTK, together with 50 ng of pCI-LRH-1. Cells were
lysed 24 h following transfection and firefly and renilla
luciferase activities were determined using the Dual Glo
system (Promega, UK). A similar method was used for
assaying ERP-luc and PII-516 aromatase reporter genes in
COS-1 or MCF-7 cells.
siRNA
Cells were transfected using Lipofectamine RNAiMAX,
according to manufacturer’s methods (Invitrogen). RNA
and protein were prepared 48 h following transfection. Cell
number was estimated using the sulphorhodamine B (SRB)
growth assay, as described previously [23]. siRNA LRH-1
On-TargetPlus Smartpool (Dharmacon) comprised siRNAs
having the sequences: 50-CAUAAUGGGCUAUUCAUA
U-30 (#1), 50-AGAGAAAUUUGGACAGCUA-30 (#2),
50-GGAGUGAGCUCUUAAUCCU-30 (#3) and 50-GAAGC
CAUGUCUCAGGUGA-30 (#4). siGenome non-targeting





Total RNA was collected, and real-time RT-PCR was per-
formed as previously described [23]. Real-timeRT-PCRwas
carried out using Taqman Gene Expression Assays (Applied
Biosystems, UK) for ER (ESR1; Hs00174860_m1),
CTD (Hs00157201_m1), LRH-1 (Hs00187067_m1), pS2
(TFF1; Hs00170216_m1), SHP (Hs00222677_m1), Dax1
(Hs00230864_m1), SF-1 (Hs00610436_m1) and GAPDH
(Hs99999905_m1) on an ABI 7900HT machine.
Western blotting
Cells were cultured and protein lysates prepared as
described previously [21]. Antibodies used were anti-ERa
(Novacastra Laboratories), and anti-LRH-1 (Perseus Pro-
temics). SHP, cathepsin D, and b-actin antibodies were
purchased from Abcam.
ChIP
Chromatin immunoprecipitation (ChIP) was performed
as previously described [23]. Antibody used was LRH-1,
and primers for real-time PCR were: LRHRE1 Fwd
50-CTAGCCCAAGTGAACCGAGA-30, LRHRE1 Rev
50-ACCTCAGGTCACGAACCAAA-30. For normalization,
qPCR was performed for the previously described control
region for the c-myc gene [24], using oligonucleotides
having the sequences: c-myc Fwd 50-GCCAGTCCAAC
CGGCTTATG-30, c-myc Rev 50-GGTTCTCCCAAGCAG
GAGCA-30.
In vitro DNA-binding assay
Binding affinities for LRH-1 to LRHRE1 sequences were
obtained using a fluorescence polarization assay, following
expression and purification of the LRH-1 amino acid res-
idues 79–184 as a MBP fusion protein in E. coli, as
described previously [12]. Carboxyfluorescin (FAM)-
labeled duplex oligonucleotides based on the LRHRE1
sequence 50-AATTGCCAAAGCTTTGGT-30 and the
CYP7A1 LRH-1-binding site described previously [12],
(Integrated DNA Technologies, USA), were used. 10 nM
of FAM-labeled oligonucleotide was mixed with MBP–
LRH-1 DBD at varying concentrations, and polarization
was measured in milli-polarization units (mP). The
experiments were performed on a Panvera Beacon 2000,
with an excitation wavelength of 495 nm, and an emission
wavelength of 520 nm. The results were analyzed by Sig-
maPlot to generate binding data and dissociation constants.
Results
LRH-1 regulates the growth of breast cancer cells
As a strategy to identify key estrogen-regulated genes in
breast cancer cells, we modified the estrogen-responsive
and ER-positive MCF-7 breast cancer cell line, to condi-
tionally express a transcriptionally repressive ER, PLZF-
ER, composed of the PLZF transcriptional repressor fused
to the ER DNA and ligand-binding domains [21]. The
resulting line grows in an estrogen-dependent manner in
the absence of PLZF-ER expression, but induction of
PLZF-ER expression blocks its growth. Gene-expression
microarray analysis carried out using this line, identified
1,627 genes which showed[1.5-fold regulation by estro-
gen within 16 h. Of these genes, 149 were repressed by
PLZF-ER, suggesting that these genes are important for
estrogen-regulated growth of MCF-7 cells (Buluwela et al.,
in preparation). One of the 149 genes whose expression
was repressed by PLZF-ER in MCF-7 cells was LRH-1.
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Estrogen treatment of MCF-7 cells showed a four-fold
increase in the LRH-1 expression (Fig. 1a), confirming the
microarray findings; no stimulation of LRH-1 expression
was observed when the cells were treated with the anti-
estrogens 4-hydroxytamoxifen or ICI182, 780. Further,
LRH-1 expression was considerably higher in ER-positive,
compared to ER-negative lines (Fig. 1b), suggestive of an
association between the ER expression and the LRH-1
expression in breast cancer cells.
Analysis of the ER-binding and PolII occupancy data,
generated from ChIP-chip and ChIP-seq profiling of global
ER and PolII binding following treatment of estrogen-
depleted MCF-7 cells with estrogen for 1 h [24, 25],
showed ER binding to a region 10.5 kb upstream from the
LRH-1 exon 1. Real-time PCR of ChIP following estrogen
treatment of MCF-7 cells confirmed that estrogen
stimulates ER binding to this region of the LRH-1 pro-
moter (Fig. 1d).
Several LRH-1 splice variants have been described [10,
26], including hLRH-1 and LRH-1v2 both of which lack
exon 2 encoded amino acids 22–67 (Fig. 2b). In perform-
ing immunoblotting for the LRH-1, we noted that many of
the commercially available antibodies, whilst detecting the
transfected LRH-1 did not detect the LRH-1 in breast
cancer lines. As these antibodies were directed to the LRH-
1 N-terminus, we wondered whether this was due to the
predominance of exon 2-deleted LRH-1 variants in these
lines. 50-Rapid amplification of complementary DNA ends
(50-RACE) for defining 50 ends of the LRH-1 transcripts in
MCF-7 cells identified three main forms (Fig. 2a), the
well-described LRH-1 variant 1 (v1) encoding a polypep-
tide of 541 amino acids, and two new variants, which we
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Fig. 1 LRH-1 is an estrogen-regulated gene that functions in breast
cancer cell growth. a Hormone-depleted MCF-7 cells were stimulated
with vehicle, estrogen, tamoxifen or ICI182780 and LRH-1 mRNA
levels were assessed by real-time RT-PCR (lower panel). Protein
lysates prepared following stimulation of hormone-depleted MCF-7
cells were immunoblotted (upper panel). b The LRH-1 and ER
mRNA levels were determined by real-time RT-PCR analysis of total
RNA. c Shown is the LRH-1 locus with the positions of ER-binding
regions (black box) and RNA PolII occupancy for MCF-7 cells treated
with estrogen for 1 h. Also shown is the region of ER binding for
ZR75-1. Shown are the ER and PolII occupancy representations,
generated by uploading the ChIP-Seq datasets to the UCSC genome
browser gateway (http://genome.ucsc.edu). d ChIP was performed
using mouse immunoglobulins (IgG) or an ER antibody, and quan-
titative PCR was carried out for the ER-binding site identified in (c).
PCR for a region in intron 3 served as a negative control for ER
binding. The results of three independent replicates are shown
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from the previously described LRH-1 variants. v4 and v5
would be expected to encode polypeptides of 501 and 482
amino acids, respectively. Interestingly, LRH-1-v4 tran-
scription is initiated in intron 1 of the LRH-1 gene,
extending the previously identified exon 2 further 50 into
intron 1 (named exon 2a) (Fig. 2c; Supplementary Fig. 1).
The mapped 50 end of LRH-1-v5 defined an exon in intron
2 (here, named exon 2b). Hence, v4 and v5 define tran-
scripts from the previously undescribed, alternative LRH-1
gene promoters. Blast searches of the NCBI database
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) identified one EST
clone, TRACH3028697 (GenBank number: DC418114.1;
the 50 end of which precisely matched the 50 end deter-
mined by 50-RACE. Also identified was an EST clone that
contained the sequences present in v4 and extended the 50
untranslated region by a further 87 bp (Fig. 2b). No cor-
roborating evidence for v5 was found in EST databases.
Expression analysis using isoform-specific real-time
RT-PCR showed that v4 and v5 are highly estrogen-regu-
lated, whereas variants hLRH-1, v1, and v2 expression
were weakly stimulated by estrogen in MCF-7 cells
(Fig. 3a). Note that using these primer sets, we did not
distinguish between hLRH-1, v1, and v2. Furthermore, RT-
PCR and immunoblotting showed that v4 is the predomi-
nant form of LRH-1 expressed in breast cancer cell lines
(Fig. 3b, c). However, extensive reporter gene analysis did
not reveal a significant difference between LRH-1 v1, and
v4 (data not shown; Fig. 3d), despite the fact that v4 lacks
the N-terminal 40 amino acids present in v1.
RNA interference (RNAi) used to determine whether
LRH-1 is an important mediator of estrogen-stimulated
growth of MCF-7 cells, showed that LRH-1 down-regula-
tion using a pool of four small interfering RNAs (siRNA)
potently inhibited MCF-7 growth (Fig. 4a). The individual
siRNAs all inhibited MCF-7 growth, with the least growth
inhibition being observed for siRNA #1, the siRNA that
gave the smallest reduction in LRH-1 expression (Sup-
plementary Figs. 2, 4b, f). Transfection with the LRH-1
siRNAs also inhibited the growth of the LRH-1 positive
ZR-75-1 and T47D cells, but growth of the LRH-1-nega-
tive cell lines, BT474 and MDA-MB-231, was unaffected
by the LRH-1 siRNA (Supplementary Fig. 3a).
LRH-1 regulates ER expression in breast cancer cells
Determination of the expression of estrogen-regulated
genes showed that LRH-1 knockdown reduced expression
of the pS2 and cathepsin D (CTD) genes (Fig. 4c, d),
prompting us to determine whether the growth inhibitory
effects of the LRH-1 knockdown could be due to the LRH-
1 regulation of ER expression. Indeed, ER mRNA and
protein were reduced following siRNA for LRH-1 (Fig. 4e,
f). Inhibition of ER expression following LRH-1
knockdown was also observed in T47D and ZR75-1 cells
(Supplementary Fig. 3b, c).
In order to confirm these findings, we investigated
whether synthetic LRH-1 activating compounds could
stimulate MCF-7 cell growth. A number of substituted cis-
bicyclo[3.3.0]-oct-2-enes have been identified as small
molecule agonists of LRH-1 and SF-1 [22]. As there was
no detectable expression of SF-1 in MCF-7 and BT-474
Fig. 2 Identification of new LRH-1 variants in breast cancer cells.
a Products of 50-RACE are shown for RNA prepared fromMCF-7 cells
treated with estrogen (E2) or vehicle (NL) for 8 h. The products were
cloned and sequenced to assign their identities, as marked. b Shown is a
schematic representation of the LRH-1 variants, including variants v4
and v5 identified here. c Sequences of LRH-1 variants v4 and v5. The
DNA sequences in italics represent the 50 untranslated regions present
in the 50-RACE cloning products. The sequences in lower case shown
for v4 are also present in an EST (UTERU3011183) (http://www.
ncbi.nlm.nih.gov/). The underlined amino acids in v5 are the residues
arising from the newly described exon (exon 2b)
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cells (Supplementary Fig. 4), we determined the effect of
three of these compounds (5A, 5B, and 5L) on cell growth.
MCF-7 cell growth was stimulated, whereas growth of the
ER-positive, but LRH-1-negative BT-474 cells, was unaf-
fected (Fig. 5a). As seen with a reporter gene assay, these
compounds stimulated the activity of an LRH-1 responsive
luciferase reporter gene (Fig. 5b), and treatment with the
compounds increased the ER levels in MCF-7 cells
(Fig. 5c). Moreover, LRH-1 transfection stimulated ER
expression in MCF-7 and BT474 cells (Fig. 5d, e), whereas
transfection of the small heterodimer partner (SHP), a NR
that acts as a co-repressor for LRH-1 [27], reduced ER
expression in MCF-7 cells (Fig. 5f, g). Further, LRH-1
transfection stimulated the growth of MCF-7 cells, while
SHP inhibited MCF-7 growth (Fig. 5h).
LRH-1 regulates ER expression by direct recruitment
to the ER gene promoter
Expression of the human ER gene is initiated at multiple
promoters spanning 150 kb [8]. RT-PCR showed that in
the lines examined, the majority of ER expression is ini-
tiated at promoters A, B, and C, with some expression from
promoter F (Fig. 5a; Supplemental Fig. 5). Analysis of the
region encoding ER gene promoters A through F revealed
the presence of 11 sequences conforming to the LRH-1
consensus binding site (YCAAGGYCR [28]), with the
closest of these sites being located less than 6 kb 50 to
promoters A/B (Fig. 6a). In addition, our analysis high-
lighted an extended palindrome centered around a HinDIII
restriction enzyme site (50-CCAAAGCTTTGG-30) which
Fig. 3 LRH-1 variant 4 is the major form of the LRH-1 in breast
cancer cells. a LRH-1 variant mRNA levels in MCF-7 cells were
determined by real-time RT-PCR using primers that specifically
amplify v4 or v5 sequences. Primers for v1/v2 amplify the LRH-1
variants 1 and 2, as well as hLRH-1. The results for three independent
RNA samples are shown, with in each case expression level in the
absence of ligand (NL) being taken as 1 and expression level in the
presence of E2 shown relative to that. b Expression of the LRH-1
variants in breast cancer cell lines is shown. Expression of v1/v2 in
MCF-7 was taken as 1 and all other values are shown relative to this.
c Protein lysates prepared from breast cancer lines and COS-1 cells
transfected with LRH-1 v1 or v4 were immunoblotted for LRH-1 and
b-actin. d COS-1 cells were co-transfected with an LRH-1-responsive
luciferase reporter gene (SF-1-luc) and increasing amounts of LRH-1
v1 or v4. Reporter gene activities are shown relative to the vehicle
control. Protein lysates prepared from these lysates were immuno-
blotted for LRH-1 to determine relative expression of the variants
(lower panel)
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encoded a sequence (underlined) similar to that identified
in the mouse SEBP gene as an LRH-1-binding site [29],
912 bp 50 to the promoter A start site (named LRHRE1).
As promoters A and B constitute the major promoters
utilized in MCF-7 cells, we generated an ER promoter
luciferase reporter gene (ERP-luc) encoding a 6.0 kb
region comprising promoters A through D and containing
two putative LRH-1-binding sites (LRHRE2, and
LHRRE3) that conform to the LRH-1 consensus binding
site sequence, as well as LRHRE1. The ERP-luc reporter
was activated by LRH-1 in MCF-7 cells (Fig. 6b). Struc-
tural studies have shown that the LRH-1 ligand-binding
domain (LBD) has phospholipids bound [13–15]. An LRH-
1 mutant (LRH-1-F342W/I416W), which is impaired for
phospholipid binding and shows reduced transcriptional
activity [14] also showed reduced activation of ERP-luc.
Mutation of LRHRE2 and LRHRE3 had modest effects on
LRH-1 regulation of the reporter gene, with a considerably
larger reduction in reporter gene activity being observed if
LRHRE1 was mutated (Fig. 6c), suggesting that LRH-1
binds to the LRHRE1 sequence.
As the LRHRE1 sequence does not conform to the
LRH-1 consensus binding site, LRH-1 binding to this
sequence was determined using a fluorescence polarization
assay using E. coli-expressed LRH-1 DBD and FAM-
labeled oligonucleotides. The Kd of LRH-1 binding to
LRHRE1 (126 nM) was similar to that obtained for the
LRH-1 site in the Cyp7A1 gene promoter (200 nM)
(Fig. 6d; Supplemental Fig. 5).
ChIP analysis of MCF-7 cell lysates with an LRH-1
antibody demonstrated LRH-1 recruitment to the region of
the ER promoter containing the LRHRE1 sequence
(Fig. 6e). Taken together, these findings indicate that
LRH-1 is recruited to the LRHRE1 sequence in the ER
gene promoter, and that this sequence is important for
LRH-1 regulation of ER expression.
Discussion
LRH-1 is an estrogen-regulated gene in breast cancer
cells
Estrogens play critical roles in the initiation and progres-
sion of human breast cancer, as well as other gynaeco-
logical cancers. Estrogen actions are mediated by ER
which acts primarily as a transcription factor that, upon
binding estrogen, regulates the expression of a large
number of estrogen-responsive genes [30], causing, in the
case of breast cancer cells, inhibition of apoptosis and
promotion of proliferation. Defining the key estrogen-reg-
ulated genes in cancer cells would provide important
insights into the mechanisms by which estrogen/ER pro-
motes breast cancer growth. Using an engineered MCF-7
cell line that conditionally expresses a dominant-negative
form of ER in which the PLZF transcriptional repressor
was fused to ER [21], we identified LRH-1 as a gene whose
expression was repressed upon PLZF-ER expression. RT-
PCR analysis and immunoblotting confirmed estrogen-
regulation of LRH-1, as has previously been described
[31]. As also described previously, siRNA-mediated
LRH-1 silencing potently inhibited the estrogen-stimulated
growth of MCF-7 cells. Moreover, we observed inhibition
of the growth of other ER/LRH-1-positive breast cancer













































































































Fig. 4 Targeted knockdown of LRH-1 inhibits Estrogen Receptor
(ER) expression. a MCF-7 cells grown in estrogen-depleted medium
were transfected with the LRH-1 siRNA, treated with vehicle or
estrogen and cell number estimated after 4 days using the sulpho-
rhodamine B (SRB) assay. Growth is shown relative to the reagent
alone control for three experiments. b–e siRNA pool for LRH-1 or
individual siRNAs were transfected into MCF-7 cells, RNA and
protein was prepared after 48 h. LRH-1 (b), pS2 (c) cathepsin D
(CTD) (d) and ER (e) mRNA levels were determined by real-time
RT-PCR analysis. Shown are the means and s.e.m. for three
experiments. Asterisks show statistically significant difference
(unpaired t-test, P\ 0.05) from the reagent or non-targeting controls.
f Immunoblotting was performed following preparation of protein
lysates from MCF-7 cells transfected with siRNAs for LRH-1
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The study by Annicotte et al. [31] previously identified an
estrogen response element 2.3 kb upstream of the LRH-1
exon 1. ChIP based global analysis of ER-binding sites did
not, however, detect significant binding to this region in
MCF-7 and ZR75-1 cells. Instead, binding to a region
10.5 kb upstream of exon 1 was seen in both cell lines. This
region contains the sequence 50-AGGaCAcacTG ACCT-30
(starting at chromosome 1 bp 198,252,853 in the NCBI hg18
human genome release, inwhich exon 1 of the LRH-1 gene is
at bp 198,263,393 (http://genome.ucsc.edu)), which con-
forms well to the consensus ERE sequence (AGGTC
AnnnTGACCT) [32]. ChIP analysis confirmed estrogen-
stimulated ER recruitment to this site, indicating that this site

























































































































































































Fig. 5 LRH-1 stimulates Estrogen Receptor (ER) expression in
breast cancer cells. a Hormone-depleted MCF-7 and BT-474 cells
were stimulated with a vehicle, estrogen or LRH-1 activator, over a
12-day period. Shown is growth at day 12, relative to the vehicle
control, as measured using the SRB assay. b COS-1 cells transfected
with an LRH-1 responsive luciferase reporter gene (SF-1-luc) were
stimulated with vehicle (DMSO) or the LRH-1 activators 5A, 5B and
5L. Reporter gene activities are shown relative to the vehicle control.
c RNA was prepared from MCF-7 cells treated with compounds 5A,
5B and 5L for 8 h. ER mRNA levels were determined by real-time
RT-PCR. d, g Protein lysates prepared from MCF-7 cells following
transfection with LRH-1 (d) or SHP (g) were immunoblotted. e, f
Real-time RT-PCR was performed using RNA prepared from MCF-7
cells transfected with LRH-1 (e) or SHP (f). h MCF-7 cells were
transiently transfected with LRH-1 or SHP and cell numbers
estimated after 4 days using the SRB assay. Growth is shown relative
to the vector control. All graphical results are shown as the means and
s.e.m. relative to the vehicle or vector controls, of at least three
replicates. Asterisks denote statistically significant difference
(P\ 0.05) relative to the appropriate vehicle or vector control,
determined using the unpaired t-test
392 Breast Cancer Res Treat (2011) 127:385–396
123
A new LRH-1 variant is the predominant form
of LRH-1 in breast cancer cells
LRH-1 transcript mapping identified two new LRH-1
variants, both of which are expressed from distinct new
promoters, one initiating within intron 1 and extending
exon 2 127 bp 50 (v4), and the second initiating in intron 2
and lacking exon 1 and 2 sequences (v5). Both of these
variants are estrogen regulated, but v5 expression is low in
breast cancer cells. LRH-1-v1 was the only other variant
whose expression was observed by 50-RACE, but it was
also expressed at low levels, with v4 being the major form
of LRH-1 in breast cancer cells, which was confirmed by
immunoblotting. Forms of LRH-1 corresponding to v4, as
well as v1 are seen in the mouse, chicken (Supplementary
Fig. 1b, c), and rat, while v4 corresponds to LRH-1
Fig. 6 LRH-1 binds to a specific site within the ER gene promoter.
a Shown is a schematic representation of the ER gene, with the
positions of ER promoters A through F highlighted. Transcription
start site positions shown are as previously described [9]. Sequences
that are similar to the consensus LRH-1-binding site are shown, either
above or below the rectangle with the sequences shown below the
rectangle denote sites on the lower DNA strand, whilst those above
the rectangle represent sites on the upper DNA strand. The region of
the ER gene used to generate the ER promoter luciferase reporter
gene (ERP-luc) is shaded. b MCF-7 cells were transfected with ERP-
luc, together with the LRH-1 or the LRH-1-F342W/I416W mutant.
c Reporter gene activities were determined for MCF-7 cells
transfected with ERP-luc, or mutants in which LRHRE1-3 were
mutated. All reporter gene activities are shown as the means and
s.e.m., for three replicates, relative to the vector control. d DNA
binding to LRHRE1 and the Cyp7A1 LRH-1 response element was
measured by changes in fluorescence polarization for the LRH-1
DBD. The results of at least three replicates are shown. e ChIP was
performed using lysates prepared from MCF-7 cells, and real-time
PCR for three replicates using primers for a control region mapping to
the c-myc locus and the ER promoter encompassing LRHRE1, are
shown. In all cases asterisks show statistically significant differences
(P\ 0.05), determined using the unpaired t-test, between sample 1
and the other samples, or relative to the control samples
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transcripts predicted to come from the xenopus and zeb-
rafish LRH-1 genes. Furthermore, analysis of the ChIP-
chip for RNA polymerase II (PolII) [25] showed that at the
LRH-1 locus, the strongest binding of PolII is centered on
exon 2 sequences (see Fig. 2c), which indicates that in
MCF-7 cells the major transcription initiation sites for the
LRH-1 gene are centered around exon 2. Finally, real-time
RT-PCR using RNA from a panel of human tissues showed
that v4 is expressed more widely than the other variants.
Indeed, we did not detect expression of the other variants in
the absence of v4 expression. Taken together, these find-
ings provide strong evidence for the in vivo importance of
LRH-1-v4. A previous study examining LRH-1 expression
immunohistochemically in invasive ductal carcinoma
showed that 43% of breast tumours are LRH-1 positive
[33], expression being negatively associated with clinical
stage and histological status and positively associated with
steroid receptor status. As this study was carried out using
an antibody directed to amino acids 2–33 of LRH-1-v1
(absent in v4), it is possible that the LRH-1 positivity was
underestimated, highlighting the need for re-evaluation of
LRH-1 in breast cancer, the lack of currently ascribed
differences in the activities of LRH-1 variants 1 and 4
notwithstanding. As the antibodies available to us have
proved to be unsuitable for immunohistochemistry, we are
currently developing new antibodies to address this issue.
LRH-1 regulates estrogen receptor expression
in breast cancer cells
LRH-1 knockdown inhibits breast cancer cell growth, as
previously described [31] and confirmed here. Importantly,
LRH-1 knockdown reduced ER expression, LRH-1 over-
expression or stimulation of its activity by synthetic ago-
nists increased ER levels, whilst the LRH-1 repressor SHP
reduced ER expression. Reporter gene studies and muta-
tional analysis showed that three sites contribute to the
LRH-1 regulation of the ER reporter gene, with an LRH-1-
binding site, named LRHRE1 (50-AATTGCCAAAGCT
TTGGT-30) having a sequence similar to LRH-1-binding
site in the mouse SEBP gene (50-CCCAAAGGCTT-30)
[29], being the most important site for the LRH-1 regula-
tion of ER expression. Finally, ChIP confirmed binding of
LRH-1 to the ER gene in a region encompassing this site.
Taken together, these results show that LRH-1 regulates
ER-positive breast cancer cell growth through a mecha-
nism involving regulation of ER gene expression through
direct recruitment to the ER promoter.
Previous study has highlighted a positive regulatory
loop in which ER and GATA-3 reciprocally regulate each
other in breast cancer cells [34], and provides a possible
explanation for the co-expression of ER and GATA-3 in
breast cancers (see [34, 35]). Other estrogen-regulated
genes have been shown to be important for ER action in
breast cancer cells, with FoxA1 being required for the
recruitment of ER to the promoters of many estrogen-
responsive genes [36, 37]. Our findings show that ER and
LRH-1 form a positive cross-regulatory loop in which each
transcription factor is required for the expression of the
other gene.
The aromatase (CYP19) gene is transcribed from a
number of different promoters, with expression from the
different promoters being highly tissue selective. The
aromatase promoter II (PII) is used in gonadal tissues, and
its regulation by SF-1 has been demonstrated [38–40].
Whilst in normal breast tissue, aromatase is expressed at
low levels, with promoter 1.4 being utilized, in tumor-
bearing breast tissue, aromatase expression is elevated,
with transcription being driven largely through PII pro-
moter [19]. These studies have also indicated that SF-1 is
not expressed in breast tumours, whilst LRH-1 is expressed
in adipose tissue, with LRH-1 and aromatase co-expression
being evident particularly in pre-adipocytes [17]. In this
context, LRH-1 regulates aromatase expression thorough
recruitment to the PII Promoter [17, 18]. Furthermore,
regulation of the PII promoter by LRH-1 occurs synergis-
tically with GATA3 [18]. Interestingly, regulation of ER
expression by GATA3 has also previously been described
[34]. Our preliminary analysis shows that LRH-1 and
GATA3 also act synergistically at the ER promoter (Sup-
plementary Fig. 7). Aromatase expression is additionally
dependent on tumor-derived growth factors, particularly
prostaglandin E2, acting through protein kinase A (PKA) to
stimulate aromatase PII activity [17, 18]. In agreement with
these findings, activity of the aromatase PII reporter gene
was strongly increased by PKA, whereas PKA did not
similarly potentiate the synergism between LRH-1 and
GATA3 at the ER gene promoter (Supplementary Fig. 7).
Together, these results indicate that aromatase and ER
expression are similarly regulated, albeit in different cell
types, indicating that the cell-type specificity may be due to
differences in cell signaling pathways, such as those
involving PKA (for potential model of aromatase and ER
regulation by LRH-1 see Supplementary Fig. 7c).
Of course, differential expression of the LRH-1 vari-
ants may also be important in specifying cell-type selec-
tivity for the differential regulation of aromatase and ER
genes in different cell types. Furthermore, we did not
observe expression of the LRH-1 regulated SHP gene in
the breast cancer cell lines; nor was Dax1 expression
evident in LRH-1 positive breast cancer lines. As SHP
and Dax1 are important regulators of LRH-1 activity [27],
their presence or absence may also be important in
defining promoter and cell-dependent activities of the
LRH-1, as well as responses to other signaling pathways,
such as PKA.
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In conclusion, our studies show that LRH-1 is a key reg-
ulator of estrogen responses in breast cancer, which acts by
regulating estrogen synthesis in breast tumour tissue and by
regulating ER expression in breast cancer cells. As such,
LRH-1 presents as an important target for the development
of new therapeutic agents for use in breast cancer treatment.
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Discovery of a New Class of Liver Receptor Homolog-1 (LRH-1) Antagonists:
Virtual Screening, Synthesis and Biological Evaluation
Jullien Rey,[a] Haipeng Hu,[b] Fiona Kyle,[c] Chun-Fui Lai,[c] Laki Buluwela,[c] R. Charles Coombes,[c]
Eric A. Ortlund,[d] Simak Ali,*[c] James P. Snyder,*[b] and Anthony G. M. Barrett*[a]
After lung cancer, breast cancer in women is the most
common cancer in the world with more than a million new
cases diagnosed every year.[1] Estrogens, acting through the es-
trogen receptor, are important drivers of breast cancer growth.
Much progress has been made in the fight against breast
cancer with the development of antiestrogen agents, such as
tamoxifen (1) and raloxifene (2), capable of competing with
the agonistic action of estradiol (3) at the estrogen receptor a
(ERa).[2] Estrogen binding to the ligand binding domain (LBD)
of ERa generates a receptor conformation that reveals a co-ac-
tivator recruitment groove involving a-helices 3, 4, 5 and 12,
allowing co-activator recruitment to agonist-bound ER and
consequent stimulation of gene expression. Through helix 12
(H12) displacement, antiestrogen agents can prevent the for-
mation of the ERa LBD co-activator binding surface, thereby
preventing co-activator recruitment and subsequent stimula-
tion of gene expression.[3] However, resistance to these thera-
pies is common, and so the identification of new molecular
targets for breast cancer treatment is an important goal.
Liver receptor homolog-1 (LRH-1) is a member of the steroi-
dogenic factor subfamily of nuclear receptors (NR) and plays
a prominent role in both adult and developmental biology.[4] It
has also been implicated in the control of aromatase expres-
sion in breast tumor-associated stroma, stimulating local estro-
gen biosynthesis.[5] Recently, LRH-1 was identified as a key reg-
ulator of ER expression in breast cancer cells[6] and was shown
to be associated with invasive breast cancer and estrogen-
dependent cell proliferation.[7] Together, these findings suggest
that the development of a small molecule capable of antago-
nizing LRH-1 could provide a powerful new strategy for inhibit-
ing estrogen signaling for the treatment of breast cancer.
Co-activator recruitment to the LBD of NRs is mediated by
a-helical motifs in co-activator proteins conforming to the con-
sensus sequence LXXLL, where L is leucine and X is any
amino acid.[8,9] As is the case for ERa, agonist binding to other
NRs reveals a co-activator recruitment groove that can accom-
modate the a-helical LXXLL region.[10] This well-studied molec-
ular switch, with conformational changes in the LBD allowing
co-activator recruitment and antagonist binding blocking co-
activator recruitment, provides a powerful screening strategy
for identifying NR agonists and antagonists. Using a high-
throughput screening (HTS) strategy based on interaction be-
tween the LRH-1 LBD and a LXXLL motif in the NR co-activa-
tor, transcriptional intermediary factor 2 (TIF2) in a fluorescence
resonance energy transfer (FRET)-based assay, Whitby et al. dis-
covered a series of substituted cis-bicyclo[3.3.0]oct-2-enes
acting as LRH-1 agonists.[11] However, to the best of our knowl-
edge, no antagonist has yet been reported in the literature,
making the development of such molecules an attractive and
challenging task.
While LRH-1 is known to bind phospholipids, recent structur-
al studies of LRH-1 suggest that these phospholipids are ex-
changeable with exogenous compounds and that a pool of
apoLRH-1 exists in cells.[12,13] Given the availability of large
chemical libraries, we employed virtual HTS and molecular
modeling strategy to identify potential LRH-1 antagonists.
Such compounds were assumed to bind within the LRH-1 LBD,
displacing the mobile a-helix H12 by means of a-helix–small
molecule steric clashes, and thereby, generate an inactive con-
formation. Using raloxifene (2) as a search template, a two-
dimensional virtual HTS of the ChemNavigator library,[14] which
contains 50 million-plus compounds, delivered 974 hits. Subse-
quent docking-based three-dimensional screening of the latter
dataset with the Glide/molecular mechanics generalized Born
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surface area (MMGBSA) algorithms[15,16] and the hLRH-1 LBD
crystal structure housing phosphatidyl glycerol (PG) (PDB:
1YOK;[17] PG removed for docking) led to identification of the
benzothiophene analogue 4. Given the flexibility of nuclear re-
ceptors,[18,19] it would have been ideal to work with LRH-
1 bound by an antagonist. However, in the absence of such
a structure, 1YOK was selected since PG is a large, weak ago-
nist whose binding pocket is expanded by comparison with
a smaller potent agonist ; the pocket created by PG can be
considered as more suitable for antagonist binding (see Fig-
ure S1 in the Supporting Information).
Docked into LRH-1, structure 4 adopted the desired antago-
nistic pose in which the C-7 side chain promotes virtual H12
displacement (Figure 1a). The benzothiophene core of 4 coin-
cides with the binding pose of the GSK8470 agonist in the X-
ray-determined complex (PDB: 3PLZ;[11b] Figure 1b). The antag-
onist is anchored in the pocket primarily by hydrophobic inter-
actions between the core and the C-3 and C-7 side chains. The
C-3 side chain is surrounded by H6 and H7, and the hairpin
linking H5 and H6. The C-7 piperidine side chain, on the other
hand, extends deeply into the space occupied by the side
chains of residues Asn530 and Leu532 of H12, causing very se-
rious steric clashes (Figure 2). This modeled juxtaposition was
precisely that sought to displace H12.
In order to validate the docking predictions, the synthesis
and biological evaluation of benzothiophene 4 were pursued.
With no precedence in the literature for the selective introduc-
tion of benzoyl moieties at the C-7 position of a benzothio-
phene ring, a novel and efficient synthetic approach needed to
be developed. Benzothiophene 9 was obtained in two steps
by nucleophilic substitution of bromoketone 6 with thiophenol
5 and subsequent cyclization in neat polyphosphoric acid at
90 8C (Scheme 1).[20] Under these conditions, a mixture of iso-
mers was formed as the cyclization can occur either at the
ortho- or para-position of the methoxy group (positions 2 and
6 from 7). Pleasingly, the compounds could be separated by
selective crystallization from refluxing acetone, giving the less
soluble and major benzothiophene isomer 9. Mechanistically,
the formation of benzothiophene 9 goes via the formation of
C-3-substituted intermediate 8 through acid-catalyzed hydroal-
kylation by the protonated ketone 7 followed by aromatiza-
tion. Protonation of intermediate 8 followed by a 3,2-shift of
the methoxyphenol ring and aromatization led to desired
product 9.[21]
A double Friedel–Crafts acylation was examined in an at-
tempt to functionalize both the C-3 and C-7 positions of the
benzothiophene ring (Scheme 2). Aluminum-chloride-mediated
double acylation using an excess of 4-fluorobenzoyl chloride
was accompanied by partial selective demethylation and gave
benzophenone 10. Selective mono-deprotection of related aryl
methyl ethers is known to proceed via the formation of a six-
membered ring chelate between the aluminum, the ortho-
ketone carbonyl, and the phenolic oxygen atom leading to, in
this case, phenol 10.[22] This was further demethylated using
boron tribromide to produce diphenol 11. Finally, the piperi-
dine side chains were introduced by nucleophilic aromatic sub-
stitutions generating benzothiophene 4.[23]
Figure 2. Interpenetration of the ethoxypiperidine moiety of 4 (space-filled
structure) into helix 12 (H12). Structure 4 is docked into LRH-1 (PDB:
1YOK[17]) without H12 and overlayed with the same receptor retaining H12
in place (red). Leu532 (red sticks) pierces the C-7 CH2O-phenyl segment of
4, while Asn530 passes through the center of the distal piperidine ring.
Figure 1. Small molecules in the ligand binding domain (LBD) of LRH-1.
a) Molecular modeling (docking pose) of benzothiophene antagonist 4 in
LRH-1. Helix 12 (H12) in the phosphatidyl glycerol-bound protein is high-
lighted in red (PDB: 1YOK[17]). Also shown is the hairpin loop (HL) linking H5
and H6. The residues Asn 530 and Leu 532 of H12 are highlighted as red
sticks. b) Whitby agonist GSK8470/LRH-1 X-ray structure (PDB: 3PLZ[11b]).
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To assay for inhibition of co-activator binding, benzothio-
phene 4 was tested in an in vitro assay using the bead-based
proximity AlphaScreen method that allows sensitive measure-
ment of protein–protein interactions by transfer of energy
from the excited donor bead to an acceptor bead in close
proximity,[24] allowing screening for compounds that promote
or inhibit protein–protein interactions. To determine inhibition
of LRH-1/co-activator interaction, an assay was developed to
measure co-activator recruitment by the LBD of LRH-1, using
a biotinylated peptide derived from human PGC1a, with the
sequence 138-AEEPSLLKKLLLAPANT, and his-tagged, purified
recombinant human LRH-1 LBD (amino acids 291–541).
Streptavidin-coated donor beads were incubated with the
biotinylated co-activator peptide, together with his-tagged
LRH-1 and nickel-nitrilotriacetic acid (Ni-NTA) acceptor beads.
Since recombinant LRH-1 LBD takes up the activated confor-
mation due to bound phospholipids,[17,25] potential antagonists
can readily be identified by a decrease in interaction with the
PGC1a peptide. Gratifyingly, compound 4 exhibits
LRH-1 antagonism in the low micromolar range
(IC50=3.1 mm ; Table 1), which is ideal for potency im-
provement by molecular manipulation. For example,
the LRH-1 agonist GSK8470 has reported EC50 values
of 0.43–0.63 mm, while chemical modification of the
structure achieved derivatives with potencies as low
as 10–100 nm.[11]
An initial attempt to optimize 4 was motivated by
a desire to decrease the molecular weight (4, MW=
704.9 amu) and improve the analogue physical prop-
erties within the context of the present synthetic
scheme. The concept eliminates the C-7 ethoxypiperi-
dine in 4, but compensates its predicted steric effect
by replacing the C-7 aroyl meta-hydrogen atoms with
methyl groups. Figure 2 illus-
trates an apparent severe steric
encounter between the H12
Leu532 residue and the meta-
centers of the aromatic ring.
Docking structures 19 and 20
carrying one and two meta-
methyl groups, respectively, into
the LRH-1 LBD pocket (H12 re-
moved) revealed predicted bind-
ing poses similar to 4. A pro-
spective clash of the alkylated
aromatic rings with Leu532, con-
sistent with antagonism, is evi-
dent (see Figure S2 in the Sup-
porting Information). According-
ly, methylated analogues 19 and
20 (MW=591.7 and 605.7 amu,
respectively) were chosen for
synthesis and bioassay.
Both substituents at C-3 and
C-7 positions were introduced
by sequential Friedel–Crafts acylation reactions. Reaction of
benzothiophene 9 with one equivalent of 4-fluorobenzoyl
chloride and aluminum chloride gave ketone 12 in a selective
manner without formation of bis-acylated intermediate 10
Scheme 1. Synthesis of benzothiophene intermediate 9. Reagents and conditions : a) KOH,
EtOH, H2O, RT, 18 h, 81%; b) polyphosphoric acid, 90 8C, 1 h, 63%.
Scheme 2. Synthesis of benzothiophene 4. Reagents and conditions : a) 4-fluorobenzoyl chloride, AlCl3, CH2Cl2, RT,
18 h, 70%; b) BBr3, CH2Cl2, 0 8C, 3 h, 79%; c) 1-(2-hydroxyethyl)piperidine, NaH, DMF, 50 8C, 5 h, 52%.
Table 1. Biological and computational evaluation of benzothiophene an-
alogues conceived by virtual database screening and molecular model-
ing.
Entry Compd IC50
[a] [mm] DG [Kcalmol!1]
1 4 3.1 (2.6–3.7) !136.7
2 19 5.8 (4.3–7.7) !132.2
3 20 8.8 (5.1–15.0) !130.9
[a] Data are the mean values of three experiments. The corresponding
95% confidence range is given in parentheses. [b] The MMGBSA algo-
rithm was used to predict the binding affinities of these compounds for
LRH-1.
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(Scheme 3).[23] Subsequent acylation of benzothiophene 12
with 3-methylbenzoyl chloride (13) gave 15, which was directly
demethylated using boron tribromide to yield phenol 17.
Finally, nucleophilic aromatic substitution of fluoride 17 by
1-(2-hydroxyethyl)piperidine gave the desired benzothiophene
19 in moderate yield (Scheme 4). A similar strategy was used
for the synthesis of benzothiophene 20 starting from inter-
mediate 12 and 3,5-dimethylbenzoyl chloride (14) (Schemes 3
and 4).
Benzothiophenes 19 and 20 were then tested in the in vitro
AlphaScreen assay to show a two to threefold decrease in an-
tagonistic activity relative to 4 (Table 1). This result was exam-
ined by evaluating the MMGBSA free energies of binding[16] for
the three compounds. The order of binding is estimated to be
4>19>20 precisely in parallel with the in vitro results
(Table 1). Consistently, the geometries of the docked structures
suggest productive ligand contacts, and the degree of pertur-
bation of Leu532 on H12 by the ligands falls in the same order
(see Figure S2 in the Supporting Information). It would appear
that to achieve more effective antagonists, the longer C-7 side





assay was used to confirm the in
vitro findings. For this, COS-
1 cells were co-transfected with
GAL4(DBD)-PGC1a DNA binding
domain and VP16-LRH-1, togeth-
er with a GAL4-responsive luci-
ferase reporter gene. As expect-
ed, GSK8470 stimulated the in-
teraction of LRH-1 with PGC1a
(Figure 3). Raloxifene (2) weakly
inhibited the interaction at con-
centrations up to 10 mm. Inhibi-
tion by compounds 4, 19 and 20
was again observed, with the
degree of inhibition at 10 mm
being in the order 4>19>20,
as observed in the AlphaScreen
assay. Investigation of the action
of these compounds towards ERa showed that they do indeed
inhibit ERa in reporter gene assays, albeit considerably less po-
tently than raloxifene (Figure S3 in the Supporting Informa-
tion). GSK8470 had little or no effect on ERa activity.
In summary, three novel benzothiophene derivatives identi-
fied as modest LRH-1 antagonists using Glide/MMGBSA dock-
ing methodology were synthesized and biologically assayed.
The identification of these analogues, derived by weak similari-
ty comparisons to the selective estrogen receptor modulator
(SERM) raloxifene (2), arose from high-throughput virtual
screening performed on a library of millions of compounds.
LRH-1 docking analysis suggests that the C-7 moiety of the
benzothiophene scaffold is directed toward H12 and can cause
a significant steric clash between the ligand terminal atoms
and the H12 a-helix. Efforts to further chemically modify the
C-7 side chain to develop novel benzothiophenes with im-
proved potency are underway.
Experimental Section
Chemistry
All chemicals were used as re-
ceived or purified using standard
procedures. Solvents were dried by
standard techniques and distilled
under N2 before use. All experi-
ments were carried out in oven-
dried glassware under an inert at-
mosphere of N2 or Ar. Analytical
thin layer chromatography (TLC)
was performed using pre-coated
aluminum- or glass-backed plates
(Merck silica gel 60 F254), and
plates were visualized by ultravio-
let light and/or treatment with
Scheme 3. Synthesis of benzothiophenes 17 and 18 by sequential Friedel–Crafts acylations. Reagents and condi-
tions : a) 4-fluorobenzoyl chloride, AlCl3, CH2Cl2, 18 h, 69%; b) AlCl3, CH2Cl2, RT, 18 h; c) BBr3, CH2Cl2, 0 8C, 3 h, for
17: 42%, for 18 : 46% (two steps).
Scheme 4. Synthesis of benzothiophenes 19 and 20. Reagents and conditions : a) 1-(2-hydroxyethyl)piperidine,
NaH, DMF, 50 8C, 5 h, for 19 : 37%, for 20 : 35%.
1912 www.chemmedchem.org ! 2012 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2012, 7, 1909 – 1914
MED
KMnO4 or vanillin stains followed by heating as deemed appropri-
ate. Flash column chromatography was carried out using silica
(Merck 9385 Kieselgel 60; 230–400 mesh) under a positive pressure
of N2.
1H and 13C NMR spectra were recorded at 400 or 500 MHz
and 100 or 125 MHz, respectively. Chemical shifts (d) are quoted in
parts per million (ppm) and are referenced to a residual solvent
peak. HSQC was used to confirm peak integration in 13C NMR spec-
tra. Mass spectra were recorded using a Micromass Platform II and
Micromass AutoSpec-Q spectrometer. The purity of the final com-
pounds tested in vitro was assessed by LC/MS and HRMS. Infrared
(IR) spectra were recorded using the attenuated total reflectance
(ATR) technique, monitoring from 4000–700 cm!1. Melting points
(mp) were determined using a hot-stage microscope and are un-
corrected.
Experimental protocols and characterization data for all intermedi-
ates are given in the Supporting Information.
2-(4-Hydroxyphenyl)-3,7-bis-({4-[2-(piperidin-1-yl)ethoxy]phenyl}-
carbonyl)-1-benzothiophen-6-ol (4): 1-(2-Hydroxyethyl)piperidine
(66 mL, 0.49 mmol) was added with stirring to NaH (34 mg,
0.86 mmol, 60% in mineral oil) in DMF (1.4 mL) at RT. After 5 min,
benzothiophene 11 (60 mg, 0.12 mmol) in DMF (0.20 mL) was
added in one portion, and the mixture was stirred at 50 8C for 5 h.
The reaction was quenched with H2O, and the aqueous phase was
extracted with EtOAc (!3). The combined organic extracts were
washed with brine, dried (MgSO4), filtered and concentrated in
vacuo. Purification by flash chromatography (CH2Cl2/MeOH: 49:1!
24:1+0.25% NH3·H2O) gave diamine 4 as a yellow solid (45 mg,
52%): mp: 129–132 8C (MeOH); 1H NMR (400 MHz, [D6]DMSO): d=
10.3 (br s, 1H), 9.74 (br s, 1H), 7.76 (d, J=8.8 Hz, 2H), 7.68 (d, J=
8.8 Hz, 2H), 7.46 (d, J=8.8 Hz, 1H), 7.15 (d, J=8.8 Hz, 2H), 7.05 (d,
J=8.8 Hz, 2H), 6.92 (d, J=8.8 Hz, 2H), 7.04 (d, J=8.8 Hz, 1H), 6.65
(d, J=8.8 Hz, 2H), 4.16 (t, J=5.9 Hz, 2H), 4.08 (t, J=5.9 Hz, 2H),
2.67 (t, J=5.9 Hz, 2H), 2.61 (t, J=5.9 Hz, 2H), 2.44–2.41 (m, 4H),
2.40–2.37 (m, 4H), 1.52–1.44 (m, 8H), 1.40–1.34 ppm (m, 4H);
13C NMR (100 MHz, [D6]DMSO): d=193.3, 192.3, 162.8, 162.5, 157.8,
141.9, 138.4, 132.7, 131.8, 131.7, 129.9, 129.7, 129.5, 129.3, 125.8,
123.4, 118.4, 116.1, 115.6, 114.4, 114.2, 65.9 (2C), 57.1, 57.0, 54.3,
54.2, 25.5, 25.4, 23.8 (2C) ppm (one quaternary carbon obscured);
IR (neat): n˜=1597, 1356, 1236, 1155, 900, 830 cm!1; HRMS-ESI: m/z
[M+H]+ calcd for C42H45N2O6S: 705.2998, found: 705.3010.
7-[(3-Methylphenyl)carbonyl]-2-(4-hydroxyphenyl)-3-({4-[2-(pi-
peridin-1-yl) ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol (19):
1-(2-Hydroxyethyl)piperidine (33 mL, 0.25 mmol) was added with
stirring to NaH (25 mg, 0.62 mmol, 60% in mineral oil) in DMF
(1.4 mL) at RT. After 5 min, benzothiophene 17 (60 mg, 0.12 mmol)
in DMF (0.20 mL) was added in one portion, and the mixture was
stirred at 50 8C for 5 h. The reaction was quenched with H2O, and
the aqueous phase was extracted with EtOAc (!3). The combined
organic extracts were washed with brine, dried (MgSO4), filtered
and concentrated in vacuo. Purification by flash chromatography
(CH2Cl2/MeOH: 99:1!19:1+0.25% NH3·H2O) gave amine 19 as an
amorphous yellow solid (27 mg, 37%): 1H NMR (400 MHz,
[D6]DMSO): d=10.4 (br s, 1H), 9.74 (br s, 1H), 7.68 (d, J=9.3 Hz,
2H), 7.59 (s, 1H), 7.54 (d, J=7.8 Hz, 1H), 7.51 (d, J=8.8 Hz, 1H),
7.45 (d, J=7.3 Hz, 1H), 7.40 (dd, J=7.8, 7.3 Hz, 1H), 7.17 (d, J=
8.8 Hz, 2H), 7.05 (d, J=8.8 Hz, 1H), 6.93 (d, J=9.3 Hz, 2H), 6.66 (d,
J=8.8 Hz, 2H), 4.08 (t, J=5.4 Hz, 2H), 2.62 (t, J=5.4 Hz, 2H), 2.39–
2.36 (m, 7H), 1.48–1.45 (m, 4H), 1.37–1.35 ppm (m, 2H); 13C NMR
(125 MHz, [D6]DMSO): d=195.2, 192.4, 162.8, 157.9, 155.0, 142.3,
138.8, 138.2, 137.7, 133.4, 132.9, 131.9, 129.8, 129.6, 129.3, 129.1,
128.3, 126.7, 126.3, 123.5, 117.9, 116.3, 115.7, 114.5, 65.9, 57.1, 54.3,
25.5, 23.8, 20.8 ppm; IR (neat): n˜=1653, 1594, 1503, 1429, 1387,
1287, 1248, 1164, 1030, 939, 841, 761 cm!1; HRMS-ESI : m/z
[M+H]+ calcd for C36H34NO5S: 592.2158, found: 592.2156.
7-[(3,5-Dimethylphenyl)carbonyl]-2-(4-hydroxyphenyl)-3-({4-[2-
(piperidin-1-yl) ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol
(20): 1-(2-Hydroxyethyl)piperidine (32 mL, 0.24 mmol) was added
with stirring to NaH (25 mg, 0.61 mmol, 60% in mineral oil) in DMF
(1.4 mL) at RT. After 5 min, benzothiophene 18 (60 mg, 0.12 mmol)
in DMF (0.20 mL) was added in one portion, and the mixture was
stirred at 50 8C for 5 h. The reaction was quenched with H2O, and
the aqueous phase was extracted with EtOAc (!3). The combined
organic extracts were washed with brine, dried (MgSO4), filtered
and concentrated in vacuo. Purification by flash chromatography
(CH2Cl2/MeOH: 99:1!19:1+0.25% NH3·H2O) gave amine 20 as an
amorphous yellow solid (25 mg, 35%): 1H NMR (400 MHz,
[D6]DMSO): d=10.4 (br s, 1H), 9.75 (br s, 1H), 7.68 (d, J=8.8 Hz,
2H), 7.50 (d, J=8.8 Hz, 1H), 7.37 (s, 2H), 7.27 (s, 1H), 7.17 (d, J=
8.3 Hz, 2H), 7.04 (d, J=8.8 Hz, 1H), 6.92 (d, J=8.8 Hz, 2H), 6.66 (d,
J=8.3 Hz, 2H), 4.08 (app-br t, 2H), 2.62 (app-br t, 2H), 2.39 (app-br
s, 4H), 2.32 (s, 6H), 1.46 (app-br s, 4H), 1.36 ppm (app-br s, 2H);
13C NMR (125 MHz, [D6]DMSO): d=195.4, 192.4, 162.8, 157.9, 154.8,
142.2, 138.7, 138.3, 137.5, 134.2, 132.8, 131.9, 129.8, 129.6, 129.3,
126.5 (3C), 123.5, 118.1, 116.3, 115.7, 114.5, 65.9, 57.1, 54.3, 25.5,
23.8, 20.7 ppm; IR (neat): n˜=1655, 1595, 1504, 1429, 1384, 1361,
1244, 1163, 1140, 1035, 939, 842, 763 cm!1; HRMS-ESI: m/z [M+H]+
calcd for C37H36NO5S: 606.2314, found: 606.2287.
Molecular modeling
For the preliminary virtual high-throughput screen, the ERa antag-
onist raloxifene was employed as a search template for mining of
the ChemNavigator database. With compound similarity thresholds
set at 55%, 974 structures were returned. The corresponding
three-dimensional structures were generated by using LigPrep 2.3,
Figure 3. Mammalian two-hybrid analysis of compound activities in COS-
1 cells : 0.01 mm : &; 0.1 mm : &; 1.0 mm : &; 10 mm : &. COS-1 cells were
transfected with GAL4(DBD)-PGC1a L2 (encoding the second LXXLL motif
in PGC1a), VP16-LRH-1(LBD), together with a GAL4-responsive Firefly lucifer-
ase gene and pRL-CMV, which encodes Renilla luciferase and acts as a control
for transfection efficiency. Firefly activities are shown relative to Renilla luci-
ferase activities, the activity for vehicle (DMSO) being taken as 1 and all
other activities calculated relative to this. The mean activities (Log10) of
three replicates are shown; error bars represent the standard error of the
mean (SEM).
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and conformational searches were performed with MacroModel
9.7.[26] The ten conformers of each structure with the lowest calcu-
lated energy were selected as starting structures for docking. The
LRH-1 LBD crystal structure (PDB: 1YOK[17]) and the Glide docking
procedure (Glide 5.5[15]) in Maestro 9.0 were used to perform the
docking studies.[26] In order to mimic the inactive state of LRH-1,
residues on H12 and the adjacent loop between H11 and H12 (resi-
dues 522–538) in the LRH-1 LBD were removed from the protein
structure during the docking investigations. In the final step,
a Prime 2.1[26] MMGBSA rescoring[16] was performed to predict the
binding affinities of the test compounds for LRH-1.
Biology
AlphaScreen (amplified luminescent proximity homogenous assay)
technology is a bead-based proximity assay consisting of a nickel-
chelate-coated acceptor bead bound to a His-tagged LRH-1 LBD
and a streptavidin-coated donor bead bound to a biotinylated co-
activator peptide (PGC1a). Following excitation with a high-intensi-
ty laser at 680 nm, a singlet ambient oxygen molecule forms on
the surface of the donor bead with the ability to diffuse up to
200 nm. If an acceptor bead is within this proximity, the oxygen
singlet reacts with a thioxene derivative on the acceptor bead,
generating chemiluminescence and further activating a cascade of
fluorophorescence emitting light at 520–620 nm, which can be
used as a measurement of proximity/binding.
This system was optimized using LRH-1 with both PGC1a and
SRC2 (EC50=35 nm and 369 nm, respectively, against 50 nm LRH-1)
and robust assay “z” scores (z >0.6). The system was validated
using the known LRH-1 agonist GSK8470 with an EC50 value of
220 nm.[11a] The AlphaScreen system has been utilized previously to
look at LRH-1 LBD co-factor recruitment.[27] Using the interaction
between a set concentration of LRH-1 and PGC1a as a baseline,
a twelve-point titration range of the experimental compounds was
added to assess for inhibition of this interaction. The results were
analyzed using Prism software, correcting for the background
signal, and expressed as a percentage relative to a vehicle-treated
control (DMSO). IC50 values with 95% confidence intervals were
then calculated. Further assay details have been included in the
Supporting Information.
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ABSTRACT
Oestrogen receptor a (ERa) is a nuclear receptor that
is the driving transcription factor expressed in the
majority of breast cancers. Recent studies have
demonstrated that the liver receptor homolog-1
(LRH-1), another nuclear receptor, regulates breast
cancer cell proliferation and promotes motility and
invasion. To determine the mechanisms of LRH-1
action in breast cancer, we performed gene expres-
sion microarray analysis following RNA interference
for LRH-1. Interestingly, gene ontology (GO)
category enrichment analysis of LRH-1–regulated
genes identified oestrogen-responsive genes as the
most highly enriched GO categories. Remarkably,
chromatin immunoprecipitation coupled to massively
parallel sequencing (ChIP-seq) to identify genomic
targets of LRH-1 showed LRH-1 binding at many
ERa binding sites. Analysis of select binding sites con-
firmed regulation of ERa!regulated genes by LRH-1
through binding to oestrogen response elements, as
exemplified by the TFF1/pS2 gene. Finally, LRH-1
overexpression stimulated ERa recruitment, while
LRH-1 knockdown reduced ERa recruitment to ERa
binding sites. Taken together, our findings establish
a key role for LRH-1 in the regulation of ERa target
genes in breast cancer cells and identify amechanism
in which co-operative binding of LRH-1 and ERa at
oestrogen response elements controls the expression
of oestrogen-responsive genes.
INTRODUCTION
Oestrogens play diverse roles in the body, most notably in
the development and maintenance of female and male
reproductive systems and secondary sexual characteristics
(1). Oestrogens are also implicated in the physiology of the
brain, bone and the cardiovascular system, as evidenced by
the increased risk of cardiovascular disease and osteopor-
osis following the decline in oestrogen levels during meno-
pause (1–3). Oestrogens also play a central role in
promoting breast cancer growth (4), as well as being
implicated in uterine and ovarian cancers (5,6). Two
closely related members of the nuclear receptor (NR)
superfamily of transcription factors, oestrogen receptor a
(ERa) and ß (ERß) mediate oestrogen actions (7,8). The
majority (70–80%) of breast cancers express ERa, and this
transcription factor is believed to drive cancer cell prolif-
eration. Therefore, ERa activity is inhibited in breast
cancer patients with endocrine therapies using anti-oestro-
gens, such as tamoxifen and fulvestrant or by inhibiting
oestrogen biosynthesis either by using aromatase inhibitors
in postmenopausal women or with lutenising hormone
releasing hormone (LHRH) agonists in premenopausal
women. These therapies are well-tolerated and have been
a major factor in the improvement in patient survival seen
in recent years. However, up to 50% of patients with ERa-
positive disease that would require endocrine therapies do
not respond, while many responders eventually relapse,
with few treatment options being available following the
development of resistance (4,9). Hence, a better under-
standing of the mechanisms of ERa action would aid
patient stratification and identify new therapeutic targets.
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Ligand binding to ERa promotes recruitment to cis-
regulatory regions by direct binding to DNA at oestrogen
response elements (EREs) in target genes, or indirectly
through interaction with other transcription factors such
as AP1 and Sp1 (10,11) and consequent activation or
repression of gene expression. Chromatin immunopre-
cipitation (ChIP) studies have shown that oestrogen
addition initiates cycles of ERa association and dissoci-
ation from EREs, with concomitant cycles of transcrip-
tional co-regulator recruitment leading to chromatin
remodelling and histone modification and cyclical recruit-
ment of the RNA polymerase II (PolII) machinery and
subsequent transcription initiation (12–15). These cycles
of co-regulator and PolII recruitment are accompanied
by cycles of reversal and re-establishment of many,
although not all, induced chromatin modifications.
While it is incontrovertible that ERa drives the growth
response in the majority of breast tumours, there is
mounting evidence that ERa does not act on its own
and that other transcription factors are essential for
ERa action in breast cancer. Gene expression profiling
and genomic approaches for genome-wide identification
of ERa binding regions, such as ChIP-chip and ChIP-
seq, have allowed the identification of direct ERa targets
in breast cancer cells (16–19) and in tumours (20). These
studies have also highlighted the importance of other tran-
scription factors in the ERa response, such as FoxA1 (also
known as HNF3a). FoxA1 expression is associated with
ERa positivity in breast cancer and FoxA1 is one of the
minimal set of genes that define ERa-positive luminal
cancer (21). FoxA1, which has been proposed to facilitate
binding of other transcription factors to DNA through its
action in promoting chromatin accessibility (22), is fre-
quently present at regions of ERa binding in the absence
of oestrogen and appears to be a key determinant of ERa
binding following oestrogen addition (16,23,24). GATA
proteins also act as ‘pioneer factors’, promoting transcrip-
tion factor recruitment (22), and GATA3 guides ERa
chromatin interactions and its expression is strongly
associated with ERa-positive luminal A breast cancer
subtype (25). Thus, FoxA1, GATA3, as well as the tran-
scription factors AP-2g, TLE1 and PBX1, act as pioneer
factors for ERa DNA binding by promoting chromatin
accessibility and long-range chromatin interactions
(26,27). Interestingly, some of these pioneer factors are
themselves ERa-regulated genes, indicating a feed-
forward mechanism that can act to reinforce oestrogenic
signals in breast cancer cells.
A role in ERa signalling for other NRs has recently
been highlighted by the finding that retinoic acid
receptor-a, an oestrogen-regulated gene in breast cancer
(28,29), localizes to ERa binding sites to modulate the
expression of oestrogen-regulated genes (30,31), providing
crosstalk between oestrogen and retinoid signalling in
breast cancer cells. Moreover, androgen receptor (AR)
expression is strongly associated with ERa positivity and
AR inhibits expression of oestrogen-responsive genes in
ERa-positive breast cancer cells (32). Indeed, a small
subset of breast tumours, termed the ‘molecular
apocrine’ subtype, which are ERa-negative but express
AR (33), typically express genes normally expressed in
ERa-positive breast cancer (34). Recent expression micro-
array and AR ChIP-seq data generated for a cell line
characteristic of molecular apocrine breast cancer,
MDA-MB-453 (ERa-/PR-/AR+), showed that AR acti-
vates transcription of many typical ERa target genes
through AR recruitment to sites that are normally
bound by ERa in luminal MCF-7 cells (35). These
findings indicate another mode of crosstalk between
ERa and other NRs mediated by co-operative and/or
antagonistic interactions.
Liver receptor homolog-1 (LRH-1) (NR5A2) is
expressed in developing and adult tissues of endodermal
origin, including liver, pancreas, intestine and the ovary
(36,37). Functionally, LRH-1 has been implicated in the
regulation of bile acid and cholesterol homeostasis (36,37)
and the regulation of inflammatory responses in the liver
and gut (38). LRH-1 is also important for steroid
hormone biosynthesis in the ovary (39), but also extra-
ovarian tissues, including preadipocytes, where LRH-1
regulates aromatase expression (40,41). LRH-1 is also
critical in development. Disruption of the LRH-1 gene
in mice is embryonic lethal at day E6.5–7.5 (42), and
LRH-1 regulates expression of the key pluripotency
factor Oct4 in the developing embryo epiblast (43).
Indeed, LRH-1 can replace Oct4 in the reprogramming
of mouse somatic cells to induced pluripotent stem cells
and induces expression of Nanog, a transcription factor
important for maintaining pluripotency in undifferenti-
ated embryonic stem cells (44,45).
LRH-1 has also been implicated in cancer. Mice hetero-
zygous for an adenomatosis polyposis coli (APC)
mutation and an LRH-1 inactivating mutation developed
fewer intestinal tumours than mice harbouring the APC
mutation only, and LRH-1 heterozygous mice developed
fewer azoxymethane-induced aberrant crypt foci (46).
LRH-1 expression is elevated in pancreatic cancer and
promotes pancreatic cancer cell growth through stimula-
tion of cyclin D1, cyclin E1 and c-Myc (47), while genome-
wide association studies implicate mutations in the LRH-1
gene in pancreatic ductal adenocarcinoma (48).
Aromatase is an LRH-1 target gene, which catalyses the
conversion of androgens (primarily androstenedione and
testosterone) to oestrogens. Aromatase expression and
activity is low in breast cancer cells; rather there is an
increase in aromatase expression/activity in tumour-
bearing breast stroma compared with normal breast
stroma, leading to the proposal that LRH-1 may aid
breast cancer progression in postmenopausal women by
promoting local oestrogen biosynthesis (40,41,49).
Although the real importance of local oestrogen pro-
duction for breast cancer remains unclear (50,51), recent
work demonstrates that LRH-1 is also expressed in breast
cancer cells where its expression is ERa-regulated (52,53).
In breast carcinoma, LRH-1 expression is associated with
ERa positivity (54). Functional studies have shown that
LRH-1 plays a direct role in regulating breast cancer cell
proliferation and promotes breast cancer cell motility and
invasion (52,53,55). Based on these findings, we have
identified LRH-1–regulated genes using gene expression
microarray profiling and ChIP-seq to map LRH-1
binding events in proliferating breast cancer cells.
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We show that LRH-1 is an important regulator of oestro-
gen-responsive gene expression that shares many binding
sites with ERa. Importantly, at shared sites, LRH-1
promotes ERa recruitment and vice versa, ERa stimulates
LRH-1 recruitment, thus providing evidence for a novel
mode of NR co-operativity in breast cancer cells.
MATERIALS AND METHODS
Cell culture
MCF-7 and COS-1 cells, obtained from American Type
Culture Collection (LGC Standards, UK), were routinely
cultured in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% foetal calf serum (FCS). For
oestrogen depletion experiments, the cells were transferred
to DMEM lacking phenol red and containing 5%
dextran-coated charcoal-stripped FCS (DSS) for 72 h.
17ß-estradiol (oestrogen) was added to a final concentra-
tion of 10 nM, and ICI182 780 (fulvestrant) was added to a
final concentration of 100 nM. The synthetic LRH-1
agonist, compound 5A was added to a final concentration
of 30 mM (53,56).
Plasmids
The Renilla luciferase reporter gene was RLTK (Promega,
UK). The LRH-1 expression plasmid pCI-LRH-1 and the
LRH-1 firefly luciferase reporter gene SF-1-luc were gifts
from Dr Donald McDonnell (57). HA-tagged LRH-1
(pCI-HA3-LRH-1) was generated by insertion of 3xHA
coding sequence from pMXB-3HA-mNR5A2 (44) into
pCI-LRH-1 to generate HA-tagged human LRH-1
variant 4 (53). The ERa expression plasmid has been
described previously (58). The pS2-luc and pS2-!ERE-
luc reporter genes were kindly provided by Dr Vincent
Giguere (59). pS2-luc mutants were generated by site-
directed mutagenesis using the Quickchange kit from
Stratagene, UK.
Reporter gene assays
For transient transfection, COS-1 cells were seeded in
24-well plates in DMEM lacking phenol red and supple-
mented with 5% DSS. Following seeding for 24 h, cells
were transfected using FuGENE HD (Promega, UK),
with 100 ng of luciferase reporter genes, 10 ng of ERa
and 50 ng of LRH-1. Oestrogen (10 nM) or compound
5A (30 mM) were added as indicated. Luciferase activities
were determined after a further 24 h, using the Dual-Glo
Luciferase Assay kit (Promega, UK). RLTK was trans-
fected to control for transfection efficiency, so firefly
luciferase activities were calculated relative to the Renilla
luciferase (RLTK) activities.
siRNA transfections
Cells were transfected with double-stranded RNA oligo-
nucleotides using the Lipofectamine RNAiMax reverse
transfection method (Invitrogen, UK), according to
manufacturer’s protocols. ON-TARGETplus
SMARTpool for LRH-1 (LU-003430, Thermofisher), or
individual siRNAs from the SMARTpool, were used as
indicated in figure legends. siLuc control (D-002050;
Thermofisher) or Control siRNA (1027251; Qiagen)
were transfected as negative controls. All siRNA experi-
ments used the double-stranded RNA oligonucleotides at
a final concentration of 80 nM.
Western blotting
Cells were cultured and whole-cell lysates were prepared
as described previously (60). Antibodies used for western
blotting are detailed in Supplementary Materials.
Quantitative reverse transcriptase-polymerase
chain reaction
Total RNA was collected and real-time reverse transcript-
ase-polymerase chain reaction (RT-PCR) was performed
as previously described (61). Real-time RT-PCR was
carried out using Taqman Gene Expression Assays
(Applied Biosystems, UK). Assay details can be found
in the Supplementary Materials.
Electrophoretic mobility shift assay
HA-LRH-1 and ERa proteins, made using the TNT
coupled transcription/translation system (Promega), were
used for electrophoretic mobility shift assay (EMSA), as
described previously (62), with the exception that the
oligonucleotides were labelled at the 50 end with DY782,
allowing detection of complexes using a LiCoR Odyssey
Infrared imaging system.
Chromatin Immunoprecipitations
ChIPs were performed as described previously (63). For
each ChIP, 10 mg of antibody (detailed in Supplementary
Information) and 100 ml of Dynalbeads Protein A
(10002D; Invitrogen) were used. Primers for real-time
PCR are also provided in Supplementary Materials.
ChIPs and Solexa sequencing
ChIP DNA was amplified as described (63). Sequences
were generated by the Illumina Hiseq 2000 genome
analyser (using 50 bp reads), and aligned to the Human
Reference Genome (assembly hg19, February 2009).
Enriched regions of the genome were identified by
comparing the ChIP samples with an input sample using
the MACS peak caller (64) version 1.3.7.1. All ChIP-seq
analyses were performed in duplicate, where only the
peaks shared by both replicates were considered. The
numbers of reads obtained, the percentage of reads
aligned and the number of peaks called are detailed in
Supplementary Figure S1.
Motif analysis, heatmaps and genomic distributions of
binding events
ChIP-seq data snapshots were generated using the
Integrative Genome Viewer IGV 2.2 (www.broad
institute.org/igv/) and the UCSC genome browser
(http://genome.ucsc.edu). Motif analyses were performed
through the Cistrome (cistrome.org), applying the SeqPos
motif tool (65). The genomic distributions of binding sites
were analysed using the cis-regulatory element annotation
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system (CEAS) (66). The genes closest to the binding site
on both strands were analysed. If the binding region is
within a gene, CEAS software indicates whether it is in
a 50 untranslated region (50 UTR), a 30 untranslated region
(30 UTR), a coding exon or an intron. Promoter is defined
as 3 kb upstream from RefSeq 50 start. If a binding site is
>3 kb away from the RefSeq transcription start site, it is
considered distal intergenic. For integration with gene ex-
pression data, binding events were considered proximal
when identified in a gene body or within 20 kb upstream
of the transcription start site. Heatmaps were generated
using Seqminer, using default settings (67).
Gene expression microarray analysis
MCF-7 cells were transfected with LRH-1 siRNA #2, #3
or with a non-targeting siRNA (siControl; D-001210-10,
Thermofisher). RNA was extracted 72 h later using the
QIAGEN RNeasy Kit (Qiagen Ltd., UK). Following
assessment of RNA integrity, four independent biological
replicates for each siRNA treatment were used for micro-
array analysis. The analysis was performed using
HumanHT-12 v 3.0 Expression BeadChiP (Illumina).
The BeadChiP image data were preprocessed using
GenomeStudio (Illumina). The expression data were
then log2 transformed and quantile-normalized using
Partek Genomics Suite. Gene ontology (GO) analyses
were performed using the database for annotation, visu-
alization and integrated discovery (DAVID) (http://david.
abcc.ncifcrf.gov) (68). The microarray data have been
deposited with the NCBI Gene Expression Omnibus
(GEO) (http://ncbi.nlm.nih.gov/geo/) under accession
number GSE47803. The ChIP-seq data are available
under accession number GSE49390.
RESULTS
LRH-1 regulates the expression of oestrogen-responsive
genes in breast cancer cells
Recent studies have shown that LRH-1 regulates breast
cancer cell proliferation and motility (52,53,55). To
identify genes that mediate LRH-1 action in breast
cancer cells, global gene expression profiling was per-
formed following LRH-1 silencing using siRNAs. RNA
was prepared from MCF-7 cells transfected with two
independent LRH-1 siRNAs that gave >90% LRH-1
knockdown (Figure 1A and B). Hierarchical cluster
Term p-value Fold 
Enrichment
1 GO:0043627~response to 
estrogen s!mulus
9.21E-04 6.18
2 GO:0048545~response to 
steroid hormone s!mulus
1.08E-03 4.34












































Figure 1. Expression profiling shows that LRH-1 regulates the expression of oestrogen-regulated genes. (A) Western blot analysis of MCF-7 cell
extracts prepared following transfection with control siRNA or four independent siRNAs for LRH-1. (B) Quantitative RT-PCR analysis was
performed using three independent RNA preparations made from siControl– or siLRH-1–transfected MCF-7 cells. Error bars represent standard
errors of the mean (SEM). (C) Gene expression profiling was carried out using four independent replicates of MCF-7 cells transfected with siControl,
siLRH-1 #2 or siLRH-1 #3. Shown are significant differentially expressed genes at P< 0.01 corrected for false discovery rate (FDR), together with a
fold change >1.5 and <!1.5. (D) GO category enrichments of the genes differentially regulated by siLRH-1 are shown.
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analysis identified 222 genes the expression of which was
significantly altered (P< 0.01, fold change >1.5) with both
siRNAs, when compared with the control siRNA
(siControl) (Figure 1C). GO analysis showed that the
most highly enriched GO terms for these genes were
‘response to oestrogen stimulus’ and ‘response to
hormone stimulus’ (Figure 1D), implicating LRH-1 in
the regulation of oestrogen-regulated genes in breast
cancer cells.
To determine if LRH-1 directly regulates the expression
of oestrogen-responsive genes, ChIP-seq in MCF-7 cells
was carried out using antibodies for LRH-1. However,
none of the antibodies commercially available provided
sufficient enrichment for peak calling to identify LRH-1
binding regions (data not shown). A recent study utilized
ectopic expression of epitope-tagged LRH-1 to identify
LRH-1–regulated genes in mouse embryonic stem cells
(44). Using a similar strategy, we performed ChIP-seq
following transfection of MCF-7 cells with HA-tagged
LRH-1 (as exemplified in Figure 2A). Aligned reads
were acquired and following stringent cut-offs using two
independent replicates, peak calling identified 4876 LRH-
1 binding sites, of which 1723 (35%) were shared with
ERa (Figure 2B). The shared and unique binding
patterns were not dictated by different thresholds in
peak calling algorithms, as shown by heatmap analyses
(Figure 2C and Supplementary Figure S1). Previous pub-
lications have demonstrated that the vast majority of ERa
binding events map to enhancers and introns, with few
sites mapping to promoter proximal regions. The
majority of LRH-1 and ERa binding events, both
unique and shared, were similarly located within introns
and regions distal to gene promoters (Figure 2D).
The majority of NRs bind as dimers to sequence
motifs arranged as two copies of a hexameric motif,
50-AGGYCR-30, organized as direct or inverted repeats,
as exemplified by ERa and the ERE (7). A C-terminal
extension to the canonical zinc binding motifs in NR
DNA binding domains mediates binding of several NRs
to DNA response elements 3 bp longer than the standard
hexameric sequences. SF1 and LRH-1 bind as monomers
to a sequence having the consensus 50-YCAAGGYCR-30,
where YCA is the 50 extension to the AGGYCR sequence
to which most NR bind (36,69). Analysis of the LRH-1
binding sites for enriched DNA sequences identified a
motif similar to this consensus LRH-1 binding element,
with the sequence 50-SYCARGGYCA-30 (Figure 2E and
Supplementary Figure S2). A motif consistent with the
Figure 2. LRH-1 associates with ERa binding regions in chromatin. (A) ChIP-seq was carried out using HA and ERa antibodies for HA-LRH-1–
transfected MCF-7 cells. Genome browser snapshot of ChIP-seq samples for ERa and HA-LRH-1 on proliferating cells. Y bar shows tag count.
(B) Venn diagram of LRH-1 and ERa binding events. (C) Shown is a heatmap, with a window of 5 kb around the binding sites, depicting all shared
and unique binding events for LRH-1 and ERa vertically aligned. Additionally, the binding events of the FOXA1 (24) and GATA3 (25) ChIP-
sequencing data sets are shown. (D) The genomic distribution of shared and unique binding events. (E) De novo motif analysis of the shared and
unique ERa and LRH-1 binding events.
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ERE consensus site was the top hit in the ERa unique
sites, while the shared LRH-1/ERa sites were enriched in
the LRH-1 motif. Motif analyses using a candidate
scanning approach identified NR binding motifs, with
the top hits for the LRH-1 unique sites being the SF1
and LRH-1 binding motifs. For the shared events, SF1/
LRH-1 and ESR1 sites were enriched, while the ESR1 site
was the top hit for the ERa unique sites. This analysis also
highlighted enrichment for TFAP2C (AP2g), FOXA1,
GATA3 and AP-1 (Fos, Jun) sites in the analysis of the
ERa unique sites (Supplementary Figure S3). This enrich-
ment is consistent with previous global binding site studies
for ERa (26,70). TFAP2C and FOS/JUN sites were also
enriched in the LRH-1 unique and LRH-1/ERa shared
sites (Supplementary Figures S4 and S5). Interestingly,
FOXA1 and GATA3, being essential components of the
ERa transcription complex and its activity (24,25), were
found present at the LRH-1/ERa shared and ERa unique
sites. Both FOXA1 and GATA3 were absent from the
regions only bound by LRH-1, suggesting that these
factors may not be important for LRH-1 binding, at
least in the case of the LRH-1 unique sites.
LRH-1 binds to EREs in regulatory regions of a subset of
oestrogen-regulated genes
To explore the potential link between LRH-1 and ERa in
regulation of common target genes, we focused on the
archetypal ERa target gene, pS2, for mechanistic investi-
gations (Supplementary Figure S6A). LRH-1 recruitment
to the ERa binding region was confirmed by ChIP
(Figure 3A). EMSA demonstrated LRH-1 binding to the
pS2 ERE and confirmed the expected sequence require-
ments for LRH-1 binding (Figure 3B, C and E).
Mutation within the 50-AGGTCA motif prevented
LRH-1 and ERa binding, whereas mutation in the
30 motif prevented ERa binding, but did not influence
LRH-1 binding. Similar results were obtained for the
ERE motif within the shared LRH-1 and ERa binding
region in the NRIP1 gene, another well-studied ERa-
regulated gene (Figure 3D and Supplementary Figure
S6A). The importance of the 50 sequences for LRH-1
binding was shown by mutation of the chicken vitello-
genin gene ERE to introduce the 50 extension. These mu-
tations allowed LRH-1 binding to the vitellogenin ERE.
LRH-1 stimulated a reporter gene encoding 1006 bp of
the pS2 gene promoter, containing the ERE (59). This
ERE sequence is required for activation of pS2 expression
by LRH-1 because deletion of the ERE sequence
(pS2!ERE-luc) largely abrogated reporter gene activation
by LRH-1 (Figure 3F and Supplementary Figure S6B).
Substitutions in the 50 extension, the 50 hexameric
sequence, but not in the 30 hexameric motif, prevented
LRH-1 activation of the pS2 reporter gene (Figure 3G).
Together, these findings demonstrate that LRH-1 can
bind to the pS2 gene promoter proximal ERE, to stimu-
late pS2 gene expression.
LRH-1 knockdown in MCF-7 cells resulted in a reduc-
tion in pS2 and NRIP1 expression for two independent
siRNAs (Figures 1B and 3I). The expression of AGR3,
PDZK1 and RET, genes to which LRH-1 is recruited at
ERa binding regions (Supplementary Figure S7), was
similarly reduced on LRH-1 knockdown (Supplementary
Figure S8). Together, these results show that LRH-1 can
be recruited to ERa binding regions, and that binding to
select EREs allows LRH-1 regulation of ERa target genes.
Synergistic recruitment between LRH-1 and ERa to
EREs at ERa binding regions
As shown above, LRH-1 knockdown gave a marked
reduction in expression of pS2, NRIP1 and other genes
for which LRH-1 binding to ERa binding regions was
observed by ChIP-seq, demonstrating that LRH-1, like
ERa, promotes expression of these genes. This raises the
possibility that ERa and LRH-1 co-operatively regulate
expression of ERa target genes. Indeed, ectopic expression
of LRH-1 in MCF-7 cells stimulated ERa recruitment to
the pS2 promoter (Figure 4A). Conversely, siLRH-1 treat-
ment reduced ERa recruitment to the pS2 promoter
(Figure 4B). To extend this finding, ChIP-seq for ERa fol-
lowing siLRH-1 treatment was carried out to determine the
importance of LRH-1 for ERa binding to ERa binding
sites. LRH-1 knockdown resulted in a reduction by
!50% in the intensity of ERa binding events (Figure 4C
and Supplementary Figure S9A). The reduction in ERa
binding exemplified for pS2 (TFF1), PDZK1, RET and
AGR3 (Figure 4D) was confirmed by ChIP-QPCR
(Supplementary Figure S9B–E). Moreover, ectopic expres-
sion of LRH-1 stimulated ERa binding at these regions
(Figure 4A and E; Supplementary Figure S10). The
ELOVL2 gene serves as an example of an ERa binding
site to which LRH-1 is not recruited (Supplementary
Figure S10). In this case, LRH-1 silencing did not influence
ERa recruitment (Supplementary Figure S9F).
To determine if LRH-1 functions to promote or
maintain cofactor recruitment, we performed ChIP for
p300 and CREB Binding Protein (CBP), well-known
ERa co-activators (12) following LRH-1 silencing. There
was a significant decrease in p300 and CBP binding at all
loci (Figure 5A and B). Binding of the AIB1 co-activator
was also decreased in the absence of LRH-1 (Figure 5C).
These data illustrate that the LRH-1 and ERa shared sites
are also occupied by typical ERa co-activators. Mining
publically available data sets for SRC1, SRC2, SRC3
(AIB1), p300 and CBP (71) illustrated that this was
indeed the case, and cofactor recruitment was found
enriched at LRH-1/ERa sites on a genome-wide level.
There was, however, no appreciable difference in p300
binding. This suggests that co-operativity between LRH-
1 and ERa promotes co-activator recruitment at co-
regulated genes. The changes in cofactor binding were re-
flected in changes in chromatin structure following LRH-1
silencing, as demonstrated by reduction in levels of histone
marks associated with gene expression, namely acetylation
of histone H3 (Figure 5E–G). Also reduced on LRH-1
silencing were levels of H3 lysine 4 trimethylation
(H3K4Me3), a marker of transcriptional activity (72) at
the pS2 promoter (Figure 5F), as well as PolII recruitment
(Figure 5H). These findings, together with the reduction in
mRNA levels of these genes (Supplementary Figure S8),
are further indicative of a requirement for LRH-1 for the
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Figure 3. LRH-1 regulates pS2 gene expression through binding to the pS2 ERE. (A) ChIP was carried out using IgG (control) or HA antibodies,
following transfection of MCF-7 cells with empty vector or HA-LRH-1, followed by real-time PCR using primers for the pS2 ERE region, or with
primers amplifying a region upstream of the pS2 ERE (control), as described (14). For each PCR, enrichment is shown relative to the vector control,
as mean values for three replicates; error bars represent SEM. Western blotting of HA-LRH-1–transfected MCF-7 cell extracts is also shown.
(B) Sequences for consensus ERa and LRH-1 binding sites are shown above the sequence of the pS2 ERE. The NRIP1 intronic ERE, chicken
vitellogenin ERE and the LRH-1 binding sites in the mouse AFP gene. Mutations generated in these sequences are shown in lower case and are
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(continued)
transcription of these oestrogen-responsive genes. Note
that there was no change in levels of these proteins with
LRH-1 knockdown (Figure 5K).
Interestingly, LRH-1 knockdown did not affect FOXA1
binding to ERa binding regions (Figure 5I). This may be a
reflection of the described presence of FOXA1 before ERa
recruitment and its requirement for ERa recruitment to
chromatin (16,23,24). The importance of FOXA1 has also
been demonstrated for other NRs, e.g. AR (35), and it
might also be required for LRH-1 recruitment. However,
binding of GATA3, which is also critical for ERa recruit-
ment, was significantly reduced following LRH-1 silencing
(Figure 5J), identifying another mechanism by which
LRH-1 regulates ERa recruitment. There was no reduc-
tion in FOXA1 or GATA3 protein levels on LRH-1
knockdown (Figure 5K).
The above results demonstrate a requirement for
LRH-1 for the transcription of oestrogen-responsive
genes in breast cancer cells. However, treatment of
MCF-7 cells with oestrogen stimulated LRH-1 binding to
these sites (Figure 6A–C and Supplementary Figure S11).
Moreover, treatment of MCF-7 cells with ICI182 780, an
anti-oestrogen that results in ERa degradation, reduced
LRH-1 binding (Figure 6D–F and Supplementary
Figure S12). Note that levels of ectopically expressed









































































































PDZK1            RET
Figure 4. LRH-1 promotes ERa binding to the ERa binding sites. (A) ERa ChIP was carried out using chromatin prepared for the ChIP shown in
Figure 3A. Enrichment is shown relative to the IgG control as mean values for three replicates. (B) ERa ChIP was performed following MCF-7
treatment with siControl (NC) or siLRH-1 (n=3). Western blotting for LRH-1 and ERa is also shown. (C) Average signal intensity of ERa binding
events is shown for MCF-7 cells treated with siControl or siLRH-1. (D) Genome browser snapshots of ChIP-seq samples for ERa from siControl– or
siLRH-1–treated MCF-7 cells are shown. Y bar shows tag count. (E) ERa ChIP for ERa binding regions is shown for vector (clear bars) and LRH-
1–transfected (grey bars) MCF-7 cells (n=3, error bars=SEM).
Figure 3. Continued
underlined. (C–E) EMSA was carried out using oligonucleotides having the sequences shown in (B). LRH-1 and ERa were produced using
coupled in vitro transcription/translation (IVTT). Western blotting of IVTT products for LRH-1 and ERa is shown in (E). (F) COS-1 cells were
transfected with pS2-luc, together with ERa and LRH-1, as shown. Reporter gene activities were corrected for transfection efficiency by normalizing
to Renilla luciferase activity and are shown relative to reporter gene activity for the vehicle-treated vector control. Shown are the mean pS2-luc
activities from three independent transfections; errors bars=SEM. (G and H) COS-1 cells were transfected with LRH-1 (G) or ERa (H), together
with pS2-luc or mutant reporters, as shown. Following normalization for the transfection control (renilla), activities are shown relative to the
activities obtained for pS2-luc.
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treatment. Together, these results demonstrate that as
LRH-1 stimulates ERa binding, ERa reciprocally
promotes LRH-1 recruitment.
DISCUSSION
LRH-1 is a NR transcription factor that plays important
roles in development, reproduction and metabolism. Its
role in reverse cholesterol transport and bile acid homeo-
stasis has been especially well studied, and it has been
shown that LRH-1 acts as a potentiation factor for the
LXR oxysterol receptors through binding to sites
proximal to LXR binding sites to induce expression of
key genes involved in these processes, including
CYP7A1, CYP8B1, CETP, SREB-1c and FAS (36,73–
77). The bile acid receptor FXR is also implicated in cross-
talk with LRH-1 and ChIP-seq for FXR and LRH-1
reveals that almost a quarter of hepatic LRH-1 binding
sites are located in close proximity to FXR binding sites,
suggesting that co-operativity between LRH-1 and FXR is
important for the regulation of metabolic genes in the liver
(78,79).
LRH-1 is a direct ERa target gene (52,53), its expres-
sion correlates with ERa in breast tumours (54) and it
promotes breast cancer proliferation and invasion (55).
We now show that LRH-1 is an important regulator
of ERa target genes because LRH-1 siRNA resulted
in reduced expression of oestrogen-responsive genes.
Moreover, LRH-1 ChIP-seq analysis shows that a sub-
stantial proportion of LRH-1 binding sites map to ERa
binding sites, with enrichment of the LRH-1 binding motif
being evident at these sites. This indicates that LRH-1
functions in breast cancer cells not only by mediating oes-
trogen action at non-ERa target genes following stimula-
tion of its expression by ERa (which may be viewed as a
classic mechanism by which a signal transduction pathway
response may be amplified) but also by potentiating ERa
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Figure 5. LRH-1 is required for co-activator loading and histone modification. MCF-7 cells were transfected with LRH-1 siRNA. ChIP was
performed using antibodies for ERa cofactors (A–C, I and J), histone H3 acetylation and methylation marks (E–G) or PolII (H), followed by
real-time PCR of the pS2 ERE, as shown. Enrichment is shown relative to the IgG control (n=3). The acetylated and methylated H3 ChIP was first
normalized to total H3, then to the IgG control. Errors bars=SEM, *P< 0.05. (D) Heatmap of ERa co-activator binding [data from (71)], showing
the percentage of overlapping SRC1, SRC2, SRC3, CBP and p300 binding events at LRH-1 and ERa unique and shared sites. (K) Western blotting
of the lysates in parts (A–C, E–J), is shown.
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co-operativity between LRH-1 and ERa was further
illustrated by the substantial overlap in binding sites
between the ERa unique binding sites and ERa/LRH-1
shared sites with FOXA1 and GATA3, both well-estab-
lished parts of the ERa transcription complex.
Of particular note was our observation of overlapping
LRH-1 and ERa binding sites, to which binding of both
factors was confirmed. This is in contrast to the metabolic
genes regulated by LRH-1/LXR and LRH-1/FXR, where
binding at proximal but non-overlapping sites has been
described (73–79). Analysis of one of these overlapping
binding sites, at the pS2 promoter ERE shows that
LRH-1 binds to the 50 hexamer of this ERE, the
sequence around this hexamer being consistent with the
extended sequence to which LRH-1 binds. This finding is
consistent with a previous report that showed LRH-1
binding to the pS2 and GREB1 EREs (80). We further
show here that LRH-1 stimulated pS2 expression and
LRH-1 knockdown showed that it is required for pS2 ex-
pression. Interestingly, LRH-1 overexpression promoted
ERa recruitment, while LRH-1 knockdown by siRNA
inhibited ERa binding to the pS2 ERE, indicative of a
requirement of LRH-1 for ERa binding. Similar promo-
tion of ERa recruitment by LRH-1 was observed for the
NRIP1 intronic ERE, as well as ERa binding regions
associated with other oestrogen-responsive genes. ERa
ChIP-seq following LRH-1 silencing also demonstrated
a reduction in ERa binding, consistent with an important
role for LRH-1 in promoting ERa binding. Further inves-
tigation of the LRH-1 ChIP-seq data also showed detect-
able LRH-1 signal at additional ERa binding sites,
excluded by the peak call algorithm, due to threshold
stringency (Supplementary Figure S13). This suggests
that LRH-1 is recruited, albeit weakly, to a considerable
proportion of ERa binding sites, further highlighting the
importance of LRH-1 for ERa action in breast cancer
cells.
Our data are indicative of co-occupancy of the two re-
ceptors at a proportion of ERa binding sites. However, we
failed to reChIP ERa following ChIP for LRH-1, or vice
versa. Nor were we able to obtain evidence for co-binding
of ERa and LRH-1 in EMSA, using the pS2 ERE oligo-
nucleotides. Immunoprecipitation of ERa did not co-
immunoprecipitate LRH-1 in MCF-7 cells, nor did we
detect an interaction in co-immunoprecipitation experi-
ments in COS-1 cells following LRH-1 and ERa overex-
pression (data not shown). Together, these results indicate
that the co-operativity between LRH-1 and ERa does not
involve co-occupancy of binding sites by these receptors.
This raises the possibility that these receptors bind the pS2
ERE through a sequential recruitment mode of action, so-
called ‘assisted loading’, recently described for binding of
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Figure 6. Modulation of ERa activity regulates LRH-1 recruitment to ERa binding regions. MCF-7 cells transfected with HA-LRH-1 were treated
with oestrogen for 45min (A–C) or with ICI182 780 for 24 h (D–F). ChIP for ERa (A and D) or LRH-1 (B and E) was performed. The mean
enrichment relative to the IgG control for three independent experiments is shown. Errors bars=SEM, *P< 0.05. (C and F) Western blotting of the
lysates is shown.
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the glucocorticoid receptor (GR) and a mutant oestrogen
receptor that can bind to a GR response element (81). This
study demonstrated that binding of one NR does not
reduce steady state binding of another NR; rather
binding of one NR can facilitate subsequent binding of
a second NR by promoting chromatin accessibility,
leading to steady state levels of several NRs at the same
response element. In agreement with this possibility,
LRH-1 silencing reduced levels of GATA3 and co-activa-
tor recruitment, histone modifications associated with
active chromatin as well as PolII binding. These results
suggest that LRH-1 promotes cofactor recruitment and
chromatin changes that facilitate ERa recruitment.
Additionally, ChIP following the addition of oestrogen
promoted LRH-1 recruitment, while ERa downregulation
with ICI182 780 treatment inhibited LRH-1 binding, sug-
gestive of a mechanism involving cyclical binding of ERa
and LRH-1 to the regulatory regions of oestrogen-respon-
sive genes. These findings show that ERa and LRH-1
co-regulate many oestrogen target genes and highlight
LRH-1 as an important mediator of the oestrogen
response in breast cancer cells.
The importance of LRH-1 for the expression of
oestrogen-responsive genes described here identifies it as
a putative drug target in breast cancer. Given that AR has
been shown to regulate the expression of ERa target genes
in ERa-negative breast cancer (35), it will be interesting to
determine the potential importance of LRH-1 in the regu-
lation of ERa target genes in endocrine resistant breast
cancer and/or in ERa-negative breast cancer and conse-
quently its therapeutic potential in breast cancer subtypes
currently lacking targeted therapies.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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